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ABSTRACT

The work presented in this dissertation aimed to localize the hydrogen-bonding
interaction sites within Aβ aggregates associated with Alzheimer’s disease using
hydrogen/deuterium exchange mass spectrometry (HDX-MS) coupled with proteolysis.
Toward this end, an on-line digestion system utilizing a triaxial electrospray probe as the
front end to MS was developed. Using this approach, regions of Aβ(1-40) fibrils and
protofibrils that are protected from HDX have been identified. The HDX data show that
the C-terminal segment 35-40 and the N-terminal segment 1-19 are highly exposed to
exchange in both fibrils and protofibrils, while the internal fragment 20-34 is highly
protected from exchange in fibrils but much less so in protofibrils. The HDX data of
fibrils match a model in which residues 11-23 and 28-36 are involved in highly protected
structures, while those of protofibrils fit a model in which residues 14-20 and 31-36 are
contained in highly protected structures. The N-terminal ~10 residues and the C-terminal
~ 4 residues appear to be unstructured in both fibrils and protofibrils. The 20-30 segment
of Aβ(1-40) is more ordered in fibrils than in protofibrils, suggesting that, if protofibrils
are a mechanistic precursor of fibrils, the transition from protofibril to fibril involves
substantial ordering of this region of the Aβ peptide.
The on-line digestion system has been extended successfully with three pepsinlike enzymes (protease type XIII, protease type XVIII and endothiapepsin). Preliminary
proteolysis results show that individual or combinational use of the enzymes leads to
production of more fragments of Aβ(1-40) (thus potentially more detailed structural
information) than using pepsin alone.
The oxidation of Aβ samples was encountered in the course of these studies. It
was found that gradual corrosion of a stainless steel electrospray emitter under conditions
of normal use can generate surface irregularities that sustain electrical discharge. The
increased emission current can affect the electrochemical reactions associated with the
spray process, including oxidation of methionine to methionine sulfoxide in Aβ(1-40)
peptides. The resultant mass shift and reduced sensitivity can adversely affect HDX
v

experiments. These effects can be avoided by adding a redox buffer or (preferably) by
re-polishing the emitter.
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ABSTRACT

The elucidation of the structure of amyloid fibrils and related aggregates is an
important step towards understanding the pathogenesis of diseases like Alzheimer’s
disease (AD), which feature protein misfolding and/or aggregation. The work presented
in this dissertation aimed to localize the hydrogen-bonding interaction sites within Aβ
fibrils and protofibrils associated with AD by using hydrogen/deuterium exchange mass
spectrometry (HDX-MS) coupled with proteolysis.

Toward this end, a novel on-line

digestion system utilizing a triaxial electrospray probe as the front end to MS was
developed. The triaxial probe allows introduction of rapid proteolysis and dissolution
reagents before addition of the pepsin-incompatible co-solvent (typically acetonitrile in
our procedures) needed to stabilize the electrospray, thereby enhancing hydrolysis
without sacrificing MS sensitivity. Using this approach, regions of the Aβ(1-40) peptide
containing backbone amide hydrogens that are protected from HDX when this peptide is
incorporated into either amyloid fibrils or protofibrils have been identified. Study of
protofibrils was facilitated by use of the protofibril-stabilizing agent calmidazolium
chloride (CLC). The HDX data clearly show that both the C-terminal segment 35-40 and
the N-terminal segment 1-19 are highly exposed to exchange in both fibrils and
protofibrils. In contrast, the internal fragment 20-34 is highly protected from exchange in
fibrils but much less so in protofibrils. The HDX data of fibrils match a model in which
residues 11-23 and 28-36 are involved in highly protected structures, while those of
protofibrils fit a model in which residues 14-20 and 31-36 are contained in highly
protected structures. This suggests that the β-sheet elements comprising the amyloid
fibril are already present in protofibrils, but that they are expanded into some adjacent
residues upon the formation of mature amyloid. The N-terminal ~10 residues and the Cterminal ~ 4 residues appear to be unstructured in both fibrils and protofibrils. The 20-30
segment of Aβ(1-40) is more ordered in fibrils than in protofibrils, suggesting that, if
protofibrils are a mechanistic precursor of fibrils, the transition from protofibril to fibril
involves substantial ordering of this region of the Aβ peptide.
vii

The on-line digestion system has been extended successfully with three pepsinlike enzymes (protease type XIII, protease type XVIII and endothiapepsin) with an aim to
obtaining complementary structural information of Aβ fibrils. Preliminary proteolysis
results show that individual or combinational use of the enzymes leads to cleavage at
different peptide amide bonds of Aβ(1-40) and production of more fragments (thus
potentially more detailed structural information) than using pepsin alone.
The oxidation of Aβ samples was encountered in the course of these studies. It
was found that gradual corrosion of a stainless steel electrospray emitter under conditions
of normal use can generate surface irregularities that sustain electrical discharge, as
evidenced by an increase in the emission current. The increased current can affect the
electrochemical reactions associated with the spray process, as evidenced by the
oxidation of the methionine residue to methionine sulfoxide in Aβ(1-40) peptides. The
resultant mass shift and reduced sensitivity can adversely affect HDX experiments.
These effects can be avoided by adding a redox buffer or (preferably) by re-polishing the
emitter.
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CHAPTER 1
INTRODUCTION

1.1
1.1.1

Amyloid Fibrils and Alzheimer’s Disease

Overview
Alzheimer's disease (AD), the most common cause of senile dementia, is manifest

by memory loss and cognitive impairments in the elderly [1]. The prevalence of AD is
around 5% among people between 65 and 74 years of age and increases to 40–50%
among persons at 85 years of age and above [2]. As human life expectancy increases, the
effects of AD will continue to escalate unless methods are discovered to delay its onset or
halt or reverse its progression.
It was early in the last century that Alois Alzheimer described his classic
observation on the dementia of Frau Auguste D., a study that gave the first insights into
the disease that now bears his name [3]. Our understanding of this and other dementing
disease comes from studies in such diverse fields as genetics, cellular and molecular
biology, epidemiology, and neuropathology [3]. Although remarkable progress has been
made over the last few years in understanding the pathologic basis of Alzheimer’s
disease, the critical events leading to neuronal dysfunction, and eventually neuron death,
are still not clear.

Microscopic examination of Alzheimer brains reveals frequent

neurofibrillary tangles, which are composed mainly of abnormally-phosphorylated tau
protein (a neuron-specific phosphoprotein that is the major constituent of neuronal
microtubules), as well as extracellular deposits called senile plaques, which consist of
protein aggregates termed amyloid fibrils [4].

Although the presence of these two

features is essential in confirming the diagnosis of Alzheimer’s disease, their significance
as factors contributing to neurodegeneration is controversial.
AD is one of several disease states termed amyloidoses in which soluble proteins
aggregate into highly ordered structures termed amyloid fibrils [5-6]. Rudolf Virchow
first applied the term “amyloid” (meaning “starchlike”) to these diseases in 1853 based
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on the staining properties of extracellular deposits in human tissue [7]. However, it is
now known that amyloid deposits are actually composed of proteins [8]. Although
proteins capable of forming amyloid in human diseases have no significant similarities to
one another in amino acid sequence, molecular weight, or native folding patterns [5],
amyloid fibrils derived from these different proteins share a number of features. For
example, they all have long, unbranched, twisted fibrillar morphology in electron
microscopy (EM) [8-9], and show similar binding ability to certain heteroaromatic dyes
(histochemical stain Congo red and fluorescent dye thioflavin T (ThT)) and
conformational antibodies [8-9]. Fibrils also share a high content of β-pleated sheet
secondary structure [5].

Moreover, they are extremely stable, insoluble under

physiological conditions, and are very resistant to degradation and proteolytic digestion
[4, 10]. These similarities suggest related mechanisms of fibril formation among the
amyloid diseases. Therefore, information derived from AD research may be applied to
other amyloid diseases, such as type II diabetes, Creutzfeldt-Jakob disease, rheumatoid
arthritis, prion diseases, Parkinson’s disease and Huntington’s disease [9].
The primary component of AD associated amyloid fibrils is the Aβ peptide [11], a
hydrophobic peptide, ranging from 39 to 43 amino acids in length (Figure 1.1). The
peptide is derived from amyloid precursor protein (APP), which is a 110-130 kDa
glycoprotein binding covalently to membranes and expressed throughout the body [1213]. During metabolism, APP is most often cleaved at a region near the membrane
within the Aβ sequence, by another membrane-bound protease termed α-secretase [14].
Cleavage by this protease results in the release of a soluble peptide, leaving the less
soluble carboxyl end of APP bound to the membrane, thereby preventing formation of the
Aβ peptide. If α secretase does not cleave APP, the protein may undergo alternative
processing where it is proteolytically cleaved by enzymes termed β-secretase and γsecretase [13, 15-16]. It is likely that the Aβ peptide is generated during this processing
step.

β-secretase cleaves APP to form C-terminal derivatives; subsequently, the -

secretase complex cleaves at position 39, 40, 42, and 43 to generate respectively A(139), A(1-40), A(1-42) and A(1-43) peptides, among which A(1-40) is most abundant
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Figure 1.1. The amino acid sequence of Aβ(1-43) peptide (each letter denotes an amino
acid). Some variants eliminate up to 4 of the C-terminal amino acids. The table inset
shows the names and abbreviations of the 20 amino acids.
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and A(1-42) is second-most abundant and most toxic [3]. An increase in brain Aβ
levels correlates with the transition from a presymptomatic state to a symptomatic state in
the progression of AD [6]. Because of this correlation, it has been hypothesized that Aβ
deposition in plaques in brain tissue is the causative factor in AD, and that all other
pathological symptoms (neurofibrillary tangles, cell loss, vascular damage, and dementia)
follow as a result of this initial deposition [17]. Most of the strong evidence in favor of
this amyloid hypothesis is genetic.
Genes responsible for early onset AD (before an average age of 60) are located on
chromosomes 1 (presenilin 2 or PS2), 14 (presenilin 1 or PS1), 19 (apolipoprotein E or
ApoE), and 21 (APP). Early onset forms of AD have been observed to correlate with
mutations in APP [12, 17-22] and in presenilin genes [23-25]. So far, 20 pathogenic
mutations in the APP gene, 124 mutations in the PS1 gene and 8 mutations in the PS2
gene have been described worldwide in families with AD [26]. The mutations have a
direct effect on A fibril formation. Most of these mutations have been found to map at
or near cleavage sites in the primary sequence of APP that are targeted by the proteases
β- and γ-secretase, and therefore generate Aβ by favoring proteolytic processing of APP,
leading to a significant increase in the A42/A40 (concentration) ratio [17]. PSs are
crucial components of the -secretase complex. Patients with PS1 mutations exhibit
significantly higher secretion levels of Aβ(1-42) (shown to be more prone to aggregation
and to be the initially deposited amyloid peptide in AD) compared to those with sporadic
non-early onset AD [27]. Finally, the other genetic loci implicated in early onset AD
encodes ApoE [24, 28-29]. ApoE’s correlation to AD does not depend on genetic
mutation but instead on genetic polymorphisms and the inheritance of one of the three
variants from each parent; the ε2, ε3, and ε4 allelles (different variations of the same
gene) [27]. The role played by ApoE in conferring AD susceptibility is not clear. One
possibility for the involvement of ApoE in the progression of AD involves the ability to
bind to neurotic plaques [24, 28]. All of the above observations are consistent with the
theory that Aβ aggregation plays a causative role in AD.
All in all, the alterations within the genes responsible for early onset AD (APP,
PS1, PS2, and ApoE) coincide with modifications of the generation, aggregation, or
4

clearance of Aβ that lead to amyloid fibril formation and deposition. Amyloid fibril
formation thus appears to stand at the crossroads of many mechanisms of AD
development.

However, there are some concerns with the amyloid hypothesis. For

example, the extent of amyloid deposits in AD brains does not always correlate with the
severity of cognitive impairment, while deposition of tau protein in neurofibrillary
tangles does seem to correlate with it [23]. On the other hand, recent findings have
suggested that tau alterations occur after alterations in APP processing, and also that Aβ
toxicity is tau dependent [23]. These observations have led to a theory that smaller
soluble Aβ aggregates were at least co-responsible for the observed in vitro as well as in
vivo neurotoxicity. These soluble oligomers called amyloid-derived diffusible ligands
(ADDLs) [30], protofibrils [31] and amylospheroids [32], are presently considered as the
relevant neurotoxic species initiating the amyloid cascade, and affecting memory
processes in vivo [33-36]. Moreover, recent studies showed the possibility that certain
amyloid morphologies may be more pathogenic than others in organs affected by amyloid
diseases, which would weaken the correlation between disease symptoms and total
amyloid deposition [37]. Therefore, further refinement of the amyloid hypothesis will
entail the identification of specific pools of Aβ that contribute to the development of Aβ
amyloid pathology and neuronal dysfunction.

Moreover, besides targeting Aβ

aggregation, it seems reasonable that drug design strategies that target Aβ production are
also viable therapeutic approaches. The goal of the research presented here is to improve
our understanding of the three-dimensional structure of Aβ fibrils and protofibrils, and of
how fibrils are formed. Detailed understanding should help development of therapeutic
approaches to curing AD.

1.1.2

Pathway of Aβ
β Peptide Fibrillization
To be able to target Aβ amyloid formation as a therapeutic approach, it is

necessary to have a detailed understanding of the molecular mechanism of Aβ
fibrillogenesis. Analytical ultracentrifugation, gel filtration chromatography, electron
microscopy (EM), atomic force microscopy (AFM), and quasielastic light scattering
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(QLS) have all shown that Aβ(1-40) and Aβ(1-42) at concentrations well above the
critical concentration (Cr: defined as the concentration of peptide at which the rates of
fibril formation and fibril dissolution are equal [38-41]) exist as both insoluble highmolecular-weight fibrillar oligomers and also soluble lower-weight oligomers [42]. The
presence of the smaller oligomeric forms of Aβ suggests that the fibril assembly pathway
involves discrete intermediates [42].

These intermediates involved in Aβ(1-42)

fibrillization have been visualized by EM in vitro [42]. In this case, the earliest observed
intermediates (after 0-0.5 h incubation) are globular aggregates (with a characteristic
“beaded” appearance) about 4-5 nm in diameter [43]. These intermediates then gradually
assemble into straight or V-shaped protofibrils (Figure 1.2a, 8.7-11.3 nm in diameter,
after 0.5-2 h incubation), which undergo lateral or ‘end-to-end’ fusion to form short, thick
fibrils with unincorporated protofibrillar branches (2-12h incubation). As the immature
fibrils grow longer and thinner, the branches gradually recede and ultimately disappear,
and subsequently amyloid fibrils (7-10nm in diameter, 12-24 h incubation) are formed
[43]. AFM measurement of the lengths of protofibrils at various time points (2-18 days)
during the fibrillization of Aβ(1-40) and A(1-42) indicate that protofibril elongation
involves both the incorporation of monomer and the association of immature (short)
protofibrils [44]. In contrast, after dilution, protofibrils dissociate via the release of
monomer only. Walsh et al. [31] independently reported similar findings, using light
scattering and dialysis experiments to show that isolated A(1-40) protofibrils are in
equilibrium with low-molecular weight species and convert irreversibly to fibrils.
Since protofibrillar structures have been observed in the fibrillogenesis of both
Aβ(1-40) and Aβ(1-42), they are perhaps a common intermediate in all Aβ fibrillogenesis
[44, 45-48]. The presence of a protofibrillar intermediate has been interpreted as being
consistent with the theory that Aβ aggregation follows a nucleation-dependent pathway
[42]. Several features characterize nucleation-dependent aggregation. First, there is no
aggregation at peptide concentrations below Cr [42]. Second, at peptide concentrations
that are higher than Cr, there is a lag time before aggregation begins [42]. Lag time is
defined as the time before amyloid formation occurs during which the peptide remains
soluble [42]. Finally, during the lag time, addition of a small amount of fibril seed results
6

(a)
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Figure 1.2. Electron micrographs of (a) Aβ protofibrils and (b) Aβ fibrils.
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in faster aggregation. Nucleation-dependent aggregation is thermodynamically similar to
micelle formation with respect to the critical concentration, but kinetically is much
slower, possibly because the process is more complex, and there is a much greater
entropic barrier to fibril organization [42].
There are thus three main steps involved in a nucleation-dependent pathway (see
Figure 1.3) [42].

The first step involves conversion of the monomer peptide to a

thermodynamically unstable “nucleus” that is presumed to be oligomeric. The nucleus is
the least stable oligomer on the assembly pathway. Once the oligomeric nucleus contains
more than the critical number of molecules, its continued growth leads to formation of
more stable aggregates, featuring progressively less and less tendency to dissociate to
monomer.

This step is the rate-limiting step. After the formation of this “critical

nucleus” comes the “elongation” step of the pathway. During this step, where addition of
further monomers is thermodynamically favorable, rapid extension of aggregates occurs
according to pseudo-first order kinetics (first order in both monomer and fibril growing
ends, with the latter unchanging over the course of the reaction). The final phase of the
pathway occurs when the peptide monomer is depleted to the point where fibril growth
and dissolution are in a dynamic equilibrium.
Although fibrillization of both Aβ(1-40) and Aβ(1-42) is nucleation-dependent,
the pathways are distinct, thus generating different types of oligomers. Teplow and
colleagues found that at the earliest stage of monomer oligomerization, Aβ(1-40) exists
as monomers, dimers, trimers, and tetramers, in rapid equilibrium, while Aβ(1-42)
preferentially forms pentamer/hexamer units that assemble further into larger oligomers
and protofibirils [49]. Recently it has also been found by using solid-state NMR and EM
that Aβ(1-40) fibril morphology and molecular structure is sensitive to growth conditions,
which suggests the existence of at least two distinct fibril nucleation mechanisms for Aβ
(1-40) depending on growth conditions [37]. One mechanism, leading to quiescent fibrils
(growing in vertical dialysis tubes containing an unstirred bath of buffer), may be purely
homogeneous. The other mechanism, leading to agitated fibrils (growing in horizontal
polypropylene tubes with gentle circular agitation using an orbital mixer), may depend on
the interface between the peptide solution and the air or the walls of the sample tube.
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Figure 1.3.

Nucleus

Large oligomers

Protofibrils
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Schematic presentation of Aβ fibril formation (not to scale).

Aβ

fibrillogenesis is a nucleation-dependent polymerization process in which monomeric Aβ
forms oligomeric nuclei, and further large oligomers from which protofibrils emanate.
These protofibrils give rise to full-length fibrils.
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Therefore, the molecular structure of Aβ(1-40) fibrils is not determined solely by amino
acid sequence and is not purely under thermodynamic control [37].
Fibril growth is more complex in vivo, however. For instance, factors such as
chemical damage and binding of other proteins can render fibrils resistant to dissociation
[42]. For example, apolipoprotein E2 (ApoE2) is an endogenous protein that has been
shown to inhibit amyloid fibril formation [42]. Also, cellular concentrations of Aβ are
much lower in vivo (in the nanomolar range) than those typically used in vitro (in the
micromolar range), which makes it unclear how nucleation can occur in vivo [42]. It may
be possible that nucleation occurs in cellular organelles supersaturated with Aβ, and
fibrils formed in this way can then be released from the cellular compartment and act as
seeds for additional fibril formation [42]. Alternatively, it is possible that the in vivo
critical concentration is lowered by endogenous species. For example, zinc is able to
induce the aggregation of Aβ at subnanomolar Aβ concentrations in vitro [42].
Amyloid fibril growth in vitro can be monitored by Thioflavin T (ThT)
fluorescence assay [50]. ThT assay is widely used because of its sensitivity, selectivity
and simplicity. ThT assay can be used to monitor spontaneous aggregation of either
unseeded Aβ aggregates (nucleation and elongation phases of aggregation), or seeded Aβ
aggregates (elongation phase of aggregation) in solution [51]. ThT is useful in that it
fluoresces upon binding to amyloid fibrils but not to precursor polypeptides, monomers,
or protofibrils.

1.1.3

Structure and Assembly of Aβ
β Amyloid Fibrils and Protofibrils

Aβ
β Amyloid Fibrils
Knowledge of the three-dimensional structure of amyloid fibrils has great bearing
on our understanding of how the fibrils are formed and on the rational design of
therapeutics. However, progress toward high-resolution structure analysis of aggregates
using X-ray crystallography or solution-state multidimensional nuclear magnetic
resonance (NMR) spectroscopy has been slow and fraught with difficulties [5], due to the
insolubility, heterogeneity and noncrystalline nature of the fibrils.
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Our current understanding of amyloid structure is based on studies at relatively
low resolution. EM and AFM show that fibrils produced by many proteins are 6-12
nm in diameter and several µm in length and are composed of a number of smaller (3-4
nm diameter) protofilaments twisted about each other along the fibril axis (Figure 1.2b)
[44, 52]. Circular dichroism of nascent fibril formation reactions shows an increase in βsheet content with Aβ incubation [53], and solid state infrared spectroscopy confirms the
high β-sheet content of fibrils themselves [54]. X-ray diffraction studies also indicate
that amyloid fibrils are rich in β-sheet, and further show that fibrils are organized in such
a way that the β-sheets run perpendicular to the long axis of the fibrils while the
hydrogen bonds between β-sheets are parallel to the axis [55] (Figure 1.4). Fibrils grown
in vitro were indistinguishable by EM from those found in neuritic plaques [42].
Amyloid fibrils from the peptide Aβ have been a major focus of structural studies.
Unfortunately, the structural roles of specific amino acid residues in the Aβ sequence
remain unclear.

However, a number of low-to-medium resolution methods have

provided valuable insights into Aβ fibril structure, based on studies of fibrils grown in
vitro in aqueous solutions [40, 56-71]. This information places significant constraints on
the types of models that can be constructed for Aβ fibrils.
Some of these constraining insights have come from work in our group. For
example, using the hydrogen/deuterium exchange mass spectrometry (HDX-MS)
technique, Kheterpal et al. showed that ~ 50% of the 39 backbone amide hydrogens of
Aβ(1-40) are not involved in protective hydrogen bonds associated with a β-sheet when
this peptide is incorporated into the fibril structure [58-59].

Several other experiments

on intact fibrils, including limited proteolysis [60], scanning proline mutagenesis analysis
[40], hydrogen/deuterium exchange nuclear magnetic resonance (HDX-NMR) [61],
scanning cysteine mutagenesis analysis [62] and scanning alanine mutagenesis analysis
[63], confirm this, demonstrating that the N-terminal 13–16 residues of the Aβ (1–40)
peptide are excluded from the packed fibril and therefore cannot be involved in the Hbonded core structure. Other groups have interpreted solid state NMR [64], electron
paramagnetic resonance spectroscopy (EPR) [65], reductive alkylation [66], HDX-MS
11

(b)

(a)

fibril axis

Figure 1.4. Illustrative diagrams shows (a) that the continuous, hydrogen-bonded parallel
β-sheets run perpendicular to the long axis of the fibrils while the hydrogen bonds
between β-sheets are parallel to the axis; (b) that bundles of protofilaments twist about
each other along the fibril axis to make fibrils.

The pitches emerging from the

protofilaments are A termini which are assumed not to be involved in the fibril
structure. (Reproduced from Ref. [60])

12

coupled with off-line proteolysis [67] as well as other methods [68-71] to suggest a
flexible N-terminal segment. Consistent with all this experimental evidence, N-terminal
truncated variants of Aβ are found in amyloid plaques [5].

Consequently, the

composition of the N-terminus is considered not to be critical for amyloidogenesis. On
the other hand, there is disagreement on whether the C-terminus is involved in an
extended β-sheet structure. Data from fluorescence quenching [72], EPR [65], scanning
proline mutagenesis [40], scanning cysteine mutagenesis [62], scanning alanine
mutagenesis [63], HDX-NMR [61] and HDX-MS coupled with off-line proteolysis [67]
indicate that portions of the C terminus have considerable mobility. In contrast, results
from reductive alkylation [66] and solid state NMR [64] suggest that portions of the Cterminus are significantly protected in the fibril.
Based on such experimental observations, many models for Aβ fibrils have been
proposed [40, 63-65, 72-87]. These models are consistent with the diameter of the
protofilaments and fibers and the cross-β sheet structure described above. While these
models differ in many structural details (such as the structure of protofilament and in the
assembly of protofilaments to form mature fibrils), they generally include antiparallel or
parallel β-sheets. Antiparallel β-sheet appears to dominate amyloid fibrils made of short
(less than 40 amino acids) Aβ peptides [76, 79-80]. Some models for Aβ(1-40) and
Aβ(1-42) fibrils which were based on antiparallel β-sheet structures [75, 77-78, 86] are at
variance with experimental intermolecular distance constraints [88-90]. Other models
including a β-hairpin centered in residues 24–29, with intramolecular hydrogen bonding
between β-strands on either side of a β-turn [75, 77, 85-86] are incompatible with the inregister parallel intermolecular alignment determined experimentally [88-90].
Compelling evidence from solid state NMR [64, 87], liquid suspension EPR [65],
scanning proline mutagenesis [40, 74], scanning cysteine mutagenesis [62], and scanning
alanine mutagenesis [63] studies on Aβ(1-40) fibrils suggests that the peptides in the
fibril core are in an in-register, parallel arrangement. However, there is no consensus on
a unique structural model for the fibril-folding motif, and in fact a number of models
involving parallel β-sheets have been proposed [63-65, 73, 70-83]. The linear parallel
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model of Aβ(16-35) [72] or Aβ(10-35) [81-83], with polar residues in the middle of the
peptides, appears unfavorable based on molecular dynamics simulation experiments by
Ma and Nussinov [84]. A growing body of evidence suggests the existence of turn(s) in
the middle of the peptide [40, 63-65, 74-78, 91]. For example, solid state NMR reveals a
possible non-β-strand region between residues 25 and 29 [64]. Kinetics analysis of fibril
formation with proline replacements in Aβ(1-42) at positions 19-26 (one residue at a
time) suggests a possible turn region at positions 22 and 23 [91]. Thermodynamic
analysis of the stabilities of fibrils derived from proline mutants of Aβ(1-40) implicates
two turn regions at residues 22-23 and 29-30 within a β-sheet-rich core region involving
residues 15-36 [40, 63]. In what follows, a detailed description of the three latest models
for Aβ(1-40) fibrils (parallel β-sheets) will be presented.
Torok et al. proposed a model based on EPR analysis of site-directed spin-labeled
Aβ(1-40) fibrils (grown under agitation) [65].

The strategy involves spin-labeling

specific cysteine residues, which is remarkably well tolerated in proteins. They identified
three regions of Aβ(1-40) fibrils: a central region of pronounced parallelism between
separate Aβ molecules from approximately residue 14 to 38, a more disordered Nterminal region with less specific parallelism, and a short C-terminal stretch where little
parallelism could be detected. This data indicated that a turn may be located at residues
23-26.
Petkova et al. presented a structural model for Aβ(1–40) amyloid fibrils (grown
under agitation) based on a set of experimental constraints from solid-state NMR
spectroscopy [37, 64, 87]. According to this model, approximately the first 9 residues of
Aβ (1–40) are structurally disordered in the fibrils. Residues 10–22 and 30–40 adopt βstrand conformations and form parallel β-sheets through intermolecular hydrogen
bonding. Residues 23–29 contain a bend of the peptide backbone that brings the two βsheets in contact through side chain-side chain interactions. A single cross-β unit is then
a double-layered β-sheet structure with a hydrophobic core and one hydrophobic face.
The only charged side chains in the core are those of Asp23 and Lys28, which form
intramolecular salt bridges. Fibrils with minimum mass-per-length and diameter consist
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of two cross-β units with their hydrophobic faces juxtaposed. This four-layered β-sheet
structure has both "internal" (between β-sheets within a single molecular layer) and
"external" (between β-sheets in different molecular layers) quaternary contacts [87]. The
internal quaternary contacts are between side chains of L17 and F19 and side chains of
I32, L34, and V36, while the external quaternary contacts are between the side chain of
I31 and the peptide backbone at G37, and between the side chain of M35 and the peptide
backbone at G33 [87].
Our group proposed a model based on scanning proline mutagenic analysis of
Aβ(1-40) fibrils (grown under quiescent conditions) (Figure 1.5) [40, 74]. Scanning
proline mutagenic analysis involves the introduction of a β-sheet-breaker - proline
residue into amyloidogenic polypeptides and then analyzing the thermodynamic
stabilities (based on ∆∆G calculated using Cr values of wild type (WT) and mutant
fibrils; ∆∆G = -RT × ln[CrWT/Crmutant]) of amyloid fibrils formed from these single
proline mutants [40]. The results show that the N-terminal 10-15 residues and the Cterminal residues 37-40 of Aβ(1-40) are not involved in the H-bonded core structure of
the fibril. Besides indicating that it is the 15-36 sequence of Aβ that is involved in
ordered, proline-sensitive structure within the amyloid core, these data also suggest the
existence of two turn regions within the 15-36 segment, one at residues 22-23 and one at
residues 29-30, which are not sensitive to proline replacement. This model agrees with
the results from the molecular dynamics simulations of the segment 15-36, which suggest
a six-layered parallel β-helical structure for Aβ(1-40) amyloid fibrils [74]. The model
was further corroborated and refined by the following data generated by our group.
HDX-NMR data indicate that Aβ(1-40) fibrils have solvent-accessible N-terminal and Cterminal amino acids, and two expanses of protective structure centering around residues
15-23 and residues 28-35 [61]. Moreover, the data suggest the residues at 25 and 26 are
freely exchangeable. Investigation of the orientations and spatial proximities of the
amino acid side chains in the amyloid core region was achieved by using double cysteine
mutagenesis analysis [93]. The results (obtained from analysis of three double cysteine
mutants (Leu17/Leu34, Leu17/Met35 and Leu17/Val36)) support models of Aβ(1-40)
15

Figure 1.5. A working structural model of Aβ(1-40) fibrils. The chain of circles
containing residue numbers represents one A molecule, with residues 1–14 and 37–40
shown as disordered elements, sequence elements 15–21, 24–28, and 31–36 shown as
highly structured elements, and residues 22, 23, 29 and 30 shown in turns. The 15–36
sequences of additional A molecules are shown stacked in the H-bonding direction
parallel with the fibril axis. (Reproduced from Ref. [40]).
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fibrils in which the Leu17 and Leu34 side chains of the same peptide pack against each
other at the β-sheet interface within the amyloid core [93]. More recent results from
scanning cysteine mutagenesis analysis not only confirm the lack of structure in the Nterminus and C-terminus, but also indicate that residues 16-19 and 31-34 are likely
packed into a hydrophobic amyloid core and residues 20, 30, and 35 are located in solvent
exposed structure [62].

Still more recent results from alanine mutagenesis analysis

suggest disordered N-terminus and C-terminus, H-bonded 16-21 segment and rigid
structure (not H-bonded structure) within the 24–30 segment as well as the structural
plasticity (ability of adjusting to packing changes) of A amylid fibrils [63].
The models described above differ in some significant details (Table 1.1). Part of
the differences may be due to limitations of experimental data and analysis; and part due
to their being based on experiments conducted on different fibril conformers [37]. The
recent discovery of growth condition-dependent conformational variants of A(1-40)
amyloid fibrils (agitated fibrils vs. quiescent fibrils) [37] complicates the goal of arriving
at a consensus fibril structure derived from comparison of the literature data, since these
data are based on fibrils prepared in a variety of ways. It also introduces the questions of
how many other conformational variants of A(1-40) might be accessible to this peptide,
and which of these several form(s) might best represent the conformation of amyloid
fibrils that is biologically relevant to brain neuritic plaques.

So far, there is little

information available concerning these uncertainties.
The goal of studying A amyloid fibrils is to decipher the structure and structural
energetics of amyloid fibrils similar to those located in the neuritic plaques in
Alzheimer's disease brains. For every specific fibril conformer, significant insight into
structure could be derived from a knowledge of the hydrogen bonding patterns within
fibrils and the number of residues that make up the rigid core of the fibril structure. As
described in details later in this chapter, hydrogen/deuterium exchange mass
spectrometry (HDX-MS) can provide information about the number and location of
residues within the Aβ peptide involved in intramolecular and intermolecular hydrogen
bonding. Information on the secondary structural role of a particular sequence element
along a fibril-incorporated peptide could be used to test model predictions of particular
17

Table 1.1. Summary of some models for Aβ amyloid fibrils.
Sequences
Studied

Methods

Conformation

IR, limited proteolysis

Anti-parallel
β-sheet

β- strand: residues 10-42
β-turn: residues 26-29
Disordered: residues 1-9

[85]

14-42, 14-23

Substitution studies,
EM, Molecular
modeling

Anti-parallel
β-sheet

β-strand: residues 14-23
and 27-40
β-turn: residues 24-26

[76]

12-42

Synchrotron x-ray
diffraction, molecular
dynamics simulation

Anti-parallel
β-sheet

β-strand: residues 12-24
and 29-40
β-turn: residues 25-28

[75]

10-35

Solid-state NMR, EM,
Small angle neutron
scattering

Parallel
β-sheet

β-strand: residues 10-35

[81-83]

Parallel
β-sheet

β-strand: residues 10-23
and 28-35
β-turn: residues 24-27

[84]

[65]

1-43, 2-43,
4-43, 8-43,
9-43, 10-43,
12-43,
10-42,
10-23, 29-42

16-22,
16-35, 10-35

Solid-state NMR,
Molecular Modeling,
Molecular dynamics
simulation

Core Structure

Ref.

1-40, 1-42

Site-directed spin
labeling EPR

Parallel
β-sheet

β-strand: residues 14-22
and 27-38
β-turn: residues 23-26
Disordered region:
residues 1-13 and 39-40

1-40

Solid-state NMR

Parallel
β-sheet

β-strand: residues 12-24
and 30-40
β-turn: residues 25-29

[37, 64, 87]

1-40

Scanning proline
mutagenesis analysis,
Molecular dynamics
simulation

Parallel
β-helix

β-strand: residues 15-21,
24-28 and 31-36
β-turn: residues 22-23
and 29-30
Disordered region:
residues 1-14 and 37-40

[40, 63, 74]
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fibril conformers and to assemble improved models of specific amyloid fibril structure.
In this dissertation, the studies were focused on quiescent A(1-40) fibrils (and
protofibrils) grown in the physiological conditions of phosphate-buffered saline buffer at
37 °C without agitation.

Protofibrils
As mentioned earlier, recent focus has been on the possible role of non-fibrillar,
oligomeric states of A in the disease mechanism [30-36]. Therefore, the knowledge of
the three-dimensional structure of protofibrils is also critical for understanding the
mechanism of how A transits from soluble forms to insoluble -sheet-rich conformers
and hence for the design of possible inhibitors. In contrast to mature fibrils, however,
much less is known about the molecular architecture of protofibrils and oligomers, which
are particularly challenging to study due to their metastable, transient nature and their
diverse morphologies [93]. They exhibit little or no response to thioflavin T [94], a
poorly understood fluorescent probe for amyloid structure that is generally considered a
probe of -sheet structure. A lack or deficiency of -sheet structure would be consistent
with early models of A oligomers as possessing a micelle-like structure [95] driven by
the polar nature of the A peptide, which possesses a hydrophobic C-terminus and a
hydrophilic N-terminus. It would also be consistent with a degree of -helical content in
protofibrils, suggested by the transient appearance of -helix in A fibril formation
reactions [96].
More recent studies from our group using HDX-MS capable of obtaining some
data from metastable oligomeric assemblies suggest the possibility that normally isolated
A protofibrils might also possess some very highly stable H-bonded structure [93]:
about 40% of the 39 backbone amide protons was protected from exchange. In fact, the
presence of -sheet structures was indicated by circular dichroism studies [31, 93].
Scanning proline mutagenesis analysis suggests that A protofibrils (stabilized by
calmidazolium chloride (CLC), Figure 1.6) contains H-bonded -sheets, involving the
same hydrophobic patches 16-21 and 30-36 as involved in fibril structure [94].
Moreover, in both fibrils and protofibrils, the N-terminal 14 residues and the C-terminal
19

Cl

Cl
N+ Cl

N
O

Cl

Cl
Cl

Cl

Figure 1.6. The structure of calmidazolium chloride.
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3-4 residues seem uninvolved in the kind of rigid structure disrupted by proline
substitution [94]. It seems that the major difference between protofibrils and fibrils lies
in the 21-30 segment [94]. It is likely that protofibrils have a simple extended hairpin
structure with a long, relatively flexible loop, involving residues 22-29, spanning the two
-structure segments [94].
Further progress in the analysis of A protofibrils and their structural relationship
to mature fibrils requires progress on two fronts: methods to stabilize protofibrils to
facilitate biophysical studies, and methods to provide structural information at segmental,
and ultimately, single residue, resolution. The first goal was achieved in our group
through the discovery of the small organic molecule - calmidazolium chloride (CLC)
(Figure 1.6), which not only accelerates the formation of A protofibrils, but also
stabilizes them against progress to mature fibrils [94]. The second goal can be realized
through HDX-MS, in which segmental exchange information can be obtained by
proteolysis before MS analysis (discussed in Chapter 4).

1.1.4

Inhibition of Amyloid Fibril Aggregation
AD is a disorder for which symptomatic treatments are available. As discussed in

the previous sections, the amyloid hypothesis, which claims accumulation of Aβ in the
brain is the primary influence driving AD pathogenesis, has been formally articulated and
supported by a wealth of studies from many laboratories worldwide over the past 10
years [5, 97-99]. Therefore, the development of anti-Aβ therapeutics remains a rational
approach to treating AD. Several therapeutic approaches have been identified which
target the production, the aggregation or the clearance of Aβ (Table 1.2) [100-101]. At
present, it is not known whether any approach will prove to be effective.
Inhibition of Aβ aggregation is a very appealing target for drug design [46].
Studies have shown that Aβ immunization in a murine model (model derived from mice)
of AD reduces both the level of fibrillar Aβ deposition in the brain and the level of
cognitive decline [124].

These findings suggest that there is a link between Aβ

aggregation/deposition in the brain and congnitive decline in AD. Therefore, screening
libraries of compounds for inhibitors of Aβ aggregation and/or deposition could lead to
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Table 1.2. Potential anti-amyloid aggregation therapeutics.
Potentially therapeutic
agent

Molecular
Target

Biological
Consequence

References

Secretase inhibitors

β-secretase,
γ-secretase

Decrease Aβ
production

[102-104]

Aβ

Inhibit Aβ
deposition ,
Enhance Aβ
clearance

[104-107]

γ-secretase

Lower Aβ(1-42)
production,
Increase Aβ(1-38)
production

[108-110]

Aβ

Inhibit
oligomerization and
fibrillogenesis

[111-115]

Secretase activator

α-secretase

Lowering Aβ
production by
enhance α-cleavage

[116-118]

Activators of Aβdegrading enzymes

Aβ-degrading
enzymes

Increase Aβ
degradation and
clearance

[119-121]

Aβ

Solubilization of Aβ
deposits and
prevention of
aggregation by
metalchelation

[122-123]

Active/passive
immunization

Non-steroidal antiinflammatory agents

Anti-aggregation
compounds

Metal chelators
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the discovery of novel drug candidates for treating AD. Interpretation of the results of
such screening is complicated, however, due to uncertainty about what the toxic
aggregate is (i.e the possibility that an intermediate on the fibril assembly pathway may
be the toxic species, while mature amyloid fibrils may actually be protective) [17]. Thus,
it seems reasonable that drug design strategies that target Aβ production may also be a
viable therapeutic approach [51].

Since Aβ generation depends on the proteolytic

cleavage of APP by - and -secretase (as mentioned previously), these enzymes are
targets for the development of novel protease inhibitors for AD. However, it has been
reported that β- or γ-secretase inhibitors induced death in rodent and human neuronal cell
lines [125]. This highlights the challenge to identify non-toxic drug candidates for
clinical trials, in particular with a view to target prevention. Moreover, it should be
realized that A has a widespread distribution through the brain and body, even in
cognitively normal individuals, and soluble Aβ serves a variety of physiological
functions, including modulation of synaptic function, facilitation of neuronal growth and
survival, protection against oxidative stress, and surveillance against neuroactive
compounds, toxins and pathogens [126]. Caution needs to be exercised when developing
therapeutic strategies to remove Aβ from the brain. Ideally, such strategies should target
forms of Aβ that are not bioavailable, such as fibrillar Aβ, or forms that are thought to be
over-expressed in Alzheimer’s disease (such as oligomers) while leaving normal soluble
Aβ(1–40) and Aβ(1–42) intact.

Finally, AD is an extremely complicated neuronal

degeneration disease. Our knowledge of the causes of the disease, of the mechanisms of
disease onset and progression is still not mature. Therefore, many issues remain to be
resolved in order to discover more promising therapies.

1.2 Mass Spectrometry
Mass spectrometry (MS) is emerging as an extremely important tool in
biochemical research capable of analyzing small and large molecules.
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Analytical

chemists have added fresh impetus to bioresearch with two revolutionizing mass
spectrometry soft ionization tools, electrospray ionization (ESI) and matrix-assisted laser
desorption/ionization (MALDI). Commercial availability of these technologies has made
routine the analysis of compounds including proteins, peptides, carbohydrates,
oligonuleotides, natural products, and drug metabolites, offering picomole to femtomole
sensitivity and enabling the direct analysis of biological fluids with a minimum amount
of sample preparation. MS allows for the analysis of small and large biomolecules
through “mild” desorption and ionization methods. Their utility now extends beyond
simple molecular weight characterization.

Nonconvalent interactions, protein and

peptide sequencing, DNA sequencing, protein folding, in vitro drug analysis, and drug
discovery are among the areas to which mass spectrometry is being applied. Rapid
technical developments in the areas of front-end sampling devices, ionization techniques,
mass analyzers, and data analysis software will ensure that MS will play an even greater
role for biophysical studies of proteins in the near future.

1.2.1

ESI-MS

ESI-MS Overview
Electropspray ionization (ESI) is an atmospheric-pressure ionization method that
produces small charged droplets from a liquid medium under the influence of an electric
field [127-134]. The first attempt to use electrospray (ES) as an ionization source for
generating gas-phase ions can be traced to the analysis of the molecular weights of
synthetic polymers (e.g. polystryrene) with electrospray/drift-tube experiments, and
achieved some limited success [135-136]. On a parallel track, the work by Evans and
Hendricks [137] and the Cook group [138] led to establishment of electrohydrodynamic
ionization MS in which the field prompts ion desorption directly from the meniscus into
vacuum. The greatest success of ESI is attributed to the creative work by Fenn and coworkers [139-141] and Alexandrov and co-workers [142] since 1984. ES MS has since
become one of the most powerful techniques for the anlaysis of biomolecules [139].
Figure 1.7 is a schematic diagram of a typical ESI-MS system in which the
electrospray ion source at atmospheric pressure is interfaced with a mass analyzer
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Figure 1.7. Schematic diagram of a typical ESI-MS system.
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through a gently heated sampling optical system (usually an orifice and skimmer) which
is maintained at reduced pressure (typically ~10-3 torr). The use of a drying gas and/or
counter-current gas in the ESI-MS interface is a key leading to production of dry ions by
eliminating ion re-solvation and ion cluster formation [141]. Sampling is accomplished
by applying high voltage (e.g. 3 - 6 kV) to the ES emitter (typically a metal tip). Sample
solution at a low flow rate (typically 1-10 µl/min) is introduced through a silica capillary
into the emitter. When the electric field is applied, the emerging liquid containing sample
ions is dispersed as a fine spray of charged droplets. The charged droplets further
subdivide into smaller “offspring” droplets as a result of solvent evaporation and
coulombic repulsion [143]. At some stage, ions are desorbed from small droplets into the
gas phase. The ions are directed into an orifice through electrostatic lenses leading to the
MS analyzer.

Since ESI is usually operated under mild conditions (e.g. moderate

electrostatic field, gentle heating and atmospheric pressure at the ion source), deposition
of energy to the molecular ions is usually low. Therefore, intact molecular ions with little
or no fragmentation can be readily detected.
The formation of gaseous analyte ions by ESI involves three main steps:
formation of charged droplets, shrinkage of the droplets due to solvent evaporation,
transfer of ions to the gas phase. Two models have been developed to describe the ESI
process: the ion evaporation model [135] and the charge-residue model [144]. The
charged-residue model predicts successive cycles of solvent evaporation and droplet
fission at the Rayleigh limit, until an isolated ion is eventually produced. The ionevaporation model, based on the transition-state theory, predicts direct ejection of ions to
the gas phase from nm-size droplets before they reach the Rayleigh instability limit. To
gain experimental evidence allowing a clear-cut discrimination between these two
alternative mechanisms has represented a major challenge for researchers in this field
[145-146]. However, recent reports suggest that small ions follow the behavior predicted
by the ion-evaporation model, whereas desolvated macroions (e.g. charged proteins) are
most probably formed according to the charge-residue mechanism [147].

26

Common Features of ESI-MS
Sampling ions from solution phase
Unlike MALDI which employs laser beams to desorb ions from a solid (crystal)
matrix [148-149], ESI generates gas-phase ions from the liquid phase at atomospheric
pressure, which is more like the natural state of most biological samples. This feature
also makes ESI-MS particularly well suited for coupling with liquid phase separation
techniques such as high performance liquid chromatography (HPLC) [150] and capillary
electrophoresis (CE) [151] for analysis of complex biological samples.

Production of multiply charged ions
A distinctive and enabling feature of ESI-MS is the production of multiply
charged ions from bio-polymer molecules [141]. Ion series corresponding to different
charge states are usually distributed as a bell-shaped envelope. This feature can impact
MS analysis in several ways. First of all, it lowers the m/z values of ions, allowing
measurement of high mass with virtually any type of mass spectrometer such as
quadrupole instruments. It also provides independent estimates of molecular weight from
ions carrying different charges, thereby improving the precision with which molecular
weight can be determined [152-153]. In addition, fragmentation of large molecular ions
through collision-induced dissociation (CID) can be facilitated at high charge states due
to high kinetic energy [154-156], which is essential for determination of biopolymer
structures.

Multiple-charged ions are also preferred for other newly-emerged

fragmentation techniques such as electron capture dissociation (ECD) [157-158] and
electron transfer dissociation (ETD) [159] because electron capture cross section is
proportional to the square of the ion charge.

Tandem MS - CID
The fragment ions produced from intact biomolecular ions can be used to deduce
the sequence of large biomolecules. A commonly employed technique in tandem MS
(MS/MS) for ion fragmentation is CID. In a CID experiment, a precursor ion is massselected by mass analyzer 1 (MS1) and focused into a collision region preceding a second
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mass analyzer (MS2). Inert gas such as N2 or Ar is generally introduced into the collision
region and collisions occur between the precursor ion and inert gas atoms (molecules).
The major fragmentation channel of electrospray-generated multiply-charged polypeptide
cations is the heterolytic cleavage of the peptide bond, yielding “b”, “y” type fragments,
as defined in Figure 1.8 [160].

Mass analyzers
In ESI-MS, different ion analyzers can be used.

Most common ones are

quadrupole [161], ion-trap [162], time-of-flight (TOF) [163], or Fourier-transform ion
cyclotron resonance (FTICR) [164]. The newly emerged hybrid quadrupole-TOF (QTOF) instruments [165] are widespread because of their full scan sensitivity, good mass
spectral resolution (> 8K) and mass accuracy (1-10 ppm), and the MS/MS ability to
select and fragment analytes using CID.

Solvent Characteristics
In conventional ESI-MS, the flow rate, applied voltage, conductivity, and liquid
surface tension must be properly balanced in order to accomplish the formation of a
stable ES spray. As for the solvent, besides its volatility, its surface tension should be
within the range that facilitates the generation of a stable spray. It is generally easy to
create a stable spray in the positive ion mode with conductive solutions that have at least
50% of a moderately polar organic solvent such as methanol or acetonitrile, and with the
rest of the solvent being water [166-171]. As the solution becomes more aqueous, its
surface tension increases, and it becomes increasingly more difficult to adjust the ES
parameters such that a stable spray can be achieved. In some cases, however, organic
content above about 80% can actually result in a decreased ES response [172]. This
decrease in response is likely due to the liquid surface tension being decreased below the
ideal for maximum spray stability. On the other hand, it is also difficult to achieve stable
ES operation with nonpolar liquids [173] such as hexane or trichloromethane, due to their
very low surface tension, high volatility, and low dielectric constant. Because spray
dynamics are highly dependent on instrumental parameters, the percentage of organic
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content that maximizes ES response will vary, depending on the parameters chosen.
Worth noting is that non-covalent interactions and protein conformations may be affected
by the incorporation of organic solvents. It is also worth noticing that nanospray can be
used to spray pure aqueous solutions from an emitter with an i.d. of ~1-3 m (as
compared with the 100 um i.d. capillary used in conventional ES) at as low as 0.2 nl/min
[174-176].

This technique not only reduces the consumption of samples, but also

enhances the concentration sensitivity due to higher ionization and/or sampling efficiency
[177].

ES ion source as a constant-current electrolytic cell
As mentioned previously, generated gas-phase ions in the ESI source are guided
to the counter electrode by the electric field. This flow of ions is collected as a current iES
(equivalent to the rate at which charge leaves the capillary in the form of charged
droplets) [130], as shown in Eqn. 1.1:
i ES = [(4π / ε ) 3 (9γ ) 2 ε 05 ](κE ) 3 / 7ν 4f / 7

Eqn. 1.1

where  and  0 are respectively the permittivity of the solvent and the permittivity of the
vacuum,  is the surface tension of the solvent,  is the conductivity of the solution, vf is
the flow rate, and E is the imposed electric field at the metallic tip [143, 178-179]. The
above equation is based on the experimental results of Pfeiffer and Hendricks [134] on
electrohydrodynamic spray, and later supported by semi-empirical derivations [131, 180182]. If the counterelectrode is large and planar, the electric field E is expressed as in
Eqn. 1.2:
E=

2V
r ln(4d / r )

Eqn. 1.2

where r is the capillary outer radius, V is the applied electric potential and d is the
distance from the capillary tip to the counter-electrode [130, 183-184]. The electric field
strength is typically ~106-107 V m-1 [130, 184].

From Eqn. 1.1 and 1.2, one can

concluded that that the ES current will increase with increasing applied potential which
was shown by Kebarle and Tang [143].

However, de la Mora et al derived and

experimentally verified an equation [185], where ES current was independent of the
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applied voltage as shown in Eqn. 1.3:
i ES = f (ε )(γκν f ε r )1 / 2

Eqn. 1.3

where f() is a function of the solvent dielectric constant (it is roughly equal to 18 for  
40, such as water and methanol) [185-186]. In Eqn. 1.3, it is seen that the charge
production is proportional to the square root of the volumetric flow rate. Therefore, the
excess charge available for a solute will increase as the flow rate increases.

For

sufficiently conducting solutions, the effect of the electric field can be neglected [182].
The magnitude of the ES current is typically not higher than a few hundred nA.
A phenomenon that has to be considered in order to fully understand ESI is its
electrochemical nature. This ionization source can indeed be seen as a special kind of
electrolysis cell, where the anode is the emitter and the counter electrode (usually the
atmospheric sampling aperture plate or inlet capillary and the various lens elements and
detector of the mass spectrometer) is the cathode (reversed polarity in negative ion mode)
[178, 187-188] (Figure 1.9). The conduction through this cell is supported by the motion
of the ions in the solution and then in the gas phase before reaching the counter electrode.
In this electrochemical flow cell, the limiting step is the droplet ejection that determines
the ES current (iES).

From an electrochemical standpoint, the ES source can be

considered as a controlled-voltage electrochemical cell, but since the resistance of the gas
phase is very large (on the order of G) and the charge separation process controls the
current in the circuit, ES ion source is often called a controlled-current electrolytic (CCE)
cell [187].

To sustain the production of charged droplets from the ES source,

electrochemical reactions must occur at the conductive contact to the solution. Oxidation
reactions in positive ion mode and reduction reactions in negative ion mode dominate at
the emitter electrode, whereas reduction reactions in positive ion mode and oxidation
reactions in negative ion mode dominate at the counter electrode. A brief list of the
electrochemical reactions on the ES electrode is shown below.
In the oxidative mode
•

Oxidation of metals like Cr and Fe present in the electrode. For example:
Cr → Cr3+ + 3e- (Eº = -0.74V vs. SHE [189])

Eqn. 1.4

Fe → Fe2+ + 2 e- (Eº = -0.443V vs. SHE [189])

Eqn. 1.5
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Figure 1.9. Schematic presentations of electrochemical processes in positive-mode ESI.
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Fe → Fe3+ + 3 e- (Eº = -0.036V vs. SHE [189])
•

•

Eqn. 1.6

Oxidation of solvents like water and methanol. For example:
2H2O→O2+4H++4e- (Eº = 1.229V vs. SHE [189])

Eqn. 1.7

2H2O→H2O2+2H++2e- (Eº = 1.776V vs. SHE [189])

Eqn. 1.8

H2O→O(g)+2H++2e- (Eº = 2.42 V vs. SHE [189])

Eqn. 1.9

Oxidation of analytes and other solutes

In the reductive mode
•

Reduction of solvent. For example:
2H2O + 2 e- → H2 + 2OH- (Eº = -0.828V vs. SHE [189])

•

Eqn. 1.10

Reduction of analytes and other solutes
The law of continuity of the current implies that the Faradaic current iF associated

with the oxidation of species from the electrolyte solution at the anode is always equal to
the spray current iES. Those species with the lowest oxidation potential will be first
oxidized, then if the current level is sufficient, compounds with a higher oxidation
potential will then undergo oxidation, in order to keep the current flowing [178]. The
Faradaic current is usually controlled by the diffusion of the reactants to the electrode,
and is given by the following equation [169]:
iES = iF = F  ni Ciν

Eqn. 1.11

i

where ni is the number of electrons involved in the electrochemical reaction of one
molecule of species i, Ci is the concentration of species i, v is the solution flow rate
through the ES capillary, and F is the Faraday constant (96,485 C mol–1).
Electrochemical events associated with ES ionization have been investigated by
Van Berkel's group [178, 190-193]. The controlled-current electrochemical behavior, as
well as the relation between the spray current and the applied electric field, proposed by
Pfeifer and Hendricks (Eqn. 1.1) [130], were later confirmed experimentally by Van
Berkel et al. [194], and Bateman [195].
The electrochemical reactions that take place in the ES emitter can alter the
composition of the solution being electrosprayed [196-197].

These changes include

modification in the mass or charge of the original analyte present in solution, changes in
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solution pH through electrolytic H+ or OH- production/elimination, and/or the
introduction/elimination of specific species to/from solution (e.g., introduction of Fe2+,
ions from corrosion of a stainless steel emitter) [198-199]. These reactions also include
electrochemical ionization that can be exploited to ionize neutral and non-polar
electroactive analytes that would otherwise go undetected in ESI-MS [200-202].
Reactions of the latter types might be troublesome for analyses involving unknown
analytes or quantification. The ability to control the extent of any or all of these analyte
electrochemical reactions would be an analytical advantage [178, 200, 202-204]. As far
as the induction of pH change due to the electrochemical behavior of ES, the relevant
concentrations of protons can be estimated from Eqn. 1.12 [197]:

[ H + ]e or[OH − ]e = i ES / ni Fν

Eqn. 1.12

Where [H+]e or [OH-]e represent the eletrolytically generated excess concentrations and
others are defined above. It was demonstrated that this shift could attain 4 pH units
decrease in a non-buffered system [197]. As seen from Eqn. 1.12, this trend is highly
dependent on flow rate and iES.
Regardless of the interface used, the electrochemical reactions need to be
considered by the scientist in order to understand the properties of the ES source. Also,
any mass spectrometrist should keep in mind that electrochemical processes involved in
electrospray ionization are likely to induce changes in the analyte solution composition.

Corona Discharge
As mentioned previously, ES process is the dispersion of a liquid into electrically
charged droplets and, as such, combines two processes: droplet formation and droplet
charging. The formation of small, micrometer-sized drop does not present a problem if
the liquid’s flow rate, surface tension and electrolyte concentration are low. An increase
in one or more of these variables makes it more difficult for the electric field to produce
the desired charged aerosol for MS. The electric field strength at the sprayer tip can be
increased to try to overcome the adverse effects of the aforementioned three variables,
but too high an electric field will give rise to a corona discharge (electric discharge)
accompanying the ES process.
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Corona discharge in ES is a phenomenon that has been described by Yamashita
and Fenn [139-141]. A corona discharge is a process by which a current develops
between two high-potential electrodes in a neutral fluid, usually air, by ionizing that fluid
so as to create a plasma around one electrode, and by using the ions generated in plasma
processes as charge carriers to the other electrode. Corona discharge usually involves two
asymmetric electrodes, one highly curved (such as the tip of a needle, or a narrow wire)
and one of low curvature (such as a plate). The high curvature ensures a high potential
gradient around one, for the generation of a plasma. Corona discharge depends on the
applied voltage, and the size, shape and spacing of the two electrodes. In ES, when a
high voltage is applied to the sharp tip of the electrode, a corona discharge is set up if the
voltage gradient exceeds the dielectric breakdown threshold of the medium in the gap.
Spray current is normally below 1 µA, while the discharge current quickly rises to 1 µA
or more.
Corona discharge is particularly troublesome in the formation of negatively
charged droplets. In the negative-ion mode, the sprayer tip is at a high negative potential
with respect to other parts of the source, and field emission of electrons from the sharp
spray needle or from the solution cone (the Taylor cone, [130, 205]) is a facile process.
Electrons are accelerated by the electric field between the sprayer and the surrounding
source walls and ionize the mixture of gases and solvent vapors in the source. The corona
discharge can be quenched by the capture of electrons by means of an electronscavenging gas, such as oxygen [140], N2 doped with Freon [206], SF6 [207], or the
vapor of a chlorinated solvent [208].

1.2.2

MALDI-MS
MALDI was introduced in the late 1980s by the group of Hillenkamp [209-210].

A related concept was developed independently by Tanaka and co-workers at the
Shimadzu Corporation in Kyoto, Japan [211]. Since MALDI is also a soft ionization
method like ESI, it can be used to obtain molecular weights of biomolecules with little or
no fragmentation [209-210]. In MALDI, the analytes are mixed with a solution of
matrix, and the mixture is then co-crystallized on a target plate. A pulsed laser beam
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irradiates the co-crystal on the target causing desorption and ionization of the matrix
containing the sample molecules. The matrix absorbs the energy from the laser. Energy
is subsequently transferred to the analyte that becomes desorbed into the gas phase. The
ionization mechanism is not fully understood and several suggestions are still debated
[212]. A diagram of the MALDI process is shown in Figure 1.10.
MALDI produces mainly singly charged ions, and this feature means it is
excellently suited for analysis of complex biological mixtures such as protein digests
[213]. The MALDI ionization process is less sensitive to salts than is electrospray
ionization [214-215]. Nevertheless, salts and other impurities will cause peak broadening
with the formation of adducts. This will lower mass accuracy and limit sensitivity [214215]. Due to its pulsed nature, the MALDI source has traditionally been coupled to TOF
mass analyzers, which have no theoretical upper limit to the m/z ratio. For example,
biopolymers with a mass of >300 kDa can be analyzed by this technique [216]. The
introduction of delayed extraction [217-219] and the mass reflectron [220] has helped
increase the resolution and sensitivity of MALDI-TOF-MS dramatically. High-mass
capability and high detection sensitivity are hallmarks of the MALDI-TOF-MS
combination. In summary, simplicity, high mass accuracy (typically ± 0.1%, and ±
0.01% for polypeptides below 10 kDa), theoretically unlimited mass range and extreme
sensitivity (pmol to subpmol range) have made MALDI-TOF-MS an excellent method
for routine mass analysis of biomolecules [221-224].

1.3 HDX-MS for Characterization of Proteins
1.3.1

History of HDX
In the mid-1950s, Linderstrøm-Lang and colleagues first introduced HDX and

described the relationship between the rate of HDX and protein dynamics mathematically
[225-227]. During the 1960s, the advent of liquid scintillation technology spurred the use
of hydrogen/tritium exchange (HTX) to study native protein exchange rates and the
amount of isotopic exchange within a sample could be determined [228]. In the 1980s,
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Figure 1.10. Schematic description of the MALDI process.
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labeled proteins were enzymatically digested and separated by HPLC prior to analysis
with liquid scintillation analysis. This improved the spatial information obtained with
HTX [229].
Because of the increase in the mass of a protein (one Da increase for each
hydrogen exchanged by a deuterium), mass spectrometry is an ideal technique to study
HDX [230-247]. Zhang and Smith [233] were the first to combine HDX with fast atom
bombardment mass spectrometry (FAB-MS), while Katta and Chait were the first
investigators to use the HDX-ESI/MS combination to probe the conformational changes
in proteins [232]. Johnson and Walsh [234] first reported the coupling of LC with ESI
for HDX studies. Although ESI is now the most commonly used mass spectrometry
approach to monitor HD isotopic exchange rates, MALDI can also be combined with
HDX to probe conformational exchanges in peptides and proteins [238-241]. HDX-MS
has become an essential tool to examine protein structure, protein dynamics, protein
stability, protein modification and aggregation, protein-ligand interactions, protein–
protein interactions and protein–DNA/RNA interactions [242-247].
Besides the combination with MS, the HDX and NMR combination has been a
great asset in determining the conformational dynamics and intermediates [248-253].
NMR has the advantage of providing structural and dynamic information at the siteresolved level.

Its disadvantages, however, include molecular weight limitations (<

30K), problems with analyzing complexes containing paramagnetic ligands, difficulties
with correlating site-specific dynamics with distinct conformers, and the need for
relatively high protein concentrations (typically 0.5 – 3 mM) and high purity [254-255].
By contrast, mass spectrometry methods require relatively little protein (micrograms at
most), mass measurements can be exact and up to 106 Da, and information is obtained
almost instantaneously [256]. Moreover, mass spectrometry is unique in that it measures
differences in individual populations within the bulk solution, whereas NMR is a sample
average technique.

HDX-MS is capable of detecting and characterizing individual

conformational states that may co-exist in solution at equilibrium.

HDX-MS in

conjunction with fragmentation procedures either in solution or in the gas phase has made
it possible to obtain residue-specific information, potentially competing with NMR as a
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high-resolution structural probe [242-247].

1.3.2

Theory of HDX
Exchange of protons between a protein and the surrounding aqueous solvent

occurs as a spontaneous chemical process. With respect to HDX, there are basically three
categories of hydrogen atoms in proteins [230, 257]. The first category is hydrogen
atoms covalently bonded to carbon, which essentially don’t exchange.

The second

category is hydrogen atoms in the side chains bound to N, O, or S, which exchange so
rapidly that their exchange rates can not be measured by isotope exchange methods. The
third category of hydrogen atoms is those attached to the amide positions in the protein
backbone, and it is these hydrogen atoms that are monitored with HDX. Each amino
acid, except proline, contains one amide hydrogen atom, which means that amide
hydrogen exchange rates can be investigated more or less along the entire protein
backbone. The intrinsic exchange time can range from milliseconds to many years and
the opening of the secondary and tertiary structures of a protein may increase the amide
hydrogen exchange rate by as much as 108 [258]. The variation in exchange change rates
reflects the diversity of local environments for individual amide hydrogens. Solventexposed amide hydrogens will readily exchange protons with water, while the slower
exchange rates are obtained for amide hydrogens located in hydrogen-bond-participating

-helixes and -sheets, and the hydrophobic core of a protein (where access to solvent is
limited) [259]. Besides a protein’s structure, the intrinsic rate of exchange for a particular
proton also depends on the experimental variables such as temperature and pH, and local
inductive or steric effects caused by adjacent amino acid side chains [260]. Implicit in
many HDX studies is the assumption that isotopic labeling does not affect the overall
properties of the protein. However, such an assumption may not always be correct [261263]. For example, Connelly et al. showed that the presence of different isotopes in
hydrogen-bonded positions may affect hydrogen bond strength; the effect on local
stability and HDX rates may be minimal, but the effect on global stability may be
significant [261]. Cioni et al. claimed that D2O significantly increases the rigidity of
most protein structures; the structure tightening effect is generally amplified by the
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increase of temperature as well as by the de-stabilization of the folded state (the folded
state is more stable in D2O than in H2O) [262]. Scheiner et al. reported that stability of H
bonds and D bonds are different in the gas phase (raising the temperature tends to
stabilize H bonds over D bonds); the difference may persist in solution [263].
Hydrogen exchange in proteins is catalyzed by H+ and OH- ions. The intrinsic
chemical exchange rate constant (kin) is the sum of the rate constants for acid (kH) and
base-catalyzed (kOH) reactions, as indicated in the following equation [260]:
kin = kH [H+]+ kOH [OH-]

Eqn. 1.13

Detailed studies of amide hydrogen exchange in polyalanine model compounds indicate
that kH and kOH have values of 41.7 and 1.12 ×1010 M-1 min-1, respectively, at 20 ºC and
low concentrations of salt [260]. As a typical example, Figure 1.11 shows the effect of
pH on the exchange rate for the unprotected amide hydrogen in polyalanine [260]. The
resulting V-shaped plot has a minimum around pH 2.7. For values greater than ca. pH 5,
kin increases by a factor of ten with each unit of pH. The high pH sensitivity of isotopic
exchange rates indictates a need for careful control of pH in all hydrogen exchange
experiments. Furthermore, this sensitivity is the basis for quenching isotopic exchange,
thereby facilitating determination of exchange rates by mass spectrometry. The exchange
rate also decreases as the temperature decreases; it changes threefold for each 10 ºC
change [260].
Currently accepted mechanisms for protein amide HDX involve two types of
reactions [230]: (i) reversible protein unfolding that disrupts the H-bonding network or
burial of amides, thus exposing them to bulk solvent, and (ii) isotope exchange at
individual unprotected amides.

Folded (H)
k ex =

k1
k-1

Unfolded (H)

kin
k-1
Folded (D)
Unfolded (D)
D2 O
k1

k1 k in
(k −1 + k in )

Eqn. 1.14

In the general case, the overall HDX kinetics is determined by both reactions. The rate
constant ( k ex ) of the overall process is given by Eqn. 1.14, where k1 , k −1 and k in are the
rates of the protein unfolding, folding and the intrinsic exchange rate constants. Usually
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Figure 1.11. Plot of the rate constant for isotopic exchange of hydrogen located on
peptide amide linkage in polyalanine as a function of pH, based on Eqn. 1.13.
(Reproduced from Ref. [260]).
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two ideal limiting cases are considered [230, 243]: if the protein refolding rate constant
k −1 is small compared to intrinsic exchange rate kin (i.e. k −1 << k in ), all of the amide

hydrogens undergo isotopic exchange during one folding event.

This exchange is

commonly referred to as EX1 (correlated exchange) and is described in Eqn.1.15:
Eqn. 1.15

k ex = k1

Hydrogen/deuterium exchange via EX1 kinetics leads to a mixture of peptide molecules
with regions that either have no deuterium or fully deuterated.

Consequently, peptides

that are deuterated under EX1 conditions have bimodal isotope patterns in MS that can be
described by two binomial distributions (Figure 1.12) [264-267]. Under conditions that
obey EX1 kinetics [268], the exchange rate constants for unfolding proteins, k1 (= k ex ),
can be determined by fitting the expression in Eqn. 1.16 to the experimental MS data.
The unfolding equilibrium constant, K (= k1 / k −1 ), can be determined from the steadystate populations of folded and unfolded forms (assessed using relative intensities of the
corresponding peaks). The concentrations of folded ([F]) and unfolded ([U]) forms under
non-equilibrium conditions are again determined by the relative intensities of the
corresponding peaks in the mass spectra at time t [269]:
[U ] = [ K /( K + 1)][1 − exp(− k1 ( K + 1) / K )t ]

Eqn. 1.16

If protein refolding is much faster compared to the intrinsic exchange (i.e. k −1 >> k in ), the
opening and refolding of a protein will occur many times before any isotopic exchange
takes place and the overall exchange will follow more complex kinetics governed by both
the unfolding equilibrium and the intrinsic rate (Eqn. 1.17), or the so-called EX2
mechanism or uncorrelated exchange.

k ex = (k1 k in ) / k −1 = Kk in

Eqn. 1.17

Hydrogen exchange via EX2 leads to a random distribution of deuteriums among the
peptide molecules or binomial isotope patterns in MS (Figure 1.12).
Protein amide HDX under native conditions occurs almost exclusively via the
EX2 mechanism [242]. On the other hand, if the native state becomes destabilized by
altering solvent conditions either with extremes of pH or the presence of detergents, then
the EX1 mechanism becomes more favorable. However, it is likely that both
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(a)

(b)

(c)

Figure 1.12. Distinctive isotope patterns characteristic of EX2 and EX1 kinetics. (a) A
protein exhibiting EX2 kinetics. A single envelope is obvious. (b) A protein exhibiting
EX1 kinetics; the overlap between the two envelopes is severe. (c) A protein exhibiting
EX1 kinetics and clear separation of the two envelopes.

0% and 100% refer to

respectively fully protonated and fully deuterated control samples.
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mechanisms operate simultaneously in a protein having regions that are in the native state
and others undergoing slow local unfolding and refolding [269]. A more extensive
review of hydrogen exchange kinetics is provided by Clarke and Itzhaki [269].
The use of hydrogen isotopes in proteins and solvent may impose a variety of
effects on measured HDX behavior. Kinetic isotope effects (a variation in the rate of a
chemical reaction when an atom in one of the reactants is replaced by one of its isotopes)
modify exchange rates, and therefore can affect measurements of protein stability. An
equilibrium isotope effect occurs when the hydrogen isotopes used partition unequally
between protein and solvent so that the isotopic ratio in the protein (i.e., proteinD/protein-H) is unequal to solvent-D /solvent-H at exchange equilibrium), and therefore
may affect the number of protein sites measured when isotopic species compete in a
labeling experiment. Solvent isotope effect is the difference between catalysis by OHand OD- and it depends on the relative basicities of these species, and may lead to
exchange rates in H2O different from those in D2O. These isotope effects in the peptide
group HDX reaction were investigated by Connelly et al. using poly-DL-alanine as the
test analyte [261]. It was found that kinetic isotope effects in amide hydrogen exchange
are small because exchange pathways are not limited by bond-breaking steps, but depend
on the concentration of the solvent species (H+ or D+ and OH- or OD-) and their diffusion
coefficients which are very similar for similar species. This is because formation of the
hydrogen-bonded encounter complex is diffusion-limited.

Only small equilibrium

isotope effects, which can lead to an excess equilibrium accumulation of the heavier
isotopes by the peptide group, were observed. Since HDX experiments are normally
done in solvents that are close to 100% of either H2O or D2O, equilibrium isotope effects
are not easily detected. For the solvent isotope effects, results show nearly identical rate
constants for acid catalysis of NH and ND in H2O. However, the exchange of NH is
faster by 2-fold in D2O than in H2O because D3O+ is a stronger acid than H3O+. For basecatalyzed exchange of NH and ND by OH-; rate constants decrease slightly in the order
NH > ND.
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1.3.3

HDX-ESI/MS

Method Overview
Although continuous FAB-MS was used for the earliest HDX-MS measurements
[233], electrospray ionization (ESI) is the preferred and most commonly used method to
produce ions from deuterated samples for subsequent mass spectrometric analysis
because of its high sensitivity and facile coupling to HPLC. Several mass analyzers,
including magnetic sector, quadrupole, ion cyclotron resonance, and ion trap, have been
used successfully for HDX-MS.
Several different approaches are used to determine the amide hydrogen exchange
rates. Continuous labeling and pulsed labeling are two common approaches [272-275].
In continuous labeling experiments, a fully protiated protein is incubated in D2O (or a
fully deuterated protein is incubated in H2O), and at various times the reaction is
quenched by moving an aliquot of sample to a quench buffer. Thus, the protein is
exposed to D2O while the populations of folded and unfolded states are changing.
Molecules or regions that are or become unfolded during the labeling time may be
completely deuterated depending on their kinetics and molecules that did not unfold
during this time have less deuterium. Deuterium levels in proteins labeled continuously
effectively integrate the number of molecules that unfold during the labeling time, which
may be as short as milliseconds or as long as days. In continuous labeling, a cumulative
summary of the populations of the molecules is evident in the spectra. Continuous
labeling is useful for looking at populations of protein molecules under conditions where
the folded state is favored since the minor contribution of the unfolded states is integrated
over time. Experiments of this kind can provide information on the conformational
dynamics of a protein under equilibrium conditions [270-273].
In pulsed-labeling experiments, the protein is put under specific conditions for a
period of time (i.e. in denaturant for 30 minutes). Then a short pulse of deuterium
(typically 10 ms) is introduced and the reaction is quenched.

In pulsed-labeling

experiments, the exposure of the protein to D2O is short relative to the time scale of the
folding/unfolding dynamics and the time required for isotope exchange in the folded form
of the protein. Failure to meet the latter requirement may lead to poorly resolved
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envelopes of isotope peaks. Since little unfolding or folding occurs during the labeling
step, the deuterium levels resulting from pulsed labeling indicate the instantaneous
populations of folded and unfolded molecules.

In pulsed-labeling, an instantaneous

snapshot of the protein populations is evident. Pulsed labeling is useful for measuring the
unfolding (starting with folded proteins) and refolding (starting with unfolded proteins)
rate constants in conditions where the population of the unfolded state has been
artificially increased by addition of denaturant, heat or pH changes [274-275].
Both continuous labeling and pulsed labeling can be used to study global as well
as localized structural changes. The technical details of these two strategies will be
described next.

(a) HDX for detection of global changes in proteins
Continuous labeling & indirect MS analysis (with HPLC separation prior to MS analysis)
Using the continuous labeling technique, the unfolding ( k1 ) and folding ( k −1 )
kinetics of an intact protein can both be studied. In a typical ESIMS procedure for the
measurement of the rate constant for the folding process, the protein is dissolved in D2O
buffered to the desired pD [276]. The solution is heated (>=75 ºC) to ensure that the
protein is completely unfolded. For proteins that can’t withstand the extreme of higher
temperatures, the unfolding is achieved alternatively by adding a suitable denaturing
agent. Because of the unfolding of the protein, all amide hydrogens can be deuterated.
The fully deuterated protein is lyophilized, and redissolved in D2O. The exchange is
initiated by diluting (100-fold) the concentrated D2O solution of the protein with H2O
that has been adjusted to the desired pH. The samples are withdrawn at several time
points, and analyzed by ESIMS.
To study the kinetics of the unfolding process, lyophilized folded protiated protein
is dissolved in D2O at a pH where folded and unfolded states coexist [276]. Samples are
withdrawn at different time intervals, and are analyzed by ESIMS.

The unfolding

process can be measured with a different approach. In this case, the protiated protein is
first dissolved in a H2O solution that was adjusted to an appropriate pH where the protein
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is not denatured, and the labeling is achieved by diluting the protein with an excess of
D2O solution of the same pH.
For the aforementioned experiments, a sample cleanup, typically done by HPLC,
is essential prior to ESI-MS analysis to remove excess buffer, salts and high
concentrations of denaturants required to destablize the protein. This strategy poses a
problem because long chromatographic runs can result in higher levels of artifactual
exchange (loss or gain of deuteriums, discussed in more details later) because the eluting
solvents in HPLC contain water and organic acid (typically formic acid or TFA) [233,
236, 247].

Continuous labeling & Direct MS analysis (without HPLC separation prior to MS
analysis)
HPLC separation can be eliminated in some experimental strategies.

For

example, ESI-MS-based online HDX experiments are used for continuous labeling
experiments on the millisecond time scale [277-279]. This approach provides a powerful
tool for monitoring protein structural dynamics under mildly denaturing equilibrium
conditions by correlating three complementary structural probes: the ESI charge state
distribution, ligand binding state, and isotope exchange kinetics.

In this technique, the

ESI mass spectrum of the protein is recorded at different time intervals after initiation of
HDX in a continuous-flow apparatus involving rapid online mixing. Labeling of the
protein is initiated by exposing the protein solution to a D2O buffer solution at a basic pH
where the protein is partially denatured, and where the chemical exchange step is fast,
thus favoring EX1 exchange. Specifically, the protein solution and the D2O buffer
solution are driven separately through two separated narrow fused silica capillary tubes
by two syringe pumps and mixed in a low dead volume mixing Tee. Varying the length
and/or the i.d of the reaction capillary that is connected between the mixing tee and the
ESI source controls the labeling time.

The experimental setup for the study of

conformational dynamics of partially denatured myoglobin is shown in Figure 1.13 [279].
Kheterpal and Cook developed a similar technique which has been successfully
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Syringe 1: Mb in 73/27
(v/v) H2O/MeCN
(pH 9.3)

Labeling Capillary
Mixer

ESI-MS

Syringe 2: 73/27 (v/v)
D2O/MeCN
(pD 9.3)

Figure 1.13. Schematic diagram of continuous-flow setup used for time-resolved ESIMS with online HDX study of partially denatured myoglobin (Mb).

The pH was

adjusted to 9.3 using NH4OH in syringe 1 and ND4OD in syringe 2. (Adapted from Ref.
[279]).
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used to study insoluble amyloid fibrils without resorting to HPLC [58-59]. The general
methodology is illustrated in Figure 1.14.

The experimental setup involves a tee

connected to a standard coaxial electrospray probe. They have monitored the kinetics of
deuterium exchange into fibrils by a process involving on-line mixing of a fibril
suspension undergoing slow deuteration with a quenching/disaggregating/dissolving
solvent (50:50:0.2 (v/v/v) water/acetonitrile/formic acid) followed by immediate infusion
into an ES source, within 10 s. The elimination of salts and buffer is achieved prior to
MS analysis by spinning down the insoluble fibrils in a centrifuge and decanting the salt,
then re-suspending the fibrils in the 2.0 mM Tris buffer, which appears to be compatible
with MS. Experimental details will be presented in Chapter 2.

Pulsed labeling in a quench-flow setup with off-line MS analysis
HDX in the pulsed-labeling technique is traditionally studied in a quenched-flow
apparatus [276, 280]. This approach is well suited to determination of the isotopic
exchange rates of rapidly exchanging amide hydrogens. The mass spectrometry-based
pulsed-labeling approach has been modeled on NMR studies of a similar nature [281282]. With the pulsed-labeling procedure, the protein is first dissolved in D2O in which a
strong denaturant is present. The unfolded and deuterated protein in a D2O buffer is
injected into a quench-flow system similar to that shown in Figure 1.15, and the refolding
is initiated by mixing (at the mixing tee marked T1) the injected protein solution with a
large excess of a denaturant-free H2O solution that is typically buffered to pH 5-6. The
length of the folding time (millisecond to seconds) in the quench-flow appraratus can be
controlled by varying the size of the folding tube. After this folding period, an exchange
pulse is applied by mixing (at T2) the protein solution with a basic pH (>7.0) H2O
solution. The labeling time is typically 10 ms and the labeling is achieved typically by
10- or 20 –fold dilution of the protein solution with the labeling reagent (such as H2O).
Because the rate of hydrogen exchange is very fast above pH 7, the exposed deuteriums
will now be exchanged essentially instantaneously. The sites where deuteriums are
retained represent the folded structure. The next step is to quench the labeling by
acidification of the solution (at T3). The spatial H/D distribution of each protein reflects
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Deuteriumlabeled
Fibrils

2 mM Tris/D2O
(pD = 7.5)

Aβ
β
Fibrils

(H)

(D)

Processing Solvent (pH 2 - 3)
- quench exchange
- dissociate fibrils

H/D mix
(pH = 2 - 3)

Mass
Spectrometer

Data Analysis

Figure 1.14. Flow chart depicting HDX methodology developed by Kheterpal et al. [58].
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H2O (pH 9)

Unfolded and
deuterated protein
in D2O

Quench buffer
(pH 2.2, 0oC)

Exchange
pulse

T1 Folding
T2

T3
HPLC/ESI-MS

H2O buffer

Figure 1.15. Schematic diagram of quench-flow apparatus that can be used in the pulsed
labeling technique.
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its conformation at the time of the labeling pulse. The isotope-exchange patterns are
subsequently studied off-line by MS. It is noted that the quenching step is necessary
because exchange would quickly start to occur in protected regions of the protein because
the exchange is fast at pH > 7, as can be seen from Figure 1.11. Moreover, a HPLC
cleanup step (involving protic solvents) prior to MS analysis is usually performed. Worth
noting is that the reverse experiment in which a protiated protein is dissolved in H2O
solution of a denaturant, and subjected to a short exchange pulse with an excess of D2O
solution, can also be performed in a similar manner.

Pulse labeling in continuous-flow setup with on-line MS analysis
In traditional pulse-labeling experiments, quenching, desalting and MS analysis
are performed off-line, making sample handling more labor intensive and limiting
reproducibility. Recently, Simmons & Konermann have shown that time-resolved ESIMS can be used to analyze pulse-labeled proteins on-line, quasi-instantaneously after
labeling [283]. Instead of terminating isotope exchange through a rapid mixing step in
traditional pulse-labeling experiments, the protein solution was injected directly into the
ESI source of the mass spectrometer. Here, HDX is quenched by analyte desolvation on
a time-scale of 1 msec [284-285]. With this approach, the different charge- and ligandbinding states in the ESI mass spectrum are directly correlated with the HDX levels
observed for each peak. This technique, therefore, allows the exchange behavior of
different protein conformations and different ligand-binding states to be monitored with
an extremely high selectivity. The experimental setup is shown in Figure 1.16. It should
be noted that the use of urea, guanidinium salts, or other nonvolatile solvent additives can
be incompatible with ESI-MS. The use of other refolding triggers such as a pH jump or a
temperature jump may be alternatives. The combination of a continuous-flow setup with
on-line dialysis techniques for rapid de-salting may increase the versatility of the on-line
approach [286].

(b) Determination of hydrogen exchange in short segments of proteins
Although substantial information can be obtained by examining the exchange
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Reaction
Capillary
Syringe 1: aMb in 1%
Acetic Acid

t = 0.09-1.9 s t = 7 m s
ESI-MS
Mixer 1

Syringe 2: Heme in 5%
NH4OH

Labeling
Capillary

Mixer 2

Syringe 3: D2O

Figure 1.16. Schematic diagram of continuous-flow setup used for time-resolved ESIMS with online pulse-labeling HDX study of myoglobin (Mb) reconstitution (formation
of native holomyoglobin from free heme and unfolded apomyoglobin (aMb)).
(Reproduced from Ref. [283]).
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pattern of the intact protein, it is possible to increase the structural resolution of the
experiment by examining exchange into localized segments. Smith and his associates
introduced a proteolytic step under quench conditions (i.e. rapid proteolytic digestion at 0
ºC and pH 2.5, where kin is minimal in Eqn. 1.15) prior to mass analysis [233, 268, 287].
A HPLC separation step is usually employed before mass analysis not only to remove
buffers and denaturant, but also to reduce peptide overlapping. The larger the protein, the
greater the likelihood that overlapping peaks of fragments will be produced, a problem
that is exacerbated as their isotopic envelopes broaden and perhaps even cross one
another during exchange.
A typical continuous-labeling procedure used in the protein fragmentation-mass
spectrometry approach is illustrated in Figure 1.17. In this protocol, the folded protein is
incubated in a D2O solution at an appropriate pD for a defined time interval. At the end
of the defined time interval, the exchange process is quenched by adjusting the pD to ~
2.5 and the temperature to 0 ºC. Next, the protein is digested with proteases (enzyme
solution or immobilized enzyme column) at an acidic pH. Peptide fragments in the digest
are measured with HPLC on-line with continuous-flow FAB [233, 288-289] or ESI-MS
[234-235, 290-291].
The pulsed-labeling approach can also be used to study the isotope exchange
reaction in short segments of a protein [234-235, 292-293]. A quench-flow apparatus is
used for these experiments. Also, an immobilized enzyme column is added to perform an
on-line peptide digestion. The proteolytic fragments are separated and analyzed by the
HPLC-ESIMS combination. A schematic diagram of this method apparatus is shown in
Figure 1.18.

Data Analysis
(a) Interpretation of mass spectra (EXI vs. EX2)
The type of exchange kinetics occurring for a protein or a region of the protein
(obtained from proteolysis) determine how the data are processed [230]. HDX via EX2
kinetics gives a binomial distribution of isotope peaks (a single envelope) (Figure 1.12),
from which the centroid or average mass can be determined. HDX via EX1 kinetics
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Protein
Dissolved in D2O buffer
(pD 7.2)
Deuterium-labeled Protein
Add quench buffer
(pH 2.4, 0oC)
Digest with pepsin
(pH 2.4, 0oC)
Peptide Fragments
HPLC/ESI-MS analysis
Deuterium Content of Each Fragment

Figure 1.17. Flow chart of a typical procedure used to determine deuterium levels at
peptide amide linkages in short segments of intact proteins following HDX.
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T3

Pepsin

Protein in H2O
(5 ul/min)

Quench buffer
(pH 2.2, 0oC)
Peptide
digestion

Hydrogen
T1 exchange
T2

HPLC/ESI-MS
D2O buffer
(100 ul/min)

Figure 1.18. Schematic diagram of quench-flow apparatus used in the pulsed-labeling
technique for the determination of HDX in proteolytic segments of proteins.

56

gives a bimodal isotope pattern, with two envelopes of mass appearance: (1) a low-mass
envelope, which indicates the non-exchanged population; and (2) a high-mass envelope,
which represents the exchanged population (Figure 1.12). The distance between the two
envelopes indicates the number of amide hydrogens involved in cooperative unfolding;
the relative intensity (area) of the two envelopes is directly related to the relative folding
and unfolding rate constant for the cooperative transition (as illustrated in Eqn. 1.16).
When the envelopes are completely separated, the average mass of each envelope can be
determined separately. If the two envelopes overlap, various computer programs (such as
Peakfit, SPSS software) can be used to estimate the relative intensities of incompletely
resolved envelopes.

(b) Correction for artifactual exchange
Even though experimental parameters are chosen to minimize isotopic exchange
at peptide amide linkages during sample workup for HDX studies, some artifactual
exchange (loss and gain of amide deuteriums) after quenching is unavoidable. In most
HDX experiments coupled with MS analyses, the exchange reaction is quenched with
acid, and then proteolytic digestion and HPLC/ESI-MS analyses are performed
immediately in undeuterated acidic solution to localize the deuterated region [235].
Since HPLC step is performed with protiated solvents, deuteriums from side chains and
amino/carboxy termini that exchange much faster than amide linkages are essentially
removed. Therefore, data obtained by this method should be interpreted cautiously.
Basically, two important sources of error during the LC-MS analysis of hydrogen
exchange must be corrected during data reduction. First, after quenching and during
digestion, deuterium in the reaction mixture continues to exchange with peptide
hydrogens, leading to forward exchange (gain of amide deuteriums, called artifactual inexchange). A second source of error is back-exchange, where deuteriums incorporated
into peptides exchange-out with hydrogen from water.

Deuterons may also back

exchange with water vapor during mass spectral analysis by ESI-MS [233] or with matrix
protons by MALDI-MS [238].

Simple adjustments can be made to correct these

artifactual exchanges, as described next.
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The method of Zhang and Smith [233] has been used widely for correcting back
exchange and further forward exchange of amide protons during HDX studies on globular
proteins and proteolytic fragments [234, 294-298]. In this approach, nondeuterated and
fully deuterated protein samples are analyzed using the same work-up (exchange-in
initiation, quenching exchange, HPLC separation and then MS analysis) as the incubated
(partially exchanged) sample, and the corrected deuterium content (Dcorr) in the backbone
amides of the target sample is then given by
Dcorr =

m − m 0%
×N
m100% − m0%

Eqn. 1.18

where m, m0%, and m100% are the observed average molecular weights of the same peptide
in the partially deuterated sample, in the zero time control and in the fully deuterated
control, respectively. N is the number of backbone amide hydrogens. The denatured
state of a globular protein is typically used to obtain a fully deuterated control. The zero
time control (m0%) is performed to measure the extent of artifactual forward exchange
occurring after quenching and during digestion, in which quenching buffer (pH 2.4) was
added to protein before D2O, with the same final ratio of D2O to acidic buffer as used in
experimental samples (partially deuterated peptides), followed by proteolysis and LC-MS
analysis. The 100% control (m100%) is conducted to measure the amount of backward
exchange, where the fully deuterated peptide is subjected to the same analysis as the
partially deuterated sample and the subsequent loss of deuteriums during the analysis is
measured.
Another method of correcting artifactual exchange was developed by Resing et al.
[299].

The forward-exchange-corrected peptide mass Mcorr

(FE)

is derived from the

following equations [299]:

M corr ( FE ) = (m − LFE M D ) /(1 − LFE )

Eqn. 1.19

LFE = (m0% − MW ) /( M D − MW )

Eqn. 1.20

where LFE is the fractional artifactual forward exchange, MD is the theoretical average
molecular weight of the fully deuterated peptide and MW is the theoretical average
molecular weight of the protonated peptide . (MD − MW) is equal to the total number of
backbone amides in a peptide excluding proline residues (having no amide proton). m
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and m0% are the same as previously defined. The fractional backward exchange LBE is
shown in Eqn. 1.21:
Eqn. 1.21

LBE = ( M D − m100% ) /( M D − MW )

Following an estimation of the forward exchange and backward exchange, the artifactualexchange-corrected mass of the protein Mcorr and Dcorr are given by the following
equations:
M corr = MW +

( M corr ( FE ) − MW )

Eqn. 1.22

1 − LBE

Dcorr = M corr − MW =

M corr ( FE ) − MW

Eqn. 1.23

1 − LBE

The two correction methods mentioned above are used for HDX experiments on
soluble or relatively soluble proteins involving HPLC separation prior to MS analysis.
There are used for correction of artifactual exchange occurring during quenching,
digestion (~30 s - 5 min) and HPLC separation. The whole process generally takes at
least 20 min [243].

These correction equations for data from soluble proteins are

considered to be accurate to approximately 5% (although deviations of >25% are noted in
some instances) [233, 299]. Resing et al. tries to account for the fact that FE and BE
exchange rates may not be equal to one another [299]. Both methods try to compensate
partially for the fact that these rates depend on the specific amino acids’ presence and
overall protein structure [233, 299].
There is one method which was developed in Cook’s group to correct for
artifactual amide exchange associated with direct on-line MS analysis of deuterated
insoluble amyloid fibrils without HPLC separation [58-59, 40].

The entire on-line

process (quenching, dissolution, and sampling) can be accomplished in < 10 s (Figure
1.14) [58]. The method is developed for treatment of data from experiments involving
solubilization before analysis. This method has been proved more proper for the 10-s
online analysis of insoluble intact amyloid fibrils than other correction methods reported
elsewhere [59]. This method involves two steps. First, artifactual exchange into rapidly
exchanging side-chains, terminal and ionization protons are corrected. These protons
exchange so rapidly that the final measured deuterium content should include an
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equilibrium distribution into these sites [58]. Therefore, the deuterium incorporation into
these sites reflects the percentage of water that is D2O in the final solvent composition.
For A(1-40) fibrils, there are totally 27 labile side-chain and terminal sites.
Consequently, the molecular masses which are corrected for side chains, terminal and
ionization protons will be calculated as {m/z × z - z - (z × %D2O) - (27 × %D2O)}(m/z:
mass-to-charge ratio; z: charge state, equal to the number of ionizing protons for A).
For example, when the fraction of water that is D2O in the T is 10%, a total of 2.7 (10%
of 27) deuteriums should be subtracted from the measured masses to correct for
artifactual exchange into side-chain and terminal protons, and a total of 0.1z (10% of z)
deuteriums needs to be subtracted from the measured masses to correct for artifactual
exchange into ionization protons. (Comment: If an HPLC step is used prior to MS
analysis, then the bulk solvent is generally 100% protonated. In that case, protons gained
during ionization and fast exchanging side-chain and terminal protons are not deuterated
and no extra correction for these protons is required.) Second, artifactual exchange into
backbone protons are corrected. This involves measuring forward exchange (FE, H
exchanged for D) and backward exchange (BE, D replaced by H) for fully protonated and
deuterated samples, respectively, using the same work-up conditions as the partially
exchanged sample of interest, and calculating the corrected deuterium content (Dcorr) in
the backbone amides of the target sample according to
Eqn. 1.24

Dcorr = m - MW + BE – FE

where m is the measured average molecular weight (after correcting for fast exchanging
protons as described above) obtained by mixing sample of interest in D2O with protiated
processing solvent, and BE and FE are as described next. Forward exchange is measured
by infusing the protonated form of the appropriate sample (fibrils, protofibrils or
monomer depending on the sample of interest) in protonated buffer into one arm of the T
in Figure 1.14 and mixing it with a “quenching” solvent containing sufficient D2O to give
a final solvent composition identical to that obtained in the analysis of the sample of
interest (Figure 1.9). Since the solvent mixture during sample processing is the sole
source of deuterium, this amount of exchange is the forward exchange taking place
during sample work-up, or
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Eqn. 1.25

FE = m0% - MW
where m0%

is the measured average molecular weight (after correcting for fast

exchanging protons as described above) of the forward exchange sample described
above, and MW is the measured average molecular weight of the monomer in protonated
fibrils. Note that the D2O percentage in the water component is determined by the
relative flow rates of the sample and processing solvent streams. For example, when
partially deuterated fibrils (the sample of interest) in D2O (0.5 µL/min) are mixed with
quenching solvent (9 µL/min of 50/50/0.5 [v/v/v] H2O/MeCN/HCOOH), then a final
sample mixture in which 10% of the water comes from D2O is produced. To obtain the
m0% value, protonated fibrils (0.5 µL/min) is mixed with quenching solvent (9 µL/min of
5.6/44.4/50/0.5 [v/v/v] D2O/H2O/MeCN/HCOOH) to generate a final solution after
mixing in the T in which 10% of the water content is D2O. (For convenience, we will
subsequently refer to this composition as 10% D2O, overlooking the acetonitrile. So we
can say 16.7% D2O in the protocols described in Chapter 2). The backward exchange
value is obtained by measuring the exchange of a fully deuterated sample treated with
protonated processing solvent. Fully deuterated fibrils and protofibrils are grown in
deuterated buffers as described in Chapter 2. If there were no back exchange taking place
during sample processing, 39 deuteriums would be measured for these samples. Any
deviation from 39 represents the amount of back exchange taking place during sample
processing, or
Eqn. 1.26

BE = MW + N – m100%

where m100% is the measured average molecular weight (after correcting for fast
exchanging protons as described above) of the fully deuterated sample and N is the total
number of backbone amide protons (39 for A (1-40)).
All the correction methods mentioned above are based on the assumption that the
amount of backward and forward amide exchange in the partially deuterated peptide is
identical to that observed in the fully deuterated and protonated same peptide [59].
Moreover, to some extent, they overlook the site specificity of the forward and backward
exchange rates [59]. All the above correction methods will be evaluated in terms of
performance for the analysis of HDX data of A fibrils obtained in this study; details
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will be presented in section 3.3.

(c) Calculation of rate constants
Following data correction for artifactual forward exchange and back-exchange
using one of the methods mentioned above, the number of incorporated deuteriums can
be plotted as a function of exchange time, from which one can estimate rate constants
describing isotope exchange. When the deuterium concentration in the solution is large
and the pH and temperature are constant, isotopic exchange of each amide hydrogen
follows first-order kinetics, i.e., the number of unexchanged hydrogens decreases
exponentially with time during the exchange period [299]. Although single amino acid
resolution is not generally possible, exchange rates describing groups of hydrogens with
similar exchange rates can be calculated. Rate constants can be fit to the experimental
data by using the equation 1.27 [230, 293, 300]:
N

Dcorr = N −  exp(−k i t )

Eqn. 1.27

i =1

where Dcorr is the corrected deuterium content of a peptide, N is the number of peptide
amide linkages in a segment, ki is the exchange rate constant for each amide hydrogen,
and t is the time allowed for isotopic exchange. Practically, the data is binned as fast-,
medium- and slow-exchanging populations. Rates and amplitudes are obtained for each
population.

The analysis can be executed using the computer program LAPLACE,

written and provided by Dr. Zhongqi Zhang [301-302].

High Resolution HDX-ESI/MS
HDX-MS coupled with proteolysis provides only medium resolution (10-20
amino acids) of localizing exchange sites, limited by the number and size of peptic
fragments. The resolution can be further increased by using tandem MS (MS/MS)
(generally with CID or ECD) to fragment the proteolytic peptides in the gas phase into
daughter ions leading to deuteration kinetics of individual amides [157-158]. Viability of
this approach has been demonstrated by several groups [235, 303-304]. Direct analysis
of the protein using MS/MS is an alternative approach [305-308]. Fourier transform ion
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cyclotron resonance mass spectrometry (FTICR-MS) will facilitate tandem MS analysis,
due to its high polypeptide ion fragmentation and detection efficiency, and the high
resolution and mass accuracy [305-308]. It is important to note that the gas-phase
fragmentation process, however, may be complicated by deuterium scrambling [235, 304,
309-313]. The extent of scrambling observed depends on the fragmentation technique
employed and the type of ion examined. For example, the b ions produced in a typical
CID MS/MS experiment appear relatively robust to scrambling, whereas the y ions
appear unreliable [304].
Non-specific proteolysis results in many peptides whose sequences may overlap.
Manual subtraction of the number of deuteriums incorporated into the overlapping
peptides can lead to increased spatial resolution for deuterium localization (within 2 to 3
amino acids) [299]. For example, overlapping peptic fragments 1-19 and 4-19 from
Aβ(1-40) can provide deuterium incorporation information for the peptide 2-4.
Therefore, another way to improve spatial resolution is to generate more proteolytic
fragments to improve the likelihood of peptide overlapping. One approach is to perform
enzyme digestion under slightly denaturing conditions [314].

Alternatively, peptide

overlap can be increased using multiple acid-stable proteases with differing specificities
[314]. Furthermore, if extensive disulfide bonding is a problem (preventing digestion
and/or resulting in liberation of large disulfide cross-linked peptides), inclusion of a
reducing agent can assist digestion [315]. Worth noting is that the more proteolytic
fragments are produced, the more likely their mass spectral peaks will overlap. The
utility of LC preparation can help reduce the problem. However, high level of back
exchange can be troubling with LC/MS.

1.3.4

HDX-MALDI/MS
Although ESI is the most commonly used mass spectrometry approach to monitor

HDX rates, MALDI has emerged as an alternative in this field [238-241]. The general
scheme for deuterium introduction prior to MS analysis is the same as that employed in
HDX-ESI/MS studies.

Only minor modifications of established MALDI sample

preparation protocols are required to carry out HDX experiments.
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To be specific,

exchange-in (incorporation of deuteriums) reactions involve dissolving lyophilized
protein or diluting concentrated protein solutions into D2O. The exchange process is
allowed to procceed for a certain period of time and is then quenched by addition of
acidified matrix solution at low temperature, and then followed by rapid drying of
samples on the MALDI target to insure minimal loss of deuterons from peptide amide
groups. Although the sample remains completely dry and is kept under high vacuum
during the analysis, the deuterium content of the peptides decreases gradually over time
[238-241]. A correction for the deuterium loss prior to mass analysis has been described
by Mandell et al. [238].

In this work, several replicate HDX samples were

simultaneously placed on a MALDI target and dried. Subsequent analysis of each sample
took 3–5 min. The measured number of deuteriums (Dmeas) decreased for successive
samples, tangentially approaching a value B1 at long sample analysis time (t). An
effective rate constant (k) for this decay process was determined by fitting Dmeas to a
single-exponential curve:

Dmeas = B1 + B2 e − kt

Eqn. 1.28

where B1 + B2 is the initial total number of amide deuteriums in the peptide prior to
sample work-up. Using values of B2 and k from the fit, the number of deuterons that
would have been present on the peptide (Dcorr) at any earlier analysis time (especially at t
=

0)

can

be

estimated

from

Dmeas

Dcorr = Dmeas + B2 (1 − e − kt )

at

a

given

analysis

time

as

Eqn. 1.29

This correction method will be evaluated in terms of performance for correcting HDX
data of A aggregates (see section 3.3).
HDX-MALDI/MS has become a standard tool for folding experiments carried out
under equilibrium conditions [238-241, 316-318]. HDX measurements of intact proteins
measured by MALDI-MS have provided insight into a variety of biological processes
[318-321].

A variation of the experiment employing varying concentrations of

denaturant has led to a methodology (termed SUPREX: stability of unpurified proteins
from rate of H/D exchange) capable of measuring stability against unfolding for both
purified and even crude proteins in cell extracts in a high throughput manner [316-318].
HDX-MALDI/MS has drawbacks of high back-exchange (30% - 40%) due to
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back-exchange with protons from the matrix, solvent or the water vapor in the
atmosphere, and lower coverage than ESI-MS due to less efficient ionization and overlap
of peaks in complex spectra [238, 240]. Efforts have been made to reduce back exchange
[323-325], such as using deuterated matrix solution, preparing samples and carrying out
exchange reactions under N2 flow [325], adjusting pH to the HDX minimum (pH 2.4),
cooling the sample target to -20 ºC before sample preparation, and using thin-layer
preparation to reduce sample preparation time. Another potential complication with
using MALDI concerns the identification of the peptide fragments. In favorable cases,
this can be done by exact mass matching or post-source decay (PSD), but more generally
it is necessary to do a separate tandem MS/MS experiment. The advent of MALDIMS/MS instruments will make online tandem MS available [326-327].
On the other hand, compared to standard ESI techniques, MALDI-MS clearly
affords the advantage of straightforward sample preparation (standard protocols
available), the tolerance to chemical denaturants and modifiers, the simple appearance of
the spectra (often dominated by singly charged ions), elimination of the HPLC separation
of proteolytic fragments before mass analysis, better sensitivity (at sub-picomolar level),
faster analysis times, and the potential for high-throughput assay [238-241, 316-318].
With the possible enhancement of spatial resolution through further fragmentation [328],
together with new developments in MALDI instruments and improvement in MALDI
experimental procedures, MALDI-MS will also become a standard tool for HDX kinetic
studies.
HDX/MALDI-MS has been utilized to study the aggregation kinetics of A (142), and C-terminally truncated peptides A (1-40) and A (1-36) [329]. However, for
the purpose of the study presented in this dissertation, only HDX-ESIMS is employed.

1.4

Enzymes for HDX-MS

As discussed in section 1.3.3, a key aspect of HDX-MS is the quenching of
isotope back exchange because digestion, as well as subsequent HPLC separation (if
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needed) and mass spectrometric analyses is realized in hydrogenated solvents and in
denaturating conditions (if employed) [233, 260, 300].

The quenching step is

accomplished at pH 2-3 and at (typically) 0 °C. Since the proteolytic step for localizing
deuterium distribution is introduced under quenching conditions, proteases working at
low pH and low temperature must be used. Pepsin-like proteinases (also classified as
aspartic proteinases), which typically have molecular weights in the range of 33,00035,000 Daltons and whose catalytic activity is due to the presence of two invariant
aspartic acid residues at the catalytic center, have optimum pH range of 1.5-5 [331-332].
Therefore, they could be used in HDX studies, given that they are readily available, costeffective, of good activity and produce characteristic fragmentation patterns. Detailed
information about various acid proteases can be found in the review by Dunn [333] and
on the website http://srdata.nist.gov/HIVdb.
Pepsin is most commonly used aspartic proteinase for HDX studies because of its
maximum activity at a pH of 2 – 4, good activity at low temperature, and easy availability
[233]. Moreover, this enzyme has no detectable effect on HDX rates [229]. Other
enzymes which have been employed for HDX studies include carboxypeptidases [314,
334], protease type XIII [237, 298, 314, 334], and protease type XVIII [237, 314, 334],
which all belong to peptidase family A1, the pepsin-like enzymes [363]. Using pepsin or
the other A1 proteases, sequence coverage is not always complete, and the spatial
resolution of the exchange rate is limited by the sizes of the resulting peptides (typically
10-20 amino acids). On the other hand, aforementioned alternative pepsin-like enzymes
can generate cleavage patterns very different from pepsin and from each other under
slowed exchange conditions [237, 314, 334].

It has been demonstrated that the

fragmentation patterns resulting from simultaneous and/or sequential proteolysis by
combinations of these enzymes are additive in their effect on fragmentation [237, 314,
334].

Therefore, pepsin-like enzymes may be used individually as complementary

experiments or together in a protease ‘‘cocktail’’. In this manner, rapid (30 seconds)
high-resolution localization of deuterium labels to 1-5 amino acid long peptides, and
highly efficient and varied fragmentation has been achieved [237, 334].
The enzymes can be used in solution or immobilized on a solid support and
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packed in a column [229, 236, 298, 314, 334]. Solution enzymes are convenient and
requires less equipment, but they may have the disadvantages of incomplete digestion,
longer digestion time (typically ~ 4-5 min, leading to high deuterium back exchange),
interference of pepsin and its autolysis products (confusing data analysis), as well as
plugging the HPLC columns [236]. In contrast, it has been claimed that immobilized
enzymes can offer the following possible advantages, including higher enzymatic
activity, higher extent of digestion, less digestion time (typically ~ 30 s, less deuterium
back exchange), lower protein concentrations, less contamination from the enzyme itself
or fragments of the enzyme, multiple use of the enzyme resulting in reduced cost and
enabling full automation such that proteins can be exchanged, quenched, and digested,
and then the resulting proteolytic peptides analyzed for deuterium content by HPLC/ESIMS [236, 314, 334-336]. When needed, sequential proteolysis by rapidly flowing a
sample over a series of different enzyme columns can be done, and it is also possible to
further proteolyze such product peptides on-line as they emerge (partially separated) from
the reversed phase HPLC column [314, 334]. Although the intensities of individual
peptides may be different for soluble and immobilized pepsin due to different degrees of
interference from the enzyme and different extent of digestion, the cleavage sites were
rather similar and highly reproducible [236].
Pepsin, protease type XIII, protease type XVIII, and endothiapepsin are 4
nonspecific proteases that cleave preferentially at hydrophobic residues, and have some
degree of secondary and tertiary structural specificity [299].

Since their cleavage

specificity is not well defined, peptide identities must be confirmed by collision-induced
dissociation MS/MS in combination with accurate peptide mass measurements [233, 236,
243]. Analysis of these digests by HPLC/ESI-MS facilitates identification the peptic
fragments. With current instruments and analysis software, it is possible to identify the
constituent peptides of large proteins in a few hours. Varying the concentration, time and
temperature often alters the sites of preferred cleavage; LC/MS/MS therefore must be
performed under conditions identical to those used in the deuterium exchange experiment
[243].
In what follows, a brief description of the four enzymes (pepsin, protease type
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XIII, protease type XVIII, and endothiapepsin) will be addressed.

Pepsin. Pepsin used in the studies presented in this dissertation is porcine pepsin, which
was crystallized in 1930 [337] and consists of a single polypeptide chain and arises from
its precursor, pepsinogen, by removal of a 41-amino acid segment from the amino end
[331]. Porcine pepsin consists of 326 amino acids, with a molecular weight of 34628.2
Da and pI value of 3.36. The pH range of peptide hydrolysis is from 1 to about 6 [338].
An assay of pepsin activity is most commonly carried out at pH near 2 using cattle
hemoglobin as substrate [339]. Pepsin has a broad specificity and it prefentially cleaves
large hydrophobic residues, such as Phe, Leu, Glu, Tyr and Trp [340-341].

Other

residues may be cleaved, with very variable rates. Important structural features of pepsin
are shared by other aspartic proteases, such as fungal enzymes.

Type XIII protease. Type XIII protease is isolated from Aspergillus saitoi fungus [342].
The optimal pH of the enzyme for milk casein digestion is in the range of pH 2.5-3.0 and
the protease is fairly stable over the range of pH 2.5-6 [343]. The activity assay is
typically conducted at pH 2.8 using cattle hemoglobin as the substrate [331]. Type XIII
protease has been observed to hydrolyzes the following bonds in the oxidized B chain of
insulin: Leu-Tyr, Phe-Phe, His-Leu, Ala-Leu and Tyr-Leu [344], which contains at least
one hydrophobic residue.

Type XIII protease consists of 325 amino acids, with a

molecular weight of 34302 [345].

Type XVIII protease. Type XVIII protease is isolated from Rhizhopus fugus [346]. The
activity maximum of this enzyme varies from pH 2.9 to 4.5, depending on the substrate
under investigation.

The activity assay is typically conducted at pH 3 using cattle

hemoglobin as the substrate [331]. Type XVIII protease exhibits a very broad specificity
and cleavages occur most readily between aromatic or bulky hydrophobic residues [346].
For example, it can cleave the following bonds in the oxidized B chain of insulin: PheVal, His-Leu, Leu-Val, Val-Glu, Glu-Ala, Ala-Leu, Leu-Leu, Leu-Tyr, Tyr-Leu, GlyGlu, Glu-Phe, Phe-Phe, Phe-Tyr. Based on the digestion of insulin, one can conclude
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that type XVIII protease seems to have a wider specificity than type XIII protease. The
amino acid sequence of this enzyme still remains unknown, but its molecular weight is on
the order of 33000 [347].

Endothiapepsin. The aspartic proteinase from the chestnut blight fungus (Cryphonectria
or Endothia parasitica) is referred to as endothiapepsin. The proteinase is secreted by the
fungus and has a digestive role in the growth medium. Endothiapepsin is a single chain
proteinase of 330 amino acids and has a molecular weight of 33.8 kDa [348-350]. It
cleaves protein substrates with a specificity similar to that of porcine pepsin, preferring
hydrophobic residues [351-352]. Williams et al. analyzed the cleavage sites in the
oxidized B-chain of insulin and found the rates of cleavage to be as follows: Phe-Phe >
Tyr-Leu > Gln-His >>> Leu-Val > Asn-Gln [382]. Its catalytic activity may be assayed
by the use of chromogenic substrates containing para-nitrophenylalanine [353-354].

1.5 Objectives
The motivation for the research efforts in this dissertation is the importance of
understanding of the roles of A amyloid fibrils and protofibrils in Alzheimer’s disease
(AD) and of finding ways to intervene in these roles. A critical issue is to find out the
details of how the polypeptide chains fold together to form the protofilament substructures of fibrils. The research aims to develop a detailed understanding of the threedimensional structure of the A amyloid fibrils and protofibrils, and of how A monomer
aggregates into insoluble fibrils, which could facilitate the design of fibril-targeted antiAD therapeutics. First, a novel on-line proteolysis (using pepsin) system involving a
triaxial electrospray probe was developed to facilitate the study of the secondary
structures of A aggregates using HDX-MS.

In the second part of this work, the

secondary structures of A(1-40) amyloid fibrils and CLC-stablized A(1-40) protofibrils
have been studied using HDX-MS coupled with proteolysis.

The novel on-line

proteolysis system has also been tested with 3 pepsin-like enzymes to obtain
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complementary structural information of A fibrils. In the course of these studies, a
peculiar electrochemical phenomenon interference (oxidized form of A samples) was
noted, identified and characterized. This work provides a proteolysis system that could
be used for the studies of other protein aggregates, and provides potent structural
information of A amyloid fibrils and protofibrils.
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CHAPTER 2
EXPERIMENTAL

2.1 Chemicals and Sample Preparation
2.1.1

Chemicals
Chemical used, their sources and purities are listed in Table 2.1. Unless otherwise

mentioned, the chemicals and biochemicals were used as received from the indicated
vendor.

2.1.2

Sample Preparation

Deuterated and protonated Tris buffers
100 mM stock solution of deuterated Tris.DCl (D-Tris-DCl) buffer was prepared
by dissolving tris(hydroxymethyl)aminomethane in D2O (99.9% D) under nitrogen (to
exclude atmospheric moisture) and DCl was used to adjust pD to 8. 2 mM D-Tris-DCl
buffer (pD 7.5) was obtained by addition of 10 µL of 100 mM D-Tris-DCl buffer to a 500
µL ampule of D2O (100% D) under nitrogen. (pD values were read directly from either
pH paper or a pH meter and have not been corrected for any isotope effects [355]). 100
mM stock solution of protonated Tris.HCl (H-Tris-HCl) buffer was prepared by
dissolving tris(hydroxymethyl)aminomethane in HPLC water, and then adding 10 M HCl
to adjust pH to 8. 2 mM H-Tris-HCl buffer (pH 7.5) was obtained by diluting the stock
solution by a factor of 50 using HPLC water.

Aβ
β samples
Monomers. Dry Aβ monomer was pretreated to remove any aggregates as described by
Zagorski and colleagues [356]. Specifically, Aβ peptide was first dissolved with TFA at
1µg/µl and sonicated for 15 min. The TFA was then evaporated off under a stream of
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Table 2.1. List of chemicals and biochemicals used in this work.

Reagent

Supplier

Purity

Aβ(1-40) peptide

Keck Biotechnology Center

Reagent grade

Acetonitrile

Fisher Scientific

HPLC grade

Ammonium hydroxide

Acros

Reagent grade

Argon

National Welders

>99.999%

Bovine serum albumin

Sigma

 98%

CLC1

Sigma

Reagent grade

Concentrated HCl

Sigma

Reagent grade (12.1M)

Deuterated oxide

Acros

Reagent grade (100%D)

Deuterated oxide

Cambridge Isotope Laboratories

Reagent grade (99.9%D)

DMSO2

Sigma

 99.9%

HFIP3

Acros

Reagent grade

Methanol

Fisher

HPLC grade

Neurotensin

Sigma

Reagent grade

Nitrogen

National Welders

Prepurified grade

Porcine pepsin

Sigma

Reagent grade

Potassium chloride

Sigma

Reagent grade

Sigma

Reagent grade

Sigma

Reagent grade

Protease type XIII
Protease type XVIII
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(Table 2.1 Continued)

Reagent

Supplier

Purity

Sodium azide

Sigma

Reagent grade

Sodium chloride

Sigma

Reagent grade

TCEP4

Sigma

Reagent grade

TFA5

Pierce

Reagent grade

Thioflavin T

Sigma

Reagent grade

Triethylamine

Acros

Reagent grade (99.7%)

Tris6

Sigma

Reagent grade

water

Fisher Scientific

HPLC grade

CLC1: Calmidazolium chloride; DMSO2: Dimethyl sulfoxide; HFIP3: 1,1,1,3,3,3hexafluroisopropanol; TCEP4 : Tris( 2 - carboxyethyl ) phosphine; TEA5: Tetraethyl
ammonium; Tris6: Tris(hydroxymethyl)aminomethane.
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argon in a fume hood. The monomer was then dissolved in HFIP to a final concentration
of 1µg/µl and incubated at 37°C for 1 hour before being dried using a stream of argon in
a fume hood. The monomer was again dissolved in HFIP at 1µg/µl. After the removal
of HFIP using argon, this processed monomer was then used to prepare protonated and
deuterated monomer samples for HDX studies, and to synthesize (ptotonated and
deuterated) fibril and protofibrils as described below.
For monomer samples used in HDX studies, dried peptide after organic solvent
treatment was dissolved in 2.0 mM protonated Tris.HCl or deuterated Tris·DCl.
Vigorous mixing at this step can result in precipitation and must therefore be avoided. To
ensure that no higher-order structures are present that can seed aggregation reactions,
solutions of monomeric peptide were subjected to high speed ultracentrifugation
(Beckman Optima TL 100 Ultracentrifuge, Fullerton, CA) overnight at 85,000g at 4°C to
remove any remaining aggregates. The supernatant was carefully collected, and the
concentration of Aβ was determined by reversed-phase HPLC (Hewlett-Packard, Palo
Alto, CA) (see details below). These Aβ peptide solutions were then snap-frozen and
stored at –80 ºC prior to use. The protonated and deuterated monomer samples were
prepared at a concentration of 5 – 42 µM in 2.0 mM protonated Tris.HCl and 2.0 mM
deuterated Tris·DCl, respectively.

Fibrils. After the organic solvent was evaporated off under argon, the monomer was
dissolved in 2 mM NaOH in H2O to 1 µg/µl. An equal volume of phosphate buffered
saline (PBS) buffer (20.4 mM Na2HPO4, 3.6 mM KH2PO4, 274 mM NaCl, 5.4 mM KCl,
pH 7.4) containing 0.05% sodium azide was added to the monomer solution to a final
concentration of 0.5 µg/µl. The resultant solution was then ultracentrifuged overnight at
85,000g at 4°C to remove any remaining aggregates. The monomer was then “seeded”
by adding fibrils from a previous stock at 1:750 (w/w) to ensure historical consistency.
Aliquots were incubated without agitation at 37°C for 4-6 days. Fibril growth was
monitored by thioflavin T (ThT) fluorescence (see details below) [50] until complete (~57 days). The quality of fibrils was assessed by electron microscopy. Fully deuterated
fibrils were prepared according to the same procedure described above for growing
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protonated fibrils, except that 2 mM NaOD in D2O (instead of NaOH in H2O), deuterated
phosphate-buffered saline and deuterated fibrils (seed) were employed. The monomer
equivalent concentration of the fibrils was determined by measuring the amount of Aβ in
an aliquot of the fibrils dissolved in 1/99 (v/v) TFA/H2O using reversed-phase HPLC (see
details below). All fibrils were snap-frozen in liquid nitrogen, and stored at – 80 ºC.

Protofibrils. To generate Aβ(1–40) protofibrils, ~ 30 µM monomer rigorously
disaggregated as described above was incubated with 100 µM calmidazolium chloride
(CLC) in 10/90 [v/v] DMSO/PBS buffer undisturbed at 37°C for 2 days. The resultant
CLC-stablized aggregates were then centrifuged at 315, 000g for 30 minutes, the
supernatant was removed, and the pellet was resuspended in PBS. This whole process
was repeated three times to remove any remaining unbound CLC from the reaction
mixture. Fully deuterated protofibrils were prepared according to the same procedure for
growing protonated protofibrils, except that deuterated phosphate-buffered saline were
employed.

The concentration of the protofibrils was determined by measuring the

amount of Aβ in an aliquot of the protofibrils dissolved in 1/99 TFA/MeOH using
reversed-phase HPLC (see details below). All the aggregates were snap-frozen, and
stored at –80 ºC until used.

Pepsin solutions
Stock solutions of pepsin were prepared daily at a concentration of 1 µg/µl in
0.01M HCl. Working solutions were prepared by dilution of the stock solution with
appropriate amounts of water, MeCN, and/or formic acid to generate solutions with final
composition consistent with the desired MS processing solvent. For the digestion of
monomer, fibrils and protofibrils, the concentration of pepsin was 0.03 – 0.7 µg/µl.
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2.2 Methods
Thionflavin T Assay
Thioflavin T (ThT) assay for monitoring fibril growth was performed on a PerkinElmer LS50B luminescence spectrometer (Norwalk, CT) by transferring an aliquot of
samples into a 1-cm quartz cuvette containing 15 µM ThT in PBS. ThT fluorescence was
then monitored by excitation at 450 nm and fluorescence emission at 482 nm. Because
the ThT signal varies linearly with fibril mass for any given amyloid fibril, the signal
(normalized for constant monomer weight) can be used as a measure of the completeness
of the fibril formation reaction [357].

Isolation and buffer exchange of fibrils and protofibrils
Since high ionic strength PBS buffers compromise the sensitivity of ESI-MS
detection, exchange reactions have to be carried out in low ionic strength deuterated
buffer [358]. Mature fibrils or CLC-stablized protofibrils were isolated by centrifugation
at ~14,000 rpm for 30 minutes in a benchtop Eppendorf centrifuge.

This long

centrifugation time is required because fibrils or CLC-stablized protofibrils do not pellet
well in low ionic strength buffer; centrifugation at very high g-forces is not a viable
option because ultracentrifuged pellets are difficult to quickly resuspend for the HDX
measurement. After decanting and discarding the supernatant buffer, the resulting fibril
or CLC-stablized protofibrils pellet was washed with 2 mM Tris-HCl (the washing
volume was the same as the starting sample volume) followed by centrifugation for 30
mins. At this stage it is critical to remove as much of the protonated buffer as possible
from the pellet. Gel loading tips (Fisher Scientific) are ideal for removing final traces of
the protonated solvent without disturbing the pellet. Deuterated 2 mM Tris-DCl buffer
was then added, under nitrogen, to the fibril pellet. This marks the start of the exchange
reaction and the formation of partially deuterated samples. The solution was vortexed
vigorously to resuspend the fibrils or CLC-stablized protofibrils from the pellet, after
which aliquots from the exchanging suspension were sampled for HDX-MS analysis as
described below. To prepare fully protonated control samples, the buffer exchange
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described above was performed with protonated Tris buffer.

For preparing fully

deuterated control samples, 2 mM deuterated Tris buffer was the solvent for washing and
resuspending.

The monomer equivalent concentrations of fibril or CLC-stablized

protofibril samples used in the HDX experiments were determined using HPLC (see
below) and were between 8 and 60 µM.

Assessment of the effect of acetonitrile on pepsin
To assess the effect of acetonitrile on pepsin activity (discussed in Chapter 3), Aβ
monomer solution in 2 mM tris was digested with freshly-made pepsin solutions in the
presence of water, 0.5% formic acid, and varying amounts of MeCN (0%, 15%, 30%,
50%). Solutions also contained 0 or 0.06 mg/ml (~14 µM) Aβ monomer and 0 or 1.2
mg/ml pepsin (providing a 20:1 w/w pepsin:Aβ ratio, or roughly a 2.5:1 mole ratio, when
both are present). Solutions containing pepsin were generally mixed in an Eppendorf vial
using a vortex mixer.

The digestions were quenched by adding sufficient 0.2 M

ammonium hydroxide to bring the final solution pH to around 8. Following quenching,
100-L aliquots were analyzed by HPLC and HPLC/MS (details below). The retention
time of Aβ was around 15.0 min. Hydrolysis products eluted in the range of 8 to 16 min.

Purification of pepsin-like enzymes
Dialysis of protease type XIII, protease type XVIII and endothiapepsin. 1 mL of aqueous
solution of proteases type XVIII (0.28 µg/µL), 1 mL of aqueous solution of type XIII
(0.38 µg/µL), and 200 µl of 1 µg/µL endothiapepsin saturated in ammonium sulfate
solution were dialyzed at 4°C against H2O with four change of the H2O buffer after 4, 8,
12 and 20 hours. The dialysis was allowed to continue overnight, totaling 26 h. The
membrane used was Fisherbrand regenerated cellulose dialysis tubing (Fisher Scientific,
Pittsburgh, PA), with a molecular weight cut-off of 12000-14000.

Concentration determination using BCA assay. The final concentrations of the three
dialyzed proteins were determined by “BCA Assay” using the BCATM Protein Assay Kit
(Pierce Biotechnology Inc., Rockford, IL). In this assay, bovine serum albumin (BSA)
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was used to as the standard to construct the standard curve. The assay procedure is as
follows. First, 25 mL of working reagent mixture was prepared by mixing BCATM
reagent A and BCATM reagent B at a ratio of 50 to 1. Second, BSA solutions for
constructing the calibration curve were prepared by mixing 1mL of working reagent
mixture with 0 (blank), 10, 20, 30, 40, 50 µL of 0.5 µg/µL BSA. Third, sample solutions
were prepared by mixing 15, 30, 50 µL of dialyzed protease type XIII, protease type
XVIII and endothiapepsin with 1 mL working reagent mixture. Fourth, all the samples
were incubated at 60°C for 30min. The samples were then cooled to room temperature
before the absorbance measurement. The absorbance of these solutions was measured at
the wavelength of 562nm using a SpectraMax Plus microplate spectrophotometer
(Molecular Devices, Sunnyville, CA). The calibration curve was constructed using the
blank-corrected absorbance of BSA solutions as a function of BSA concentrations. The
concentrations of the enzyme samples in H2O were then determined based on the
calibration curve and their absorbance as well as their sampling volumes. Totally 1 mL ~
0.8 µg/µL protease XVIII, 1 mL ~ 0.2 µg/µL protease XIII and 200 µl of 0.75 µg/µL
endothiapepsin were obtained after the dialysis.

Preparation of pepsin-like enzyme solutions for on-line proteolysis.

The aqueous

solutions of the three enzymes after dialysis were added with formic acid to such an
extent that the final solutions contained 0.5/100 (v/v) HCOOH/H2O. The stock solutions
of unpurified protease type XIII and protease type XVIII were prepared at 1 µg/µl in
0.5/100 (v/v) HCOOH/H2O. Working solutions were prepared by diluting the above
stock solutions with the solvent containing 0.5/100 (v/v) HCOOH/H2O.

The final

concentrations of the enzymes employed in the on-line digestion experiments presented
in Chapter 4 were ~ 0.05 µg/µl - 0.2 µg/µl.

Procedure for polishing eroded electrospray emitter tips
A Dremel model 395 Moto-Tool (Montreal, Canada) equipped with a ¾ inch
diameter medium sander disc was used to polish the emitter tips described in Chapter 5.
Polishing compound (#421, Dremel) was applied to the tip to help obtain a smooth
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rounded surface. After polishing, the tube was flushed with 500 µL chloroform to
remove any residual polishing compound using a syringe connected to the unsmoothed
end through a 1/16 in. Valco metal union with Teflon ferrules. The capillary was then
rinsed with 500 µL of HPLC water, and then blown dry with nitrogen gas.

2.3 Instrumentation
Mass Spectrometry
Q-Star XL mass spectrometer
A Q-Star XL quadrupole time-of-flight hybrid instrument (Applied Biosystems,
Foster City, CA) equipped with an Ionspray source was used to acquire ESI-MS mass
spectra presented in Chapter 3 (unless otherwise mentioned) and in Chapter 5, and all
ESI-MS/MS mass spectra presented in this dissertation. All experiments were performed
in the positive ion mode.

Source parameters including the sprayer position were

optimized for high sensitivity and stability. The IonSpray voltage and declustering
potential were 4500 V and 60 V, respectively. Except as noted, the sprayer tip was
positioned about 12 mm away from the curtain plate with a lateral displacement about 5
mm off-axis at an angle of 45 degrees to the ion sampling axis. A microammeter (Model
27, Simpson Electric Co., Chicago, IL) was connected between the high voltage power
supply and the ion source connector to enable monitoring of the emission current.
Nitrogen from liquid boil-off was used as nebulizer, curtain, and collision gas. The
pressure of nebulizer and curtain gases were respectively 40 psi and 25 psi, while the gas
pressure in the collision cell was set at 3 for the MS mode and 5 for the MS/MS mode.
All MS spectra were acquired in the multichannel accumulation mode from m/z 650 to
1200 for intact peptide and from m/z 300 to 1200 Da for proteolytic fragments for 1 min
(60 scans). MS/MS spectra were acquired using a 3 Da window for MS1 and collecting
data from MS2 over the range 100-2000 m/z for 5 - 10 min. To minimize artifactual
deuterium exchange, the hole from the source leading to the venturi pump was blocked so
that moist laboratory air was prevented from being sucked into the source housing. Also,
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extra nitrogen gas (500 mL/min) was introduced into the source through the “make-up”
hole on the ionspray source housing.
The Q-Star IonSpray™ probe includes two stainless steel microvolume tees
(Figure 2.1). The tee nearer the spray tip (T3) is used to introduce nebulizing gas via
stainless steel Tube 3, while the other tee (T2) can be used to provide a continuous stream
of sample via Tube 2. A third tee (T1; 0.25-mm diameter PEEK; Valco Instruments,
Houston, TX) was added to enable on-line addition of processing solvent. Sample and
processing solvent were infused into T1 via separate 100-µm i.d. fused silica capillaries
(Polymicro Technologies, Phoenix, AZ) using the built-in and Harvard Apparatus (South
Natick, MA) model 11 syringe pumps, respectively.

The resulting mixture flowed

through the fused silica Tube 1 (75 µm ID × 190 µm OD) to the spray tip.
The probe was operated in two modes. In the standard (“coaxial”) mode, the
spray end of Tube 1 was flush with the end of the stainless steel (316 grade) Tube 2 (220
µm ID × 410 µm OD) and the third arm of T2 was unused (so that Tube 2 was left open
to air). In the “triaxial mode”, Tube 1 was retracted slightly (~ 5 mm) from the spray end
of Tube 2, thus providing a small volume (~ 0.19 µL) for mixing with a secondary
solvent that was delivered from T2 via Tube 2 using a Harvard Model 22 syringe pump.
For both modes, Tube 3 was ~ 0.5 mm back relative to Tube 2. For simplicity and
convenience, “coaxial probe” and “triaxial probe” are the terms used for describing the
two configurations in the following discussion.
When the Q-Star Ionspray™ probe was used as a coaxial probe, flow rates for A
sample

solution

and

processing

solvent

(generally

46/54/0.5

H2O/MeCN/HCOOH) were 0.85 µl/min and 9.25 µl/min, respectively.

(v/v/v)

For analysis

using the triaxial probe, sample (0.85 µL/min) was mixed with the initial processing
solvent (generally 0.5% formic acid in water, 4.25 µl/min) in T1 and then mixed with
MeCN (containing 0.5% formic acid, 5 µl/min) at the probe tip. The total flow through
Tube 1 was twice as high in the coaxial probe, so the length of Tube 1 was doubled (46
cm vs. 23 cm) in the coaxial probe, to match the total time from mixing to the end of
Tube 1 (~12 seconds). With the triaxial probe, there was an additional 1.1 second transit
time for the 0.19-L volume after Tube 1. Electrical contact was made at T2, making
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(a)
Counter
electrode
N2 make-up gas

SS Tube 2

T3
SS Tube 3

T2
Fused silica Tube 1

T1
SS tee

Aβ
β
samples

Nebulizing N2

Orifice

Acetonitrile
PEEK tee

Processing solvent
IonSpray source housing

(b)
Tube 2
Tube 1
Tube 3

Triaxial probe:
Tube 1: 190um (OD) × 75um (ID) × 23 cm (length) (fused silica)
Tube 2: 420 um (OD) × 220um (ID) (stainless steel)
Coaxial probe:
Tube 1: 190um (OD) × 75um (ID) × 46 cm (length) (fused silica)
Tube 2: 420 um (OD) × 220um (ID) (stainless steel)

Figure 2.1. (a) Diagram of the modified electrospray probe (not to scale) on the Q-Star
XL instrument, shown in the triaxial configuration (Tube 1 ~ 5 mm back relative to Tube
2). For coaxial operation, Tube 1 is extended flush with the end of stainless steel (ss)
Tube 2; (b) tube diameters associated with both probes.
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Tube 2 the anodic emitter for both geometries.
ProteinProspector 4.0.5 software (University of California, San Francisco, CA)
was used to identify possible matches for proteolytic fragments from the Aβ primary
sequence, which were then confirmed using MS/MS analysis of protonated Aβ monomer
with collision energies between 30 and 45 eV (as needed for adequate dissociation of a
given fragment).

Quattro II mass spectrometer
All HDX kinetics studies presented in Chapter 4 were carried out with a
Micromass (Manchester, U.K.) Quattro II triple quadrupole electrospray ionization mass
spectrometer equipped with a Z-spray source.

Experiments were performed in the

positive ion mode with a capillary voltage of 3.5 kV (unless otherwise noted) and a cone
voltage of 20 V. Source temperature and desolvation temperature were maintained at
100°C and 110°C, respectively. The spectrometer was modified to allow monitoring of
the ES emitter current by connecting a Keithley 600A electrometer (Keithley
Instruments, Cleveland, OH) in series with the high voltage emitter power supply line.
All MS spectra were acquired in the multichannel accumulation mode from 650 to
1200 m/z for the intact peptide and from 300 to 1200 Da for the proteolytic fragments.
Triplicate spectra were collected for each sample.
For on-line proteolysis experiments, a home-made triaxial probe was used as a
front end to the Z-spray source (Figure 2.2). A samples (0.85 µL/min) and the solvent
(pepsin in 0.5% formic acid, 4.25 µL/min) were infused into a 0.25-mm inner diameter
Valco T union (mixing T in Figure 2.2) using two 50-µm i.d. fused silica capillaries
(Polymicro) connected to Harvard Bioscience Model 22 and Model 11 syringe pumps.
Fibrils were dissolved and proteolyzed as this mixture was delivered through the
innermost silica tube (Tube 1) of the triaxial probe (50 µm i.d. and 360 µm o.d.).
Acetonitrile with 0.5% formic acid was infused using a third Harvard Bioscience Model
11 syringe pump (10 µL/min, unless otherwise specified) into the middle stainless steel
tube (Tube 2) (410 µm i.d. and 720 µm o.d.) and mixed with the dissolved and
proteolyzed samples only near the tip of the electrospray emitter. Tube 1 was ~ 3 mm
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(a)

Acetonitrile/formic acid
A Samples
Tube 2
Tube 3
MS

Mixing T
Tube 1

Data
Analysis

Proteolyzing Solvent
(water/formic acid/pepsin)

N2

(b)
Tube 2
Tube 1
Tube 3

Tube 1: 360um (OD) × 50um (ID) × 52cm (length) (fused silica)
Tube 2: 720 um (OD) × 410um (ID) (stainless steel)
Tube 3: 1100um (OD) × 860um (ID) (stainless steel)

Figure 2.2. Schematic of the triaxial probe (not to scale) on the Quattro II instrument
designed for HDX-MS experiments in conjunction with on-line proteolysis. Tube 1 is ~
3 mm back relative to Tube 2, while Tube 3 is ~ 0.5 mm back relative to Tube 2.
Processing solvent is optimized to quench exchange, disaggregate and dissolve fibrils,
and generate defined peptide fragments; the acetonitrile-formic acid stream prepares the
same for the mass spectrometer; (b) tube diameters associated with the probe.
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(unless otherwise mentioned) back with respect to Tube 2, creating a dead volume of ~
0.4 µl (corresponding to ~ 1.6 s mixing time when the total liquid flow rate is ~ 15
µl/min). Nebulizing gas (nitrogen) was delivered to the outermost stainless steel tube
(Tube 3) (860 µm i.d. and 1100 µm o.d), which was ~ 0.5 mm back relative to Tube 2.
The flow rates of N2 nebulizing gas and N2 drying gas were set at 50 liter/h and
300 liter/h, respectively. The length and diameter of Tube 1, and the flow rates, control
the time from mixing to the end of Tube 1 (i.e. the time for digestion: ~ 12 s). This
approach provides effective and rapid (~ 12 s) on-line proteolysis, while minimizing
artifactual exchange (discussed in Chapter 3 and Chapter 4)).
The standard coaxial probe on the Quattro II is made up of two stainless steel
tubes. A samples were infused to one arm of a 0.25 mm internal diameter Valco T
union (Mixing T, Figure 2.3) using a Harvard Biosciences model 22 syringe pump and a
75 µm i.d. fused silica capillary. Solvent was pumped through a second fused silica
capillary to another arm of the Mixing T using a Harvard Biosciences model 11 syringe
pump. The third arm of the mixing T is connected to an ESI probe via a ~23 cm long and
~110 µm i.d. stainless steel capillary (Tube 1, Figure 2.3). Tube 2 passes through a larger
tube, accommodating nitrogen nebulizing gas (to assist the spray process). Tube 2 is ~
0.5 mm back relative to Tube 1. During the use of this probe, the flow rates of nebulizing
gas and drying gas were set at 20 liter/h and 300 liter/h, respectively.

Tips for HDX data collection
To obtain reproducible mixing time between sample and solvent, and hence
reproducible data, the syringe pumps delivering sample and solvent into the mixing T
should be turned on and off simultaneously. Aggregates tend to settle in the syringe
during long-term kinetics experiments resulting in a loss of MS signal; it is therefore
important to make sure that the sample in the syringe is either changed frequently (30-60
min in our hands), or is remixed periodically. It is also very important to clean the
mixing T and the capillaries used for sample and solvent delivery, by flushing with water
and solvent respectively, between each run.

Adequate cleanliness is validated by

collecting data for a blank run between each new sample. Any clogs in the mixing T can
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Figure 2.3. Schematic of the coaxial probe (not to scale) on the Quattro II instrument.
Tube 2 is ~ 0.5 mm back relative to Tube 1. Processing solvent is optimized to quench
exchange, disaggregate and dissolve fibrils, and prepare sample for mass spectrometry;
(b) tube diameters associated with the probe.
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be removed by dismantling the T and sonicating it in the processing solvent.
During HDX-MS experiments, since the processing solvent is generally
protonated and the sample exchange buffer is deuterated, there is always a percentage of
D2O present in the final solvent mixture.

The expected percentage can be easily

calculated from the ratio of the solvent and the sample flow rates, and can be confirmed
by comparing the ratio of the acetonitrile dimer peak at mass-to-charge (m/z) 83
[(CH3CN)2 + H]+] and at m/z 84 [(CH3CN)2 + D]+. The ratio of this pair of peaks should
be monitored during data collection to ensure consistency in flow rates. Any blockage in
the experimental set-up will affect the mixing rate and this change is reflected in the ratio
of the acetonitrile peaks at m/z 83 and 84. MS data on control samples (fully protonated
and fully deuterated fibrils) should be collected at least once a day, to ensure that the
instrument has worked fine and to provide data for correcting artifactual exchange of the
partially deuterated samples.

High performance liquid chromatography (HPLC) and HPLC-MS

Revered-phase HPLC instrument used for determination of the concentrations of
monomer, fibril and protofibril samples was an Agilent 1100 LC system with a ZORBAX
SB-C3 column (3×150mm), an autosampler, and a UV detector. The solvent flow rate
was 1 mL/min, and the temperature was controlled at 25 °C. The solvents used were
0.1% TFA in water (solvent A), and 0.1% TFA in MeCN (solvent B). The column
equilibrated to 1% solvent B prior to injection, and then the sample was eluted with a
linear gradient of 1%-51% solvent B over a 40 min period.

The separation was

monitored by absorbance at 215 nm.
HPLC-MS experiments were conducted with an Agilent 1100 Series LC/MSD
system with a ZORBAX SB-C3 column (3×150mm), an autosampler, serial UV and
electrospray MS detectors, and a splitter (splitting ratio: 100:1). The solvent flow rate
was 1 mL/min, and the temperature was controlled at 25 °C. Solvent A was 0.1% formic
acid in water, and solvent B was 0.1% formic acid in MeCN. The column equilibrated to
1% solvent B prior to injection, and then the sample was eluted with a linear gradient of
1%-51% solvent B over a 40 min period. The separation was monitored by absorbance at
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215 nm and by MS scans from m/z 300 to 2000.
The LC-MS experiments employed a single quadrupole instrument equipped with
a standard Agilent electrospray source operating in the positive ion mode. The drying
gas flow (N2), nebulizer pressure (N2), drying temperature, and capillary voltage were set
at 3 L/min, 35 psig, 300 ºC and 3000 V, respectively.

Scanning electron microscopy (SEM)

Electron micrographs were taken on a Hitachi S-3500N Scanning Electron
Microscope (Hitachi High Technologies America, Inc., Schaumburg, IL).

X-ray

fluoresence mapping was conducted using a Leo 1525 Scanning Electron Microscope
(Carl Zeiss SMT inc., Thronwood, New York). The magnification was 200, unless
otherwise noted. The voltage was 20 kV for both microscopes. The samples (stainless
steel tubes) were attached to the sample stage via scotch tape for SEM analysis.

2.4

Data Analysis

Calculation of average masses

MS data obtained from the Q-Star instrument were isotopically resolved due to
the high resolution (up to 11000), so calculation of average molecular weights was done
using the equation

 (I × M
I
n

MWavg =

n

)

n

Eqn. 2.1

n

n

where In is the intensity (height) of nth isotopic peak and Mn is the centroid mass of that
peak (corrected for ionizing protons). For ions detected with multiple charge states,
neutral molecular masses obtained from those charge states were averaged to obtain the
molecular masses.
To obtain molecular masses of MS data acquired using the Quattro II instrument,
peaks were first smoothed by using the Savitzky Golay method incorporated in the
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Micromass Masslynx software package. For cases where isotopic clusters were resolved
and only a single peak cluster was identified, the molecular masses were determined
using Eqn. 2.1. For cases where isotopic clusters were not resolved and only a single
peak envelope was identified, centroids of the unresolved peak envelopes were used to
obtain the average molecular weights.

For cases where overlapping peaks were

identified, data were first deconvoluted using the Pearson VII equation in the PeakFit
(Systat) program (see details in Chapter 4), and then the centroids of the deconvoluted
peaks were used to obtain the average molecular weights.

For ions detected with

multiple charge states, neutral molecular masses obtained from those charge states by
subtracting the mass of ionizing groups (protons) were averaged to obtain the molecular
masses.

Determination of the amount of water oxidation participating in oxidation of Aβ
β

The

18

O incorporated into Aβ in experiments involving H218O (described in

Chapter 5) was estimated by treating each isotopic cluster in the experimental spectrum
as a linear combination of the spectrum obtained with unlabeled water, and a hypothetical
spectrum for fully labeled Aβ. The latter spectrum was modeled simply by shifting each
peak in the unlabeled cluster upward by 2 Da (shifting m/z upwards by 2/z). This
avoided the need for an expensive, fully deuterated standard, and will be accurate as long
as the sensitivities to the labeled and unlabeled Aβ are the same - a very reasonable
assumption. All peaks in a given isotopic cluster were considered. (Note that not even
the Q-star resolution (up to 11000) was adequate to distinguish isobars in the Aβ isotopic
clusters, given its molecular weight of 4329.9 Da.).
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CHAPTER 3
A TRIAXIAL PROBE FOR ON-LINE PROTEOLYSIS
COUPLED WITH HDX-MS

HDX-MS analysis of intact proteins provides insight into the overall exchange
protection of the entire protein molecule.

Determination of specific exposed and

protected sites by HDX-MS requires coupling with proteolysis and/or MS/MS (typically
CID or ECD). There is some risk of intramolecular scrambling of deuterium labels
during CID or ECD [235, 304, 309-313], as discussed in section 1.3.3. Peptide digestion
can offer an alternative or supplement to direct CID or ECD for localizing incorporated
deuterium with HDX-MS. Pepsin has proven to be particularly useful for this purpose
because of its good activity at the low pH values used to minimize artifactual hydrogen
exchange (spurious incorporation or loss of deuterium) during sample work-up after
exchange (section 1.4). A typical protocol involves incubation of deuterium-labeled
proteins with pepsin at about pH 2 for ~5 min at 0 ºC (low temperature also reduces
artifactual exchange). The digest is then subjected to liquid chromatography (LC), with
on-line MS or MS/MS analysis to assess the deuterium content of individual digestion
products (section 1.3.3) [230, 235]. Relatively high quantities of pepsin are used to
minimize digestion time and the corresponding opportunity for scrambling; this can
complicate direct analysis of the hydrolysate without LC separation (due to increased
background) [236]. Use of an immobilized enzyme in a continuous-flow column can
mitigate these problems (section 1.4) [236, 314, 334-335].
ESI-HDX/MS methodologies have been adapted by our group for analysis of the
Aβ amyloid fibrils [58-59]. To dissolve fibrils after deuteration and prior to MS analysis
while limiting artifactual exchange, we have used continuous flow mixing of the
deuterated fibril suspension with a low-pH quenching and dissolving solvent that
contains acetonitrile (MeCN) to facilitate electrospray and to reduce artifactual exchange
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(by reducing the protic solvent concentration in the final mix) (Figure 1.14). Using this
approach we have determined that roughly half of the 39 Aβ (1-40) amide protons are
protected from HDX in fibrils grown from the peptide [58-59]. In anticipation of efforts
to further localize the protected sites, we needed a way to achieve rapid proteolysis with
minimal scrambling. Use of an immobilized enzyme would require fibril dissolution
prior to passing through an enzyme column; a faster sample treatment protocol would be
desirable. This Chapter will demonstrate the utility of a triaxial electrospray probe
(Figure 2.1) to facilitate effective and rapid on-line dissolution and proteolysis of fibrils
at room temperature. The performance is compared with that of the coaxial probe used
previously [58-59]. Validation of a method for correcting HDX data obtained from the
triaxial probe for artifactual exchange is also presented.

3.1
3.1.1

Why Use a Triaxial Electrospray Probe?

Conditions for On-line Proteolysis Using a Coaxial Probe: The Effect of
Acetonitrile on Pepsin Activity
Given the compatibility of pepsin with low pH and the occasional enhancement of

enzyme activity by organic solvents [359-360], the simplest approach to on-line
proteolysis of fibril-derived A would be to add pepsin to the processing solvent used to
arrest H/D exchange, dissolve the fibrils, and facilitate ESI. Figure 3.1a illustrates the
results obtained using this simple approach with A monomer. There is no evidence of
pepsin digestion of A even at an enzyme:monomer weight ratio as high as 40:1, using
the 50/50/0.5 (v/v/v) H2O/MeCN/HCOOH processing solvent used previously for fibril
analysis without proteolysis [58-59]. Only intact A is detected (labeled peaks); all other
peaks above noise were attributable to solvent and/or pepsin background. Similar results
(not shown) were obtained with the digestion of A fibrils at the same weight ratio.
There are two possible explanations for these observations: either the enzyme is inactive
under these conditions, or the signals due to proteolysis products are suppressed (e.g., by
more hydrophobic intact material) [361].
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Figure 3.1. ESI mass spectra obtained from on-line digestion of A(1-40) monomers
with pepsin (a) in 50/50/0.5 (v/v/v) H2O/MeCN/HCOOH using a coaxial probe
(enzyme/peptide = 40/1 [w/w]); (b) in 85/15/0.5 (v/v/v) H2O/MeCN/HCOOH using a
coaxial probe (enzyme/peptide = 43/1 [w/w]); (c) in 100/0.5 (v/v) H2O/HCOOH using a
triaxial probe (enzyme/peptide = 0.9/1 [w/w]). Intact peptide and digestion products are
labeled and marked with asterisks; unlabeled peaks are from pepsin and solvent
background.
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To distinguish between these possibilities, digests with varying MeCN
concentrations were analyzed by HPLC using UV and MS detection (described in section
2.2). In the first control experiments, pepsin was omitted, allowing determination of the
chromatographic retention time of the intact A monomer. In the absence of pepsin, the
monomer peak was detectable with roughly constant sensitivity and retention time (15.0
min) for all digestion solvents tested. Upon addition of pepsin (20:1 w/w pepsin:A),
incubation for 20 sec (approximating the time available for on-line digestion using the
coaxial probe) and quenching with NH4OH, the monomer peak disappeared if the solvent
contained 0 to 30% MeCN, indicating effective hydrolysis. At 50% MeCN, pepsin
attenuated the monomer peak to about 31% of the peak area observed when pepsin was
absent, indicating significant inhibition of enzyme activity (Table 3.1). When the amount
of enzyme was reduced to 2:1 (w/w) with 50% MeCN, the intensity of the monomer was
not attenuated measurably unless the mixing time was increased substantially; after 1 min
of digestion, the signal for intact peptide was attenuated by 6%, and 5 min digestion
resulted in 23% attenuation.
In addition to the attenuation of the peak for the intact peptide, enzyme activity
was evidenced by the appearance of new peaks in the HPLC experiments. With the MS
detector it was possible to confirm that these arose from proteolytic A fragments (Table
3.1). The prominence of fragment 1-19 (resulting from cleavage between Phe19 and
Phe20) is consistent with the known preference of pepsin for cleavage of Phe-Phe bonds
[362]. The complementary 20-40 fragment grows with increasing MeCN concentration,
at the expense of smaller fragments which result from cleavage between Leu34 and Met35,
and between Gly33 and Leu34, presumably subsequent to the Phe19/Phe20 cleavage. This
and the overall inhibition of enzyme activity in the presence of MeCN are consistent with
the reported effect of organic solvents, including MeCN [334, 363-365], on pepsin
activity. As evident from Figure 3.2, the seven fragments observed are consistent with
the preferences of the relatively non-specific proteolysis of pepsin (cleavages on the Nand/or C-terminal side of Phe (F), Leu (L), Glu (E), Trp (W), and Tyr (Y) [362, 366]).
Based on the LC results, a preliminary on-line experiment was attempted using
30% MeCN and an enzyme:Aβ ratio of 20:1 [w/w]. Relatively little hydrolysis, plus a
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Table 3.1. Fragments observed by LC following digestion of A(1-40) monomer with
pepsin (20 sec digestion time, enzyme:substrate = 20:1 w/w, except where noted) in the
solvents indicated. Also listed are the observed LC retention times and peak areas.
Fragment assignments were confirmed by MS/MS.

Solvent composition
(H2O : MeCN : HCOOH) (v/v/v)
100 : 0 : 0.5

Fragment

Retention

85 : 15 : 0.5

70 : 30 : 0.5

50 : 50 : 0.5

UV Area (arbitrary unit)

time (min)

[4-19]

8.2

128 ± 6

0

0

0

[35-40]

8.5

62 ± 2

93 ± 4

76 ± 15

9±2

[1-19]

9.0

638 ± 13

994 ± 19

970 ± 47

257 ± 54

[20-33]

9.5

110 ± 7

48 ± 3

28 ± 4

0

[34-40]

11.4

20.0 ± 0.4

46 ± 2

14 ± 2

0

[20-34]

12.1

387 ± 3

359 ± 4

266 ± 23

14 ± 6

[20-40]

15.5

12 ± 3

27 ± 5

138 ± 23

145 ± 24

[1-40]

15.0

0

0

0

468 ± 12

[1-40]1

15.0

-

-

-

1531 ± 26
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1-40
1-19

20-40

4-19

20-33

34-40

20-34

35-40

NH2-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-COOH

Most favored cleavage between residues 19 and 20 [22]

Figure 3.2. Comparison of the favored and observed pepsin cleavage sites on the Aβ(140) peptide. The down arrows represent the experimentally observed cleavage sites
during 12 seconds digestion using a triaxial probe, while the up arrows indicate the
cleavage sites expected to be preferred by pepsin. Phe (F)-Phe (F) cleavage is especially
favorable.
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strong background similar to that shown in Figure 3.1a were detected, possibly due to the
shorter (12 sec vs 20 sec for the LC experiments) reaction time and suppression of signal
by autolysis products (data not shown). Given the necessity for some MeCN to assure
stable spray [171, 361, 367], 15% MeCN was selected as a reasonable compromise
between acceptable signal and retention of enzyme activity. Even under these conditions
(85/15/0.5 H2O/MeCN/HCOOH), a high enzyme concentration (roughly 43:1 w/w
enzyme:A) was needed to fully attenuate the signal from intact peptide during on-line
digestion of 15-M monomer samples, and roughly 110:1 was needed for 16-M
(equivalent monomer concentration) fibrils. The higher pepsin requirement for fibrils
likely reflects the shorter time available for hydrolysis due to the finite time needed to
dissolve the fibrils and to expose cleavable sites.

Under these extreme conditions,

hydrolysis products were detectable (Figure 3.1b).

However, at such high enzyme

concentrations, autolysis of pepsin can become a significant competing reaction, leading
to a strong background (Figure 3.1b). Furthermore, in the absence of pepsin, the signalto-background ratio (S/B) (background assessed as the average intensity between m/z
1100 and m/z 1200) for the 5+ charge state base peak for the intact A monomer using
15% MeCN was around half that obtained using 50% MeCN. Thus, such an on-line
digestion system is far from being ideal.

3.1.2

On-line Proteolysis Using a Triaxial Probe
The triaxial probe pictured in Figure 2.1 was used to allow separate optimization

of proteolysis and electrospray conditions by delaying introduction of MeCN until just
before spraying. For this setup, the processing solvent 0.5/100 HCOOH/H2O serves to
dissolve fibrils, quench H/D exchange and accommodate pepsin, while the sheath liquid
0.5/100 HCOOH/MeCN serves to facilitate ESI operation. With the triaxial probe, only a
0.9:1 (w/w) pepsin:A was required to reduce the monomer signal from 15 M A to
baseline, vs 43:1 with the coaxial probe; the final solvent composition was 50.5/49.5/0.46
H2O/MeCN/HCOOH for the triaxial probe (vs 86.3/13.7/0.46 H2O/MeCN/HCOOH for
hydrolysis with the coaxial probe). Moreover, the same 7 major A fragments were
observed (S/N > 70; Figure 3.1c) as from the bench-top digestion (Table 3.1), vs only 4
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fragments (among strong interfering background peaks) using the coaxial probe (Figure
3.1b). The performance for digestion of fibrils (18 M) was also enhanced; the 10.6:1
weight ratio pepsin:A needed to eliminate the signal from intact fibrillar A was roughly
1/10 the amount needed using the coaxial probe (final solvent composition:
86.3/13.7/0.56 H2O/MeCN/HCOOH). Under these conditions the fibrils gave the same
fragments as those observed for monomer in Figure 3.1c.
Although some expected cleavages were “missed” in the 12-second digestion time
(evident in Figure 3.2), the fragments produced have the potential to provide structural
information about the N-terminus (1-19), C-terminus (35-40), and part of the protected
core (20-34) [40, 63, 74]. The observed cleavage between positions 19 and 20 for the
fibrils is particularly significant, since this site is believed to be involved in the -sheet
network [40, 63, 74]; dissolution of fibrils evidently precedes hydrolysis, exposing sites
involved in the secondary structures. HDX studies of these peptic fragments should
contribute to the testing and refinement of structural models [40, 63, 74]. Although
detailed discussion is presented in Chapter 4, feasibility of such HDX experiments is
considered next.

3.2

Triaxial Probe vs. Coaxial Probe for HDX-MS Studies

In order to be useful for HDX-MS studies of amyloid fibrils, the triaxial probe
must not only provide effective proteolysis, but it must do so without compromising
sensitivity, impairing the dissolution of fibrils, or introducing additional artifactual
exchange. These figures of merit were assessed in the series of experiments described
next.

Sensitivity and signal stability. Similar sensitivity was achieved for both probes, as
evidenced by nearly identical base peak ([1-40]5+ at m/z 867) absolute intensities ((1.8 ±
0.06) × 104 for the triaxial probe, vs (1.9 ± 0.04) × 104 for the coaxial probe) and signalto-background ratios (750 for the triaxial probe, vs 850 for the coaxial probe) for A
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monomers run on the two probes under conditions where the final solution composition is
identical (50.5/49.5/0.46 H2O/MeCN/HCOOH) (Figure 3.3).

The relative standard

deviation (RSD) of the absolute intensity of the base peak from 600 scans averaged over
a 10-minute period is also nearly identical for the two probes (3% RSD for the triaxial
probe, vs 2% for the coaxial probe), suggesting good signal stability for both probes.
It is interesting to note that while the base peaks and overall charge-state
distributions in Figures 3.3a and 3.3b are similar, the relative abundance of the +6 charge
state is somewhat higher with the triaxial probe (29% ± 2%, vs 21% ± 3% with the coax
probe), despite the fact that the emission current was lower (0.25 A, vs 0.5 A for the
coaxial probe) so that the pH would be expected to be higher [197, 368-370]. This
difference was reproducible from scan-to-scan, but sensitive to tuning parameters, as
observed elsewhere [371]. One contributing factor could be the difference in spray tip
and “electrode” geometries. For the triaxial probe, electrical contact is made at least ~ 5
mm from the sprayer tip, whereas for the coaxial probe the contact is made only when the
liquid from the silica tube 1 wets the steel tube 2 near the emitter tip. Other possible
contributors include space charging and mixing efficiency, which are considered next.

Space charge effect. Space charge effects are a consequence of the mutual repulsion
between particles of like charge [372]. To test for contributions from space charge
effects to the enhancement of the 6+ peak in Figure 3.3 [373-374], the relative intensities
of the +6 and +5 charge state monoisotopic peaks of A monomer were monitored while
moving the emitter horizontally across the entrance aperture. Results are shown in Figure
3.4. The profile for the coaxial probe was obtained while running 0.5-M A monomer
in 50/50/0.5 (v/v/v) H2O/MeCN /HCOOH at 10 L/min in tube 1. The results for the
triaxial probe were generated by running 1-M A monomer in 0.5/100 (v/v)
HCOOH/H2O at 5 L/min in tube 1 and 0.5/100 (v/v) HCOOH/MeCN at 5 L/min in
tube 2, giving the same final composition and total flow. The two curves show similar
trends. The fact that the biggest ratios were obtained when the probe tip was farthest
away from the orifice is consistent with space charge, which would preferentially repel
more highly charged ions to the periphery of the electrospray. Also plotted in Figure 3.4
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Figure 3.3. Mass spectra of Aβ(1-40) obtained using (a) the triaxial probe and (b) the
coaxial probe. The inset shows the absolute intensity (counts) and signal-to-background
ratio (S/B) of the highest monoisotopic peak (m/z 867) accumulated over a one-minute
period. Background was assessed as the average intensity between m/z 1100 and m/z
1200.
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Figure 3.4. The intensity ratio of the +6 charge state peak to the +5 charge state peak
versus the position of the probe tip relative to the sample orifice. Data were obtained
from solutions containing Aβ(1-40) monomer in 50/50/0.5 (v/v/v) H2O/ MeCN /HCOOH
in tube 1 on the coaxial probe ( ); Aβ monomer in 100/0.5 (v/v) H2O/HCOOH in tube 1
mixed on-line with 100/0.5 (v/v) MeCN/HCOOH through tube 2 using the triaxial probe
( ); or pre-mixed Aβ (1-40) monomer with 50/50/0.5 (v/v/v) H2O/ MeCN /HCOOH in
both tube 1 and tube 2 on the triaxial probe ( ). The axial displacement was fixed at 12
mm. At 0 mm, the probe tip is on-axis with the sample orifice. Error bars represent the
standard deviation of ratios from triplicate mass spectra.
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are the ratios obtained when the premixed solution was run through both tube 1 and tube
2 of the triaxial probe (5 L/min in each tube). The curve is indistinguishable from that
obtained using the separated solvents, suggesting little (if any) effect of imperfect mixing
which could have affected the solvent dielectric and therefore the charge–state
distribution [375]. We conclude that space charge and resulting ion sampling effects are
the primary contributors to the small differences evident in Figure 3.3. The higher
currents for the coaxial probe may result in higher space charge, and therefore more
scattering and less efficient sampling of more highly charged ions [373].

Mixing. Because of the rapid kinetics of proton exchange of reasonably strong acids and
bases, the protonation/deuteration of triethylamine (TEA) was used as a probe of mixing
efficiency. To mimic the flow conditions used above, 10/90 (v/v) D2O/ MeCN was
pumped at 5.1 µL/min through tube 2, while 0.1µM TEA in 0.5/100 HCOOH/H2O was
delivered to both arms of T1 in Figure 2.1 (flow rates of 0.85 µL/min and 4.25 µL/min),
and then to tube 1 (total H2O flow rate 5.1 µL/min). If the mixing at the sprayer tip is
100% efficient, the [TEA+D]+:[TEA+H]+ ratio would be 1:10, so that the signal intensity
at m/z 103 would be ~ 16.8% of that at m/z 102 (including contributions from D, 13C and
14

N). If there is no mixing at all at the sprayer tip, there would be no excess [TEA+D]+

and the signal at m/z 103 would be just 6.8% of that at m/z 102, reflecting the normal
isotopic abundance. Experimentally, the measured ratio was 14.8% ± 0.3%, suggesting a
mixing efficiency of roughly 80% ± 3% ((14.8-6.8)/(16.8-6.8); the

13

C and

14

N

contributions are subtracted). This in turn would provide 36% ± 1% MeCN in the “final”
mix, instead of the expected 45%. By contrast, when the solutions were premixed 1:1
and run through all tubes at the indicated flow rates, the experimental ratio was 17.1 % ±
0.2%, very close to the theoretical prediction. The mixing efficiency at T1 in Figure 2.1
was tested separately using the coaxial probe. In this case, 0.1µM TEA in D2O (0.85
µL/min) was mixed with 46/54/0.5 (v/v/v) H2O/ MeCN /HCOOH (9.25 µL/min) in T1,
and then the whole mixture was delivered and sprayed through tube 1. The measured
i103/i102 ratio was 26.8% ± 1.0%, matching the expected value of ~ 26.8% for perfect
mixing, indicating that the mixing efficiency in T1 is ~ 100% within the experimental
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error. For comparison, a value of 27.5% ± 0.7% was obtained from a 0.85:9.25 premixed
solution, also within the experimental error of the expected value.

These mixing

efficiencies should be interpreted as maximum values, since they are based on the mixing
of water, protons and the small TEA molecule; slower diffusion or increased viscosity in
solutions of a larger molecule like Aβ might result in less homogeneity. Nevertheless, it
is clear that mixing at the emitter tip for the triaxial probe is reasonable, though not
perfect.

Fibril dissolution. Rapid disaggregation/dissolution of fibrils into monomers is essential
for HDX-MS studies of fibrillar structure. Earlier studies found that more than half of the
fibrils present in suspensions with ~11 M equivalent monomer concentration could be
dissolved in < 10 sec using the coaxial probe [58]. Studies of the kinetics of deuteration
and parallel work with HDX-NMR suggest that the dissolved fraction represents full
dissolution of a representative fraction of all fibrils, rather than sampling a readily
dissolved fraction of each fibril or a subset of fibrils [58-59, 61]. To compare the
dissolution efficiency achieved with the coaxial and triaxial probes, the intensities from
on-line dissolution of fibril suspensions of varying effective monomer concentrations
were compared with those obtained from monomer calibration curves (5 to 42 M
monomer flowing into one arm of T1 in Figure 2.1 at 0.85 µL/min for both probes). To
improve precision, neurotensin was incorporated as an internal standard in the processing
solvent (0.23 M in 46/54/0.5 (v/v/v) H2O/MeCN/HCOOH flowing at 9.25 µL/min for
the coaxial probe and 0.5 M in 100/0.5 (v/v) H2O/HCOOH flowing at 4.25 µL/min for
the triaxial probe). For the triaxial probe, 100/0.5 (v/v) MeCN/HCOOH at 5 µL/min was
introduced through T2 as usual. Quantitation was based on the ratio of the summed
intensities of monoisotopic peaks from the observed charge states of Aβ (+4 to +7) and
neurotensin (+2 and +3).
Table 3.2 summarizes the results of this study.

The measured monomer

concentration increases monotonically with increasing fibril load, suggesting that
saturation (equilibration) is not achieved. At monomer equivalent concentrations of ~8
M or ~14 M, the dissolution of the fibrils with either probe is efficient, but the coaxial
101

Table 3.2. Comparison of on-line solubility of Aβ(1-40) fibrils in the mixing tee (T1 in
Figure 2.1) using the triaxial probe and the coaxial probe. Indicated concentration is the
monomer concentration equivalent to the quantity of fibrils in 2 mM tris buffer flowing
into one arm of T1 (Figure 2.1). The indicated uncertainties are standard deviations
based on triplicate acquisitions of mass spectra.

Initial fibril concentration in

Measured concentration (% dissolved)

2mM tris buffer

Triaxial probe

Coaxial probe

8.0 µM

7.3 ± 0.9 (91 ± 11)

7.9 ± 0.7 (99 ± 8)

14.0 µM

11 ± 1 (81 ± 9)

12 ± 1 (89 ± 9)

29.6 µM

12.6 ± 0.5 (43 ± 2)

16.0 ± 1.5 (54 ± 5)
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probe is slightly more efficient than the triaxial probe. At ~30 M, neither probe is
efficient, and the difference is somewhat bigger. The decrease in dissolution efficiency
(reflected as % dissolution) with increasing fibril concentration confirms kinetics control,
with slower dissolution and faster redeposition at higher fibril loads.

Even though

different loadings of A fibrils demonstrate different solubility on the two probes,
preliminary results from HDX-MS studies of Aβ fibrils at different equivalent
concentrations (13 M, 18 M and 28 M) using the triaxial probe gave rise to similar
deuteration levels in the same time frame, indicating the preservation of the core structure
at the concentrations studied (details to be reported in Chapter 4).
To ascertain whether the evident poorer dissolution efficiency of the triaxial probe
is related to the incomplete mixing described above and/or to the shorter exposure to
MeCN, a series of experiments was undertaken to assess the dependence of fibril
dissolution on the concentration of MeCN. For these experiments, fibrillar suspensions
were prepared with equivalent monomer concentration of 2.0 M, 0.5% formic acid, 0.2
mM tris, and MeCN concentrations of 0%, 15%, 30%, 45%, 60% or 90% (v/v). A
suspension was centrifuged and decanted 2 hr after mixing, and the monomer
concentration in 100-L aliquots of the supernatants was determined using HPLC/UV (as
described above). The fibrils were then resuspended by shaking in a vortex mixer for 1
min. Centrifugation and LC measurements were then repeated 22 hour later. As evident
in Figure 3.5, fibril solubility in 90% MeCN was negligible. Otherwise, dissolution was
enhanced whenever both MeCN and water were present, with essentially complete
dissolution after 24 hr in 30% MeCN. In contrast, the solution with no MeCN achieved
only about 47% dissolution after 2 hr, and solubility did not increase after an additional
22 hr; this sample apparently reached its equilibration concentration within the first 2 hr
(although it is possible that further dissolution may have occurred after a longer
incubation time). Comparison of data from Figure 3.5 and Table 3.2 suggests that fibrils
may equilibrate in the aqueous solution with no MeCN even within the short mixing time
in the triaxial probe. Table 3.2 shows 43% dissolution of 29.6 M (initial equivalent)
fibrils in the triaxial probe. Under the conditions of Table 3.2, these fibrils will have
been diluted to ~6 M with 100/0.5 (v/v) H2O/HCOOH for about 12 sec, followed by
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Figure 3.5. Effects of acetonitrile on the solubility of 2-µM (monomer equivalent
concentration) Aβ(1-40) fibrils (2 hours and 24 hours incubation). The solvent mixture
contains 0.5% formic acid, 0.2 mM tris and the indicated percentage of acetonitrile
(balance water). The concentration of acetontrile-water-formic acid mixtures is reported
as percentage volume-volume (v/v).
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further dilution to ~ 3 M with MeCN for the last 1.1 sec at the probe tip. Although the
final MeCN concentration was 41%, the 43% dissolution more closely resembles that for
the pure aqueous solution in Figure 3.5 (47%, vs > 60% at 45% MeCN). The imperfect
mixing described above is unlikely to cause such a large effect, given the relatively weak
dependence of solubility on MeCN concentration around 41% in Figure 3.5; the triaxial
probe evidently does not allow adequate mixing time to realize the full enhancement of
dissolution afforded by MeCN. More complete fibril dissolution might be obtained by
using slower flow rates (longer time), but this would lead to increased exposure to backexchange and therefore to loss of structural information. Use of relatively low fibril
concentrations to assure good dissolution appears to be a reasonable compromise.

Artifactual exchange. As noted in section 1.3.3, post-incubation sample processing steps
involving protic solvents can introduce artifactual exchange in HDX-MS, adding to
(forward exchange – FE) or removing (back-exchange – BE) the deuterium incorporated
during incubation in D2O.

While methods exist to correct for these artifacts when

calculating total deuterium incorporation (see section 1.3.3 and 1.3.4) [233, 361],
assessment of the extent of exchange and especially localization of exchange (e.g., by
MS/MS) will be more reliable if artifactual exchange can be minimized [233, 59]. Such
minimization contributed to the choice of MeCN as a non-protic co-solvent in earlier
studies [58-59], reducing the effective concentrations of H2O and D2O while facilitating
electrospray. This proved to be effective with the coaxial probe [58-59]; artifactual
exchange was within the range reported elsewhere using other methods [59]. However,
effectiveness might be compromised by delayed introduction of MeCN and incomplete
mixing. Thus, as a final measure of the utility of the triaxial probe for HDX-MS studies,
the extent of artifactual exchange was assessed and compared with that using the coaxial
probe.
A monomers were chosen as probes for these tests because they represent a
“worst-case scenario”; their exposure to artifactual exchange is not mitigated by slow
dissolution, as is the case for fibrils. FE was assessed by mixing a 25 µM aqueous
solution of monomer in 2mM tris (0.85 µL/min) with processing solvent (80/20/0.5
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(v/v/v) H2O/D2O/HCOOH at 4.25 µL/min in T1 (Figure 2.1) followed by addition of
MeCN at 5 L/min via tube 2 for the triaxial probe; 36.8/9.2/54/0.5 (v/v/v/v) H2O/D2O
/MeCN/HCOOH at 9.25 µL/min in T1 for the coaxial probe) chosen to generate a final
solution in which 16.7% of the water was D2O. For assessment of BE, 25 µM fully
deuterated monomer in 2 mM fully deuterated tris (0.85 µL/min) was mixed in T1 with
an H2O-based processing solvent (100/0.5 (v/v) H2O/HCOOH at 4.25 µL/min followed
by 100/0.5 (v/v) MeCN/HCOOH in T2 for the triaxial probe; 46/54/0.5 (v/v/v)
H2O/MeCN/HCOOH at 9.25 µL/min for the coaxial probe), which again gave a final
solution in which 16.7% of the water was D2O. Such analyses represent standard steps in
obtaining data for correction of artifactual exchange (discussed in section 1.3.3) [59]. As
in previous studies, labile side chain, terminal and ionizing protons are assumed to be
statistically labeled; their contribution was subtracted to allow assessment of BE and FE
relevant to backbone amides [59]. BE and FE were then calculated using Eqn. 1.26 and
Eqn. 1.25 (presented in section 1.3.3), respectively.
Results show that BE was 6.5 ± 0.05 (D replaced by H) and FE was 1.5 ± 0.03 (H
exchanged for D) using the coaxial probe, while the numbers are slightly higher with the
triaxial probe (BE: 6.8 ± 0.1; FE: 2.0 ± 0.03), probably reflecting the slightly longer
mixing time (13.1 vs 12 sec for the coaxial probe) and the higher effective water
concentration due to imperfect mixing. In both cases, the difference is less than 1
exchanged proton/deuterium, well within the uncertainty with which total exchange is
usually determined. BE exceeds FE, reflecting the fact that H2O (rather than D2O) is the
primary water component (83.3%) after mixing.

3.3

Validating a Method for Correcting Artifactual Exchange on the
Triaxial Probe
As discussed above, BE and FE are evident on both probes. This artifactual

exchange (occurring during quenching and further sample processing prior to injection
into the mass spectrometer) compromises the accurate and precise assessment of the
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extent of exchange [59, 233]. Therefore, correcting data for artifactual exchange is
necessary. As addressed in Chapter 1, several approaches are available to determine the
extent of amide exchange prior to quenching [59]. The correction method (Eqn. 1.241.26 in section 1.3.3) developed by our group demonstrated its robustness when it was
applied to correcting HDX data of Aβ(1-40) intact fibrils obtained from the coaxial probe
[59]. The validation of the method was based on a study of the flow rate dependence of
the corrected deuterium content [59]. The sum of the sample and processing solvent flow
rates determines the time available for artifactual exchange, whereas the relative flow
rates of the sample and processing solvent determine the final solvent composition.
Because neither of these should affect the pre-processing deuteration, the constancy of
corrected values obtained at various flow rates should provide a sensitive test for the
robustness of a correction method. To validate a method for correcting artifactual
exchange of Aβ fibrils on the triaixial probe, we took a similar approach.

In this

approach, the flow rates of the sample (partially deuterated Aβ(1-40) fibrils incubated in
D2O for 100 h) and the processing solvent stream (0.5/100 HCOOH/H2O) were
proportionally varied, resulting in times of 25.8, 12.0, 9.1 and 7.3 seconds for the mixing
between the sample and the processing solvent (Table 3.3). At the same time, the flow
rate of the sheath liquid (0.5/100 HCOOH/MeCN) was varied accordingly to attain final
total flow rates of 10, 15, 20 and 25 µL/min (Table 3.3). The percentage of water that is
D2O in the final solvent mixture was maintained at 16.7%. For all the studies presented
in this section, the experiments were conducted on the Quattro II mass spectrometer, and
the molecular masses are corrected before substitution into various equations by
subtracting artifactual exchange into ionization, side-chain and terminal protons as
described in section 1.3.3.
Figure 3.6 presents the flow-rate dependence of the measured (uncorrected)
deuterium content (= m-MW, m and MW are defined in section 1.3.3) in partially
deuterated Aβ(1-40) fibrils (d-fibrils). Cursory inspection of Figure 3.6 shows that, as
expected, longer mixing times before MS analysis (slower flow rates) led to increased
undesired exchange.

For example, the amount of deuterium measured in backbone

amides of d-fibril samples varied from ~ 11.0 to 13.0 as the flow rate changed from 10 to
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Table 3.3. Summary of the flow rates used in the experiments to provide HDX data for
testing correction methods.

Flow Rate (µl/min)
Total

Mixing Time

Sample

Solvent

Sheath liquid

Flow Rate

(Aβ(1-40)

(0.5/100

(0.5/100

(µl/min)

d-fibrils)

HCOOH/H2O)

HCOOH/MeCN)

0.56

2.82

6.62

10

25.8

0.85*

4.25*

10.0*

15*

12.0

1.13

5.63

13.24

20

9.1

1.41

7.04

16.55

25

7.3

(second)

* Flow rates optimized for the triaxial probe setup on the Quattro II mass spectrometer
(see section 2.3).
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Figure 3.6. Measured amide deuterium content for partially deuterated A(1-40) fibrils
versus total flow rate. The error bars were calculated using propagation of errors [376].
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25 µl/min.
Ideally, plots of corrected deuterium content versus flow rates should be
horizontal lines if a correction method is perfect. That is, the slope of the least squares
line should be zero and the Y-intercept should be equal to the average corrected
deuterium value. These values should provide a quantitative means for evaluating the
performance of a correction method. Figure 3.7 and Table 3.4 show the applications of
various correction methods (discussed in section 1.3.3 and section 1.3.4), using fibrilbased m100% and m0% values to calculate the corrected deuterium content. The data
(corrected using Method E: Eqn. 1.24-1.26) obtained in the previous study using the
coaxial probe are used as the benchmark for comparison and are included in Table 3.4.
As evident from Figure 3.7 and Table 3.4, none of the methods gave perfect results
(Figure 3.7 and Table 3.4). For Method A (Eqn. 1.18, by Zhang and Smith [233]) and
Method B (Eqn. 1.19-1.23, by Resing et al. [299]), the Dcorr values vary significantly as
the flow rate is changed (Figure 3.7a and 3.7b, and Table 3.4). Indeed, the slopes are
much higher (0.66 ± 0.02 for method A; 0.14 ± 0.03 for method B), the intercepts much
lower (10.8 ± 0.4 for method A; 9.7 ± 0.5 for method B) and the corrected number of
deuteriums much lower (12.5 ± 0.4 for method A; 12.2 ± 0.5 for method B) than the
corresponding data obtained in the previous study using the coaxial probe [59] (Table
3.4).
Method C (Eqn. 1.28-1.29, by Mandell et al. [238]) was developed to correct for
artifactual exchange occurring during HDX-MALDI-MS.

The decay in deuterium

content is analogous to the changes in Dmeas (= m-MW) observed with increasingly long
mixing times (lower flow rates). By replotting these data as a function of mixing time
(calculated using the flow rate and the length of the capillary from the mixing T to the ES
source) and fitting a single-exponential decay curve, it was possible to calculate k, B1, and
B2 as in equation 1.28; resulting parameters are listed in the legend to Figure 3.7c. The
corrected amide deuterium content (Dcorr) was then calculated at each mixing time using
equation 1.29. For comparison with the other correction schemes, the resulting data are
plotted as a function of flow rate in Figure 3.7c. It can be seen that this method provides
both flow rate independence (slope for the linear fit = 0.04; Table 3.4) and a good match
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Figure 3.7. Amide deuterium content (corrected using various methods) versus total flow
rate. (A) Method A, as described in Eqn. 1.18 (Zhang and Smith 1993). (B) Method B,
as described in Eqn. 1.19-1.23 (Resing et al. 1999). (C) Method C, as described in Eqn.
1.28-1.29 (Mandell et al. 1999). The parameters needed for use of Eqn. 1.28 were
determined by plotting Dmeas (= m-MW) as a function of mixing time (calculated from
flow rate), and then fitting to a single exponential function (Eqn. 1.28) as described in the
text. The best-fit equation was Dmeas = 11.0 + 7.0 (e- 0.168t). (D) Method D, a modification
of Method C using Eqn. 3.1 instead of Eqn. 1.28 to determine the parameters needed for
use of Eqn. 1.29. The best-fit equation was Dmeas = 6.5 + 7.2 (e-0.0186t). (E) Method E, as
described in Eqn. 1.24-1.26 (Kheterpal et al. 2001). The error bars were calculated using
propagation of errors [376].

111

20

(D)

15
Corrected Deuterium Content

Corrected Deuterium Content

(C)
19

18

17

16

14

13

12

15
8

10

12

14

16

18

20

22

24

26

8

10

12

14

Total Flow Rate (µl/min)

20

(E)
Correct Deuterium Content

19

18

17

16

15
8

16

18

20

Total FlowRate (µl/min)

10

12

14

16

18

20

Total Flow Rate (µl/min)

(Figure 3.7 continued)

112

22

24

26

22

24

26

Table 3.4. Quantitative analysis of the performance of correction methods based on
HDX data obtained from analysis of A(1-40) fibrils incubated for 100 h using the
triaxial probe on the Quattro II mass spectrometer.

Correction method (16.7% D2O
in the final solvent mixture)

Average corrected

Intercept2

Slope2

12.5 ± 0.4

10.8 ± 0.4

0.66 ± 0.02

12.2 ± 0.5

9.7 ± 0.5

0.14 ± 0.03

deuterium content

1

Method A
(Eqn. 1.18; Zhang and Smith 1993)

Method B
(Eqn. 1.19-1.23; Resing et al. 1999)
Method C
(Eqn. 1.28-1.29; Mandell et al. 1998)
Method D (Eqn. 3.1 and Eqn. 1.29)

1×10-5 ±

18.0 ± 0.04

18.0 ± 0.08

13.7 ± 0.3

13.4 ± 0.5

0.02 ± 0.03

17.3 ± 1.6

18.6 ± 0.2

-0.07 ± 0.01

18.9 ± 0.5

19.6 ± 0.4

-0.06 ± 0.03

0.004

Method E
(Eqn. 1.24-1.26; Kheterpal et al. 2001)
Data from the coaxial probe 3
(using Method E)

1
2
3

The average of the corrected deuterium content at all measured flow rates.
Intercept and slope for linear fit to plots of corrected deuterium content vs. flow rate.
The data is from analysis of A(1-40) fibrils incubated for 100 h using the coaxial probe

on the Quattro II mass spectrometer [59]. The percentage of D2O in the final solvent
mixture was 18.18%.
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to the expected average corrected deuterium content ( Dcorr = 18.0 ± 0.04, consistent with
the expected value of 18.0 ± 0.08 and close to the value of 18.9 ± 0.5 obtained from the
coaxial probe; Table 3.4).

One limitation to Method C is that it requires routine

collection of data at several flow rates in order to obtain k and B2 from Eqn. 1.28.
Method D (Eqn. 3.1 and Eqn. 1.29) is a modified form of the method C. The
ultimate equilibrium value of Dmeas (B1) in Eqn. 1.28 of Method C can be predicted
independently of the fitting routine since the final solution conditions in the ES
experiments described here are relatively well-defined. For example, 16.7% of the water
in the final solvent mixture was D2O, so that at equilibrium (t = ), 6.5 amide protons
(16.7% of the 39 amides) will be deuterated (i.e., B1 = 6.5). Equation 1.28 can be
modified

slightly

to

reflect

this

added

Dmeas = 6.5 + B2 e − kt

information:
Eqn. 3.1

Fitting the d-fibril data presented in Figure 3.6 to the exponential decay function
described in Eqn. 3.1 resulted in k and B2 values (reported in the legend of Figure 3.7d).
These k and B2 values were again used with Eqn. 1.29 to determine a corrected amide
deuterium content for data at each flow rate; results are presented in Figure 3.7d. Method
D provides results with little flow-rate-dependence, as evident from the slope of 0.02 for
the linear fit (Table 3.4). However, the average Dcorr value is too low: 13.7 ± 0.3
compared with the benchmark of 18.9 ± 0.5 obtained from the coaxial probe [59]. Thus,
the performance of Method D was deemed to be inadequate for fibril HDX.
For Method E (Eqn. 1.24-1.26; Kheterpal et al. [59]), the results show a slight
flow-rate dependence, as evidence by the small slope of the linear fit of these data (-0.07
± 0.01) (Figure 3.7e and Table 3.4). Moreover, the average Dcorr value from Figure 3.7e is
17.3 ± 1.6 deuteriums, equivalent to the intercept (18.6 ± 0.2) and to that (18.9 ± 0.5)
obtained using the coaxial probe [59] within the experimental error (Table 3.4). Among
all the methods evaluated above, Method E shows a good compromise in terms of
practicability and performance. Unlike Method C, it offers a practical compromise that
requires determination of m, m100%, and m0% at only one flow rate. Method E is the
method which has been used to correct for all the HDX data presented in this dissertation.
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Note that Method E uses fully protonated fibrils and fully deuterated fibrils (rather
than corresponding monomers) as the control samples to correct HDX data for BE and
FE (discussed in Chapter 1). The basis for these choices is evident in Figure 3.8. FE of
protonated A(1-40) fibrils (H-fibrils) has a less extent than protonated monomer (Hmonomer), as indicated by the lower m/z of the H-fibril peak than that of the H-monomer
peak in the M0 solvent (Figure 3.8a). There is also less BE in fully deuterated A(1-40)
fibrils (D-fibril) compared to fully deuterated monomer (D-monomer) (Figure 3.8b), so
that the D-fibril peak falls at a higher m/z than the D-monomer peak.

All this is

attributable to the finite time required for fibril dissolution, which reduces the time
available for forward exchange and back exchange, explaining why fully protonated and
deuterated fibrils are grown for our forward exchange and back exchange control
samples. Also worth noting is that the molecular weight measured for the protonated
A(1-40) sample (MW in Eqn. 1.24-1.26), instead of the theoretical molecular mass
(4329.9 Da), was used to correct for the day-do-day variability in mass calibration of the
Quattro II instrument, although the latter two numbers generally agree to within 0.5 Da.
Also worth noting is that isotopic effects on BE and FE are negligible when using
Method E to correct HDX data obtained from fibrils incubated in D2O buffer for 24 hours
or longer.

The exchange essentially reached a plateau after 24 hours incubation

(discussed in Chapter 4), so the exchange was under equilibrium control. Since kinetic
isotope effects and equilibrium isotope effect in HDX are small (see section 1.3.2), the

rates for BE and FE were mainly determined by the concentration of D2O and H2O in the
processing solvent. Since 16.7% D2O and 83.3% H2O were used in our experiments, BE
was bigger than FE (see section 3.2).

3.4

Conclusions

The triaxial probe represents a classic compromise in trying to optimize
independent processes. While its performance in terms of signal stability, artifactual
exchange, and fibril dissolution, does not match that of the standard coaxial probe, the
115

724.3

724.2

Relative Intensity

100

(a)

80

60

40

20

0
722

724

726

m/z

728.6

Relative Intensity

100

728.9

(b)

80

60

40

20

0
726

728

730

732

m/z

Figure 3.8. ESI-MS of the +6 charge state peak of A(1-40) peptide obtained using (a)
fully protonated fibrils (solid line) and fully protonated monomer (dashed line) as m0%
sample; (b) fully deuterated fibrils (solid line) and fully deuterated monomer (dashed
line) as m100% sample. Each peak is labeled with centroid m/z values. The data shown
here have been smoothed using Savitzky Golay method implemented in the MassLynx
program from the Quattro II mass spectrometer.
116

differences are relatively small, especially when compared with the major enhancement
in the effectiveness of on-line proteolysis.

By decoupling reaction and spray

optimization, the probe may enable a wide range of on-line reactions to facilitate system
characterization in HDX-MS and other applications. Performance with respect to the
other figures of merit in other applications may be improved by re-optimizing flow rates
and tube diameters.
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CHAPTER 4

CHARACTERIZATION OF Aβ
β(1-40) AMYLOID FIBRILS
AND PROTOFIBRILS USING HDX-MS COUPLED WITH
ON-LINE PROTEOLYSIS

As discussed in Chapter 1, high-resolution structural information about fibrils and
protofibrils is lacking because of the insoluble, heterogeneous and non-crystaline nature
of fibrils, and because of the metastable, transient nature of protofibrils. Therefore,
structural information of Aβ fibrils and protofibrils at lower resolution has become
increasingly important. HDX-MS studies have shown that both fibrils and protofibrils
have a core resistant to HDX; about 60% (for fibrils) and 40% (for protofibrils) of the 39
backbone amide protons in the Aβ(1-40) are protected from exchange after two days of
incubation in aqueous deuterated buffer [58-59]. This suggests that a significant portion
of this relatively short sequence is in fact not involved in the presumably protective Hbonded structure. Such data immediately introduce the questions of which regions of the
peptide are exposed to exchange and which portions are involved in β-sheet structure.
One method to obtain such information is to proteolyze deuterated fibrils and protofibrils,
inject the samples into the MS system, and measure the amount of deuterium exchanged
in the smaller peptides.

The triaxial probe discussed in Chapter 3 enables on-line

digestion to gain insights into regional exchange protection of Aβ(1-40) fibrils and
protofibrils, thus to elucidate the extent and pattern of individual residues involved in βsheet formation within the fibril and protofibril structure. This chapter will discuss the
structural information obtained from the HDX-MS data of peptic fragments derived from
fibrils and protofibrils, and the potential of obtaining complementary structural
information using 3 pepsin-like enzymes.
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4.1 Hydrogen/Deuterium Exchange and Proteolysis (Using Pepsin) of
A(1-40) Amyloid Fibrils and Protofibrils
4.1.1

Hydrogen/Deuterium Exchange and Proteolysis of A(1-40) Amyloid Fibrils
With the on-line proteolysis approach using the triaxial probe on the Quattro II

mass spectrometer, A(1-40) fibrils (grown in PBS under quiescent conditions described
in section 2.2) were disaggregated and digested using pepsin. Fragments 1-19, 4-19, 2034, 35-40, 20-33, 34-40, and 20-40 were observed for protonated fibrils and confirmed
using MS/MS as described in Chapter 2. However, for fragments 20-33, 34-40, and 2040 derived from partially and fully deuterated fibrils, they were of insufficient intensities
(or poor S/N) for accurate mass measurement. As a result, only HDX data of fragments
1-19, 4-19, 20-34, 35-40 were discussed here. Representative spectra of the intact fibrils
and four non-overlapping fragments after 24 h of exchange are presented in Figure 4.1.
The blue and red lines in each panel of the Figure 4.1 correspond to the spectra obtained
from fully protonated and fully deuterated A(1-40) monomers (H-monomer and Dmonomer, respectively). In all cases, broadening of mass spectral peaks was observed
due to the natural isotope distribution as well as deuterium exchange. All the HDX data
discussed below were corrected for fast exchanging side chain, terminal, and ionization
protons, as well as artifactual exchange into backbone amide protons, as described in
section 1.3.3 [59]. Note that while the proteolysis strategy gives information on the
segmental spread of protection within the A peptide, it also inevitably leads to some loss
of information. Pepsin cleavage generates a rapidly exchanging amino group from a
slow-exchanging amino group, so that the HDX information housed in the amino proton
is completely lost by the time the fragment is analyzed in the MS. This loss of exchange
protection information has to be kept in mind, for example, when comparing fragments to
full length peptide or to fibril structure models.
The spectrum of partially deuterated intact fibrils (d-fibrils, solid black lines in
Figure 4.1a), obtained by exposure of A fibrils to D2O exchange conditions, shows two
A populations represented by two peaks (peak A and peak B). The centroid of peak A
varies with exchange time, while the higher mass peak B is superimposable with that of
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Figure 4.1. ESI-MS of (a) intact A(1-40) fibrils and proteolytic fragments (b) 1-19, (c)
20-34, and (d) 35-40. The blue and red lines in each spectrum represent fully protonated
monomer (H-mon) and fully deuterated monomer (D-mon), while the black solid line
represent partially deuterated fibrils (d-fib). The charge states shown for each fragment
are marked in each panel.

120

fully exchanged D-monomer. The number of deuteriums exchanged into intact A fibrils
was calculated using the molecular mass obtained from the centroid of peak A. Since
charge states +5 and +6 were consistently observed with good signal-to-noise ratio for
intact A fibrils, molecular masses obtained from these charge states were averaged for
all calculations. The corrected number of deuteriums after 24 h of exchange for intact
A(1-40) fibrils (peak A) was determined to be 17.1 ± 1.3 (Table 4.1), in good agreement
with our previously published data for a similar exchange time obtained using the coaxial
probe (17.0 ± 1.1) [58-59, 61]. The corrected number of deuteriums in peak B is
equivalent to the number of deuteriums exchanged into the unprotected monomeric A
peptide. The existence of a fully deuterated component (peak B) in the analysis of A(140) fibrils and its growth with time was reported previously [58]. The origin of peak B
requires further investigation, but it does not interfere with the analysis of exchange
protection in peak A. A number of possible sources of the fully exchanged component
will be discussed later in this chapter.
Figure 4.1b-d illustrates the differences in the extent of exchange in four nonoverlapping fragments (20-34, 1-19, 4-19 and 35-40) after 24 h of exchange time. The
mass spectrum of the peptide spanning residues 20-34 (Figure 4.1b), from the digestion
of partially deuterated A(1-40) fibrils, contains two peaks, with peak B corresponding to
the fully deuterated species, in analogy to that observed for the intact A peptide as
discussed above. The lower m/z peak A clearly contains a population of A significantly
protected from HDX compared to the fully exchangeable species in peak B.

The

deuterium exchanged into this fragment was determined from the m/z of peak A in Figure
4.1b. The charge state obtained for this peptide is +2, based on its mass and confirmation
by MS/MS as described in Chapter 2. The total number of amide protons is 14, and the
total number of side-chain and terminal protons is 10. (Note that even if residues 20 and
34 are protected in the fibril, they become terminal sites in the proteolytic fragment and
will therefore be statistically deuterated.) The resulting corrected number of deuteriums
exchanged into the amide sites of this peptide after 24 h was only 4.3 ± 0.3, indicating
that most of the 14 amino acids in this segment of the peptide were protected from
exchange.
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Table 4.1. Summary of segmental protection data for A(1-40) aggregates after 24 hours
of exchange.

Amyloid Fibrils

Fragment

Amide protons
exchanged

CLC-stablized protofibrils

Protected amide
protons (Total
amide protons)

Amide protons
exchanged

Protected amide
protons (Total
amide protons)

1-40

17.1 ± 1.3

21.9 ± 1.3 (39)

26.2 ± 1

12.8 ± 1 (39)

1-19

10.2 ± 0.5

7.8 ± 0.5 (18)

12.4 ± 0.6

5.6 ± 0.6 (18)

4-19

6.5 ± 0.5

8.5 ± 0.5 (15)

9.9 ± 0.6

5.1 ± 0.6 (15)

20-34

4.3 ± 0.3

9.7 ± 0.3 (14)

9.5 ± 0.4

4.5 ± 0.4 (14)

35-40

3.9 ± 0.1

1.1 ± 0.1 (5)

4.1 ± 0.1

0.9 ± 0.1 (5)
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Mass spectra of the N-terminal peptide 1-19 obtained from partially deuterated
fibrils and fully deuterated monomer showed considerable overlap (Figure 4.1c),
consistent with the low level of protection expected for this region [37, 40]. If the B peak
in Figure 4.1a derives from fully-exchanged monomers as described above, proteolysis of
these monomers would be expected to give analogous B peaks for all product peptides.
However, there is only 1 peak evident in the spectrum of the 1-19 (and 4-19) fragment
derived from partially deuterated fibrils (Figure 4.1c and Figure 4.1d; charge state 5+ is
shown), and that peak is at an m/z slightly lower than expected for the corresponding B
peak.

This can be explained by the relatively low resolution, which would cause

coalescence of the A and B peaks to a single peak representing the weighted average, if
the degree of protection and the resulting mass difference were small.
Assuming then that there are two unresolved peaks in Figure 4.1c (as for the 1-40
and 20-34 spectra), the m/z of the partially exchanged component (peak A) was obtained
by deconvolution of this composite peak, as follows. First, the m/z of the peak derived
from fully deuterated A monomer was determined (466.8). The envelope for this peak
was fit using a Pearson VII function in the PeakFit (Systat) software, as this function
gave a better fit than the other available functions (e.g., Gaussian). The mass spectrum of
the fragment 1-19 obtained from partially deuterated fibrils was then deconvoluted into A
and B peaks using the Pearson VII equation with the number of peaks fixed at 2, the
position of peak B fixed at the value determined from the monomer, and the relative
abundance of peaks A and B fixed at the value measured for the 20-34 fragment (A:B ~
1.5:1; Figure 4.1b). This ratio was selected in preference to the (clearly larger) ratio for
the intact monomer (Figure 4.1a), since proteolysis was observed to preferentially
attenuate the B peak of the intact 1-40 (data shown later). Data from all fragments are
part of a single spectrum and should reflect the same relative contributions from materials
derived from A and B peaks of the intact 1-40. Non-linear regression analysis was run
iteratively until convergence of the single variable constituting the position of the
fragment 1-19 A peak, giving a value of 466.2 for the data shown in Figure 4.1c. The
corrected number of backbone amide protons exchanging into the fragment 1-19 after 24
h of incubation in deuterated buffer was thus 10.2 ± 0.5 (averaged over the +4 and +5
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charge states), based on the centroid of the calculated peak A; roughly 8 (of a possible
18) amide protons are protected in this portion of the molecule. The mass spectra of the
4-19 proteolytic fragment of d-fibrils (Figure 4.1 d) were deconvoluted into A and B
peaks in a similar way. After the deconvolution, the number of backbone amide protons
exchanged into this fragment after 24 h of incubation in deuterated buffer was determined
to be 6.5 ± 0.5 (averaged over the +4 and +5 charge states), again based on the centroid
of the calculated peak A. The difference in deuterium content between 1-19 and 4-19 is
3.7 ± 0.7, suggesting the first 3 amino acids are completely exchanged. This is consistent
with a fully exposed N-terminus [37, 40].
The C-terminal peptide 35-40 showed the least amount of protection as illustrated
by the almost complete overlap of mass spectra derived from partially deuterated fibrils
and fully deuterated monomer (Figure 4.1e). As discussed above, one would still expect
there to be distinct contributions from A and B peaks of the intact 1-40. However, the
mass spectra of the singly charged 35-40 fragment are isotopically resolved, which makes
fitting using Peakfit (as described above) difficult. Instead, molecular masses were
calculated assuming that the centroid of the isotopic distribution is a simple linear
combination of the centroids of A and B distributions, with the latter estimated from the
data for the deuterated monomer:
Centroidd-fibril = 0.6 × CentroidX + 0.4 × Centroidd-monomer

Eqn. 4.1

Here, Centroidd-fibril and Centroidd-monomer are the experimental values from the partially
deuterated fibril and the fully deuterated monomer (564.2 and 564.4, respectively, from
Figure 4.1e), and CentroidX is the desired value for the unresolved A peak.

The

weighting factors (0.6 and 0.4) are those derived from Figure 4.1b, as described above for
the [20-34] fragment.

Solving for CentroidX in the above equation yields the

deconvoluted m/z of 564.2, which indicates a neutral mass within experimental error (~ ±
0.2 Da) of the value for the B peak. The corrected number of deuteriums exchanged into
this fragment after 24 h of H/D exchange time was 3.9 ± 0.1 (of a possible 5).
The course of isotopic exchange can be visualized through plots of the content of
deuterium per peptide molecule versus incubation time. Time-dependent HDX results for
the Aβ(1-40) intact peptide and the peptic fragments are presented in Figure 4.2a. As
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Figure 4.2. Number of deuteriums incorporated as a function of time for (a) A(1-40)
fibrils () and peptic fragments 1-19 (), 4-19 (), 20-34 (), 35-40() obtained from
digestion of A(1-40) fibrils; (b) A(1-40) protofibrils () and peptic fragments 1-19 (),
4-19 (), 20-34 (), 35-40() obtained from digestion of A(1-40) protofibrils
(stabilized by CLC).
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evident from Figure 4.2a, exchange was essentially complete in 24 hours, justifying the
selection of this time point as the example to illustrate exchange kinetics as described in
this section. Table 4.1 summarizes the number of backbone amide protons exchanged
(exposed) and protected (buried or involved in secondary structure) in both intact
monomer and proteolytic fragments from A(1-40) fibrils exposed to 24 h of incubation
in deuterated Tris buffer.

The proteolytic fragmentation results reveal significant

variations in protection from exchange within different regions of the A(1-40) peptide.
The order of protection, as a percentage of available backbone amide protons, was found
to be 20-34 > 4-19 > 1-19 > 35-40. These data exhibit a gratifying degree of internal
consistency. The sum of the number of amide protons exchanging in fragments 1-19, 2034 and 35-40 is 18.4 ± 0.6, which, within error, is equivalent to the 17.1 ± 1.3 exchanging
backbone amide protons obtained for the intact peptide under similar conditions. As
discussed earlier, two amide protons are lost in proteolytic cleavage at 19-20 and 34-35
and therefore cannot be directly accounted for in the fragment analysis. If these were
unprotected (and therefore exchanged) in the fibril, the revised total for exchanging
amide protons in the fragments would be 20.4, significantly higher than the full length
value of 17.1. This suggests that the “invisible” amide protons from residues 20 and 35
are also protected in the fibril, consistent with most other available data on PBS/quiescent
A(1-40) amyloid fibrils [63] (see below). Assuming that protection is an all-or-none
phenomenon, these data suggest that 8, 10, and 1 backbone amide protons are protected
in fragments 1-19, 20-34 and 35-40, respectively.
Figure 4.3 shows an interpretation of the fibril data, in the context of literature
data on this particular A(1-40) amyloid conformation. Line B shows the consensus
secondary structure prediction from a combination of proline and alanine scanning
mutagenesis, coupled with HDX experiments monitored by NMR (summarized in section
1.1.3) [63], with “x” signifying residues in loose structure expected to be open to
exchange, and “” indicating residues expected to be in protected, -sheet structure. Part
C shows a model for -structure in these fibrils generated by incorporating the exchange
protection data on fibrils summarized in Table 4.1 into the consensus model from line B.
Each dash in the sequence represents an amide proton; thin dashes represent exchanging
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Figure 4.3. Models of secondary structure in A(1-40) aggregates. A. Amino acid
sequence of A(1-40). B. Consensus model of -extended chain regions in mature
fibrils grown in PBS at 37 °C without stirring, derived from Pro and Ala scanning
mutagenesis and HDX-NMR experiments (presented in section 1.1.3) [63]. C. Model
for -extended chain segments in mature fibrils grown in PBS at 37 °C without stirring,
derived from HDX-MS / pepsin analysis (this work). D. Model for -extended chain
segments in mature fibrils grown in low salt with agitation, as analyzed by solid state
NMR (presented in section 1.1.3) [87]. E. Model for -extended chain segments in
CLC-protofibrils derived from HDX-MS / pepsin analysis (this work). In C and E, the
top line shows the model for the entire A(1-40) peptide and the three lines below top
show the models for how -extended chain might be distributed within each pepsin
fragment.
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protons and thick dashes represent protected protons. Below the full length sequence in
Part C are the three proteolytic fragments showing how the amount of protection within
each fragment is consistent with the model for the exposed/protected amide hydrogens in
the full-length peptide. Since the pepsin cleavage sites at residues 19-20 and 34-35 are
both modeled to be in -structure, the sum of the protected residues of the fragments is
expected to be about two less than the number of protected residues in the intact peptide,
consistent with the reasoning above. The model assumes that strongly protected N-H
groups will not be isolated in the linear sequence, but rather will be collected in a limited
number of contiguous stretches of -structure. While the H-bond status of most of the Nterminus cannot be directly addressed by our data, the difference in protection levels
between the 1-19 and 4-19 fragments (3.7 ± 0.7, Table 4.1) suggest that the very Nterminus of A(1-40) is not involved in H-bonded structure in the PBS/quiescent fibril.
The results presented here are in agreement with HDX-NMR [61], and scanning
proline [40] and scanning alanine [63] analysis of PBS-quiescent amyloid fibrils of A(140). The data for a free C-terminus are in contrast with solid state NMR results showing
that the entire C-terminal segment of A(1-40) is involved in H-bonded -sheet structure
in amyloid fibrils [37, 87].

The distribution of secondary structure in A(1-40)

incorporated into amyloid fibrils grown with agitation under low salt conditions, as
deduced from solid state NMR experiments 19, is shown in Part D of Figure 4.3. These
differences are consistent with the unusual plasticity (the capability of adjusting to
packing changes) of the amyloid fibril structure [40, 63], as well as with the observation
that at least two stable, self-propagating conformations of fibrils can be formed from the
A(1-40) peptide depending on growth conditions [Petkova 2005].

There is little

information about the nature of the structural differences between the reported
conformations. The work presented here suggests that one difference may be in the
nature of the H-bonding network that defines the -sheets within the amyloid fibril. As
evident in Figure 4.3, the major secondary structural differences between low salt,
agitated fibrils (Figure 4.3D) and PBS, quiescent fibrils (Figure 4.3C) are the number of
residues in the 30-40 and 35-40 segments that are in protective, H-bonded structure.
Note that interpretation of the HDX data assumes that sites which are protected
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from exchange in fibrils and protofibrils (discussed later) are involved in H-bonded sheet structure because previous studies suggested fibrils and protofibrils are rich in sheets [33, 53-55, 58-65, 93-94] (see section 1.1.3). This does not rule out other possible
mechanisms for exchange protection. For example, some amide hydrogens may be
positioned within or near the fibril core so that they have limited access to deuteriums in
the solvent and are protected from exchange. Alternatively, D2O may be inaccessible to
some amide hydrogens in the protein because of hydrophobic interactions.

4.1.2

Hydrogen/Deuterium Exchange and Proteolysis of CLC-stabilized A(1-40)
Protofibrils
The on-line triaxial probe proteolysis methodology was also used to determine the

hydrogen exchange protection pattern in a form of A(1-40) protofibrils.

These

aggregates of A(1-40), promoted and stabilized by the small organic molecule CLC
(Figure 1.6), resemble transient authentic A protofibrils in a number of features,
including their EM image and overall HDX protection [94].

Figure 4.4 displays

representative spectra of intact CLC protofibrils and three non-overlapping fragments
after 24 h of exchange, with the blue and red lines in each panel corresponding to spectra
obtained from fully protonated and fully deuterated A(1-40) monomers. In contrast to
the corresponding spectra for the A amyloid fibril analysis shown in Figure 4.1, CLC
protofibrils exhibit only a single peak, one that reflects intermediate exchange (i.e., peak
A), and no fully exchanged peak (B). This is true for both full length (undigested) A(140) peptide as well as for all the pepsin fragments. The results show that these CLC
protofibrils consist of a very homogeneous structural population.

The numbers of

deuteriums exchanged into intact A(1-40) and proteolytic fragments of these CLC
protofibrils were calculated using the centroids of the unresolved isotopic envelopes, and
these data were corrected for fast exchanging side chain and terminal protons and
artifactual exchange into backbone amide protons as described previously [59]. The
corrected numbers of deuteriums exchanged into A peptides in CLC protofibrils after 24
h are summarized in Table 4.1. The time-dependent HDX exchange results for intact
peptide of CLC protofibrils and its peptic fragments are presented in Figure 4.2b.
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Figure 4.4. ESI-MS of (a) intact A(1-40) calmidazolium stabilized protofibrils and
proteolytic fragments (b) 1-19, (c) 20-34, and (d) 35-40. The blue and red lines in each
spectrum represent fully protonated monomer (H-mon) and fully deuterated monomer
(D-mon), while the balck solid line represent partially deuterated fibrils (d-fib). The
charge states shown for each fragment are marked in each panel.
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Using the triaxial probe procedure, the number of backbone amide protons found
to exchange in intact A peptide in CLC protofibrils after 24 h of exchange time is 26.2 ±
1. These data are in good agreement with our previously reported value for these CLC
protofibrils, 27.6 ± 1.3, using the coaxial probe methodology [94]. An almost exact
match between the sum of exchange into the three non-overlapping fragments (12.4 + 9.5
+ 4.1 = 26.0) and the value for intact CLC protofibrils (26.2) is another remarkable
feature of these data. That this agreement between the exchange observed in fragments
and intact CLC protofibrils is better than that observed in fibrils (Table 4.1) is possibly
due to the more homogenous nature of these CLC protofibrils, and because
deconvolution of A and B peaks was not required in the analysis of the CLC protofibril
data. If the “silent” amide protons at the 19-20 and 34-35 pepsin cleavage sites also
significantly exchange in the CLC protofibril, the fragment total would be 28.0,
significantly higher than 26.2. This implies that these two protons are probably largely
protected from exchange in the protofibril as in the fibril.
Our interpretation of this data is shown in Part E of Figure 4.3, which places the
highly protected, presumably -sheet residues in two contiguous elements of -extended
chain analogous to the two segments of -extended chain elements in fibrils. This is
supported by previous proline scanning analysis of CLC protofibrils, which found highly
proline-sensitive residues concentrated in the 16-21 and 30-36 segments of A(1-40)
[94]. Figure 4.3E shows that the segmental HDX data fit best to a model in which
residues 14-20 and 31-36 are contained in highly protected structure. The model shows
that the C-terminal segment of A(1-40) is not involved in highly protected structure in
the protofibril. As with the similar conclusion for quiescent amyloid fibrils above, this
assignment appears to be unequivocal, given the almost complete lack of protection in the
short 35-40 pepsin fragment that encompasses these residues. The model also suggests
that the main difference in secondary structure between quiescent A(1-40) amyloid
fibrils and CLC protofibrils is that the 21-30 segment of A is completely lacking in
highly protected structure in the latter. A second difference is that residues 11-13, which
are in protected, H-bonded structure in the fibril, appear to be open to facile exchange in
the CLC protofibril and hence not in strong H-bonded structure. It is significant that this
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distribution of presumed -extended chain residues in the CLC protofibril generates two
-sheets of similar widths of seven and six residues. This is easily accommodated into a
duplex -sheet such as that recently observed in the X-ray crystal structure of a small,
amyloidogenic peptide fragment of the yeast prion protein sup35 [377].

4.1.3

Implications of Peak B in Fibrils, Authentic Protofibrils and CLC-stablized
Protofibrils
As mentioned above, a striking difference in the data from CLC-stablized

protofibrils, compared to that from mature fibrils as well as from normally isolated
authentic protofibrils (chromatographically isolated from amyloid assembly reaction of
A(1-40)) [59], is the absence of a significant fully exchanged peak B in either the fulllength peptide or fragments. Since the fully exchanged peak B may limit the ability of
HDX-MS to provide interpretable data in other systems, some discussion of this technical
issue is warranted.

In our experiments, since fibrils are isolated by centrifugation

immediately prior to subjecting them to the deuterium exchange, this completely
deuterated A component is not a result of any monomer present in the original fibril
suspension. In principle, the presence of peak B in the HDX-MS of an aggregate could
come from a second class of peptide molecules that are part of the aggregate structure but
not held in place by strong H-bonds. Alternatively, it could derive from the dissociation
of A from the aggregate during the exchange period, generating a relatively
unstructured, and unprotected, monomer.

A third mechanism is one involving

dissociation, full exchange, and reassociation. The latter two possibilities would be
consistent with the demonstrated ability of A(1-40) fibrils and protofibrils to dissociate
[41, 44, 378].
The fully exchanged peak B we observe in analysis of mature amyloid fibrils is
probably due to a dissociation-exchange-reassociation mechanism, since we typically
observe a larger proportion of material in peak B than can be accounted for by the known
Cr of the peptide under these buffer conditions.

A similar dissociation-exchange-

reassociation mechanism has been invoked to explain the appearance of fully exchanged
material in the HDX-MS of other amyloid fibrils [379]. According to this mechanism,
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there may be a dynamic system - an equilibrium existing between the insoluble fibril and
the soluble monomer. In a mass spectrometric analysis of the solubilized fibrils, two
peaks would then be observed since MS can detect and characterize populations of
molecules with different degrees of exchange [265]: peak A, which represents the
population of molecules that has not yet dissociated from the fibrils and that is still
exposed to the deuterated solvent, and peak B, which represents the population that has
dissociated from the fibrils, exchanged and then been reincorporated.
The fully exchanged peak B observed in the analysis of authentic A(1-40)
protofibrils not stabilized by CLC [59] probably derives from dissociation to a monomer
pool during the exchange reaction, contributed by (a) the relative ease with which these
aggregates dissociate [44] coupled with (b) their poor ability to act as a template for
(re)addition of monomeric A(1-40) molecules [94]. In contrast, the lack of a fully
exchanged peak in the CLC protofibril data reported here is most consistent with a barrier
to dissociation due to the stabilizing influence of the CLC [94]. Even after 14 days of
incubation at 37 °C, the CLC protofibrils contain a single homogeneous structural
population exhibiting similar amount of deuterium exchange as the CLC protofibrils
isolated after day 2 shown in Figure 4.4a.
It is noted that as the incubation time increased, the intensity of peak B increases
relative to that of peak A for both full-length peptide (Figure 4.5a) and fragment 20-34
(Figure 4.5c) obtained from mature fibrils. However, the relative intensity ratio of peak
B to peak A is much bigger for fragment 20-34 than for full-length 1-40 peptide at the
same time point. For example, at the 100-h time point, the ratio was 1.1 for fragment 2034, while the ratio was only 0.5 for intact peptide. It was found that after the on-line
proteolysis of A(1-40) fibrils, some of the peak A of intact A still exists (Figure 4.5b),
suggesting that proteolysis of this class of A molecules is not complete. Also, the ratio
of peak B to peak A is lower in the MS spectra of “leftover” intact 1-40 peptide obtained
after digestion (Figure 4.5b) than in the MS spectra of intact 1-40 peptide obtained in the
absence of pepsin (Figure 4.5a) for the same time point. For example, at the 100 h time
point, the ratio was 0.23 for the leftover intact 1-40 peptide, while the ratio was 0.53 for
the intact 1-40 peptide obtained in the absence of pepsin. The fact that the ratio of peak
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Figure 4.5. Mass spectra illustrated of (a) intact Aβ(1-40) (+6 charge state) in the
absence of pepsin; (b) leftover intact Aβ(1-40) (+6 charge state) after the digestion; (c)
20-34 segment (+2 charge state) following incubation of 4 h, 24,h, 48 h and 100 h. The
intensity insets are for the base peaks in the spectra.
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B to peak A is smaller for the intact A(1-40) than for the fragment 20-34 is consistent
with longer exposure to pepsin,

possibly due to more rapid detachment of fully

exchanged molecules comprising peak B than partially exchanged molecules (comprising
peak A) present in the core structure of A(1-40). The fact that peak B of the intact
A(1-40) was attenuated more relative to peak A can be attributable to easier digestion of
monomers by pepsin than fibrils (discussed in Chapter 3). The observation here further
validates the use of the peak B to peak A ratio obtained from the fragment 20-34 (instead
of intact A(1-40)) to deconvolute the peaks of the fragments 1-19 and 4-19, as described
above.

4.1.4

Possible Correlation of Protofibrils with Fibrils
Although the efforts of a large number of research groups using technological

approaches have led to much insight into the structures of organized A aggregates
associated with Alzheimer’s disease (see section 1.1), there remain a number of critical
issues left to be resolved. Which aggregates are toxic and what is the mechanism of their
toxicity?

What are the structural differences between protofibrils and fibrils, and

between different conformational states of mature fibrils? What is the role of protofibrils
in the assembly mechanism of mature fibrils? The HDX-MS analysis reported here helps
to address some of the latter questions on structure and assembly.
Studies on spontaneous fibril assembly by A(1-40) as well as by the NM
fragment of the psi yeast prion protein sup35 have led to the suggestion that protofibrils
are on-pathway intermediates that are capable of (a) undergoing a key conformational
rearrangement to generate the nucleus for fibril growth and (b) adding intact to the
growing end of fibrils as a mechanism for elongation [42, 380]. Other studies show that
all aspects of this mechanism are not absolutely essential for fibril growth.

Thus,

solutions of monomeric A(1-40), even at very low concentrations where protofibril
formation is slow, can support fibril elongation [381-382].

Likewise, solutions of

monomeric Sup35 NM are able to elongate mature fibrils through monomer addition
[383]. In addition, monomeric Sup35 NM preparations are able to support spontaneous
fibril formation through a nucleation mechanism involving a critical nucleus containing
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very few monomers, rather than a transformation within a protofibril [383]. While the
latter studies suggest that protofibril formation is not an absolute requirement for fibril
growth, it nonetheless remains of great interest how fibril nucleation and growth is
mediated by protofibrils under those conditions in which they are involved.
Even if protofibrils are on-pathway intermediates in fibril formation, they may not
bear a structural resemblance to fibrils at the molecular level. That is, the transition from
protofibril to fibril could involve a massive structural reorganization. Likewise, the fact
that protofibrils share a number of structural features with fibrils (as shown above) is not
an absolute proof of an on-pathway role in fibril assembly, although the structural
relationship between these two forms is certainly consistent with an on-pathway role.
Previous studies of protofibrils isolated from an on-going fibril assembly reaction
revealed a structural relationship, in showing that (a) protofibrils, like fibrils, possess a
complement of very highly protected backbone amide protons, consistent with H-bonded
-sheet, and (b) protofibrils, like fibrils, selectively incorporate an A point mutant
Glu22Gly (the residue glutamic acid at position 22 replaced with glycine) into the
aggregate from a 1:1 mix of wild type and mutant A monomers [59]. The results
described in this chapter provide further support for a structural relationship, by showing
that the distribution of HDX-sensitive and resistant amide hydrogens within protofibrils
is similar to that within quiescent fibrils: the N-terminus and C-terminus of A are open
to exchange in both, as are some residues in the center of the hydrophobic C-terminal half
of the molecule. The fact that protofibrils contain very stably protected backbone amide
protons most consistent with H-bonded -structure does not rule out the possibility that
these or other temporal intermediates in A fibril assembly might not also contain some
-helical structure, as suggested by others [96].
The results presented here suggest that the 21-30 segment becomes progressively
more ordered as assembly proceeds toward mature fibrils. Thus, quiescent fibrils exhibit
more backbone amide hydrogens protected from HDX in this segment compared to
protofibrils (Figure 4.3). In addition, previous studies reveal no sensitivity of aggregate
stability to Pro insertions in this segment in protofibrils [94], while in mature fibrils Pro
insertion at several residue positions in the segment lead to fibril destabilization [40]. If
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protofibrils prove to be on-line assembly intermediates in amyloid fibril formation, the
structural comparison of these two aggregate forms suggests that early formation of
packed, central -sheet elements are likely to be the critical first steps in the formation of
organized aggregates, with acquisition of order in other sequence elements occurring
subsequently.

4.2

Proteolysis of A (1-40) Fibrils Using Pepsin-like Enzymes

As evident from previous discussion, the digestion of Aβ fibrils on-line using
pepsin in a relatively short time period (12 seconds) gives rise to limited fragmentation,
thus providing limited structural information. Although increasing the digestion time
could increase the extent of digestion, shorter digestion time is preferred because of the
reduction of artifactual exchange in HDX-MS studies. One way to obtain more structural
information is to use other enzymes that could produce more and/or different fragments.
As addressed in section 1.3, type XIII protease, type XVIII protease and endothiapepsin
are HDX-compatible pepsin-like enzymes (working at low pH and low temperature to
limit artifactual exchange during proteolysis). In this section, results are presented for the
digestion of Aβ samples using each enzyme as well as using combinations of enzymes
simultaneously. The triaxial probe was used to allow separate optimization of proteolysis
and MS solvents.

4.2.1

Comparison of Digestion Efficiency: Before Cleanup vs. After Cleanup
As presented in Figure 4.6b, the on-line digestion of Aβ(1-40) monomer using

protease type XVIII (used as received from Sigma) produced 8 fragments at a 45/1 [w/w]
enzyme/monomer ratio, which reduced the signal for intact monomer to the baseline.
Unfortunately, the spectrum contains a strong background from the enzyme solution, as
evident in Figure 4.6a. Those interfering peaks could be due to autolysis of the enzyme
or from contaminants present in the enzyme sample. As a test for autolysis, a type XVIII
water blank (formic acid omitted) was measured. The same interfering peaks as those in
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Figure 4.6. Mass spectra obtained from (a) 0.1 g/l type XVIII protease in 0.5/100
HCOOH/H2O; (b) digestion of Aβ(1-40) monomer with unpurified type XVIII protease
at an enzyme-to-monomer ratio of 45-to-1; (c) digestion of Aβ(1-40) monomer with
purified type XVIII protease at an enzyme-to-monomer ratio of 18-to-1 (Only peaks of
fragments with S/B

5 are labeled).
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Figure 4.6a were present in this blank, despite the fact that the enzyme is completely
inactivated above pH 6 [331].

Therefore, purification of the enzyme is apparently

necessary to achieve higher digestion efficiency and cleaner mass spectra.
Since the interfering peaks are of MW <3000 and the enzymes type XVIII have a
MW of ~33,000, dialysis using a membrane with a MW cutoff at 12000~15000 was
undertaken (see section 2.2). Dialysis substantially improved Aβ spectra obtained with
this enzyme, as shown in Figure 4.6c. Totally 18 fragments were identified for the
monomer digestion, vs 8 obtained using unpurified enzyme. Also, the lower background
gives better sensitivity for the fragments. For example, the signal-to-background ratio
(S/B, background assessed as the average intensity between m/z 1100 and m/z 1200) of
the base peak at m/z 674 ([34-40]+ ion) increased by a factor of 5 after dialysis. The
complete digestion (defined as reducing the signal for intact Aβ to the baseline) of Aβ
monomer with purified type XVIII protease was achieved at an enzyme-to-monomer
ratio of 18:1 (w/w), a factor of two and a half decrease as compared to using unpurified
protease type XVIII. However, the mass recovery of this enzyme after dialysis was only
~ 30%, indicating a small net loss of activity per microgram. This may be attributable to
the loss of some enzyme, while removing contaminants.
Protease type XIII is another enzyme employed in this study. Before purification
of the protease type XIII, the complete digestion of Aβ(1-40) monomer with this enzyme
produced totally 9 fragments at a 25/1 [w/w] enzyme/monomer (Figure 4.7b). However,
the spectrum is dominant with intense peaks from the enzyme solution. The peaks from
the fragments are of relatively low intensities (Figure 4.7b). For example, the intensity of
the peak of the most abundant enzymatic fragment ion (i.e. [24-40]2+ ion at m/z 786 in
Figure 4.7b) was only around 20% of the base peak at m/z 354.

Purification though

dialysis improved Aβ spectra obtained with this enzyme dramatically, as shown in Figure
4.7c. Totally 18 fragments were observed in a very clean and nice mass spectrum with a
S/B of 180 for the base peak at m/z 378 (Figure 4.7c), 9 more fragments than using the
unpurified type XIII enzyme (Figure 4.7b). The amount of enzyme needed for complete
monomer digestion decreased by a factor of 5 (from 25:1 to 5:1). However, the mass
recovery of this enzyme was only ~ 5%, suggesting substantial contamination and/or
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possible loss of some enzyme, as well as some loss of activity per microgram. Although
digestion of monomer using the enzyme type XIII shares the same 18 fragments as the
digestion using the enzyme type XVIII, the intensities of the fragments are different, as
evident in Figure 4.7c and Figure 4.6c.
The enzyme endothiapepsin was also used in this work. It was a generous gift
from Dr. Chris Dealwis at the University of Tennessee-Knoxville. This enzyme was of
crystallographic purity and was stored in saturating ammonium sulfate salt. Except for
desalting by dialysis (described in section 2.2), no other purification was conducted prior
to digestion experiments.

The complete digestion of Aβ(1-40) monomer using this

enzyme needed an enzyme-to-monomer ratio of 6:1 and 12 fragments were identified
(Figure 4.8).
The results from the digestion of monomer using all four enzymes (protease type
XVIII, protease type XIII, endothiapepsin and pepsin) are summarized in Table 4.2 and
the sequences of the peptides obtained with each protease are shown in Figure 4.9.
Compared to pepsin, which requires an enzyme-to-monomer weight ratio of 0.9:1 to
attenuate the monomer peaks to background level (discussed in Chapter 3), all three
pepsin-like enzymes are much less active; protease type XVIII is the least active one.
Like pepsin, none of these pepsin-like proteases is really specific, but the digestion
pattern was of good reproducibility. These pepsin-like enzymes prefer the cleavage of
hydrophobic residues on the N- and/or C-terminal sides, such as Phe (F), Leu (L), Met
(M) and Val (V), as evident from the results summarized in Table 4.3. Pre-purified
protease type XVIII and protease type XIII were used in the fibril experiments discussed
below. (Due to the limited availability of endothiapepsin, no digestion of fibrils with this
enzyme was undertaken.).

4.2.2

Proteolysis of Aβ
β(1-40) Fibrils with Individual Enzymes
Figure 4.10 shows results for the digestion of Aβ fibrils using proteases type

XVIII and type XIII. At a 5-to-1 enzyme-to-fibril weight ratio, the digestion of fibrils
was not complete using either enzyme. For the digestion using protease type XVIII, the
same number of fragments (18 fragments) were identified as for the digestion of
141

[34-40]+

100

[2-4] +

%

[24-33]2+

[1-4] +

[17-19]+

[1-16]4+
[36-40] +

[23-33]2+
[35-40]+

[4-16]4+

0

350

Figure 4.8.

400

[20-33]2+

[23-34]2+

450

500

550

600

650

700

750

800

850

m/z
900

Digestion of Aβ(1-40) monomer with endothiapepsin at an enzyme-to-

monomer ratio of 6-to-1.

142

Table 4.2. Summary of results from digestion of Aβ(1-40) monomer using protease type
XVIII, protease type XIII, endothiapepsin and pepsin.

Wenzyme:Wmon

Total # fragments
(before vs after dialysis

Weight
Recovery

Enzymes

Before
cleanup

After
cleanup

Type XVIII

45:1

18:1

8 vs 18

30%

Type XIII

25:1

5:1

9 vs 18

5%

Endothiapepsin

6:1

12

N/A

Pepsin

0.9:1

7

N/A
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DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
Type XVIII

Type XIII

Endothiapepsin
Pepsin

Figure 4.9. Peptide mappings. The sequences of the peptides obtained with digestion of
Aβ(1-40) monomer using pepsin, desalted endothiapepsin, pre-purified protease type
XVIII and pre-purified type XIII are shown as underlining bars under the Aβ(1-40)
sequence.
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Table 4.3. A summary of peptide fragments identified.
Fragment

M/Z

1-4

2-4

481.19
489.48
652.30
391.78
517.75
772.04
579.28
463.63
616.05
493.04
411.03
926.10
694.82
556.06
463.55
397.47
366.17

Charge
State
1+
3+
4+
5+
4+
3+
4+
5+
4+
5+
6+
3+
4+
5+
6+
7+
1+

4-16

410.70

4+

667.00
500.50
400.61
334.01
378.35

3+
4+
5+
6+
1+

689.35
459.91
745.90
497.60
1017.04
678.36
943.51
629.34
472.26
378.01

2+
3+
2+
3+
2+
3+
2+
3+
4+
5+

1-16

1-19

1-20

1-23

4-19

17-19
20-33
20-34
20-40

21-40

Mass

Peptide Sequence

480.19

DAEF

Cleavage
Site
F-R

1953.87

DAEFRHDSGYEVHHQK

K-L

2313.09

VGSNKGAIIGLMVGGVV

F-F

2460.16

DAEFRHDSGYEVHHQKLV
FF

F-A

2775.27

DAEFRHDSGYEVHHQKLV
FFAED

D-V

365.16

AEF

1638.77

FRHDSGYEVHHQK

D-A
F-R
E-F
K-L

1997.99

DAEFRHDSGYEVHHQK
LVF

E-F
F-F

377.35

LVF

1376.69

FAEDVGSNKGAIIG

K-L
L-V
G-L

1489.78

FAEDVGSNKGAIIGL

2032.07

FAEDVGSNKGAIIGLMVGG
VV

1885.00

AEDVGSNKGAIIGLMVGG
VV
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F-F
L-M
F-F

F-A

(Table 4.3 Continued)
Cleavage
sites
E-D
G-L
E-D
L-M
E-D

Mass

Peptide sequence

515.78

Charge
state
2+

1029.55

DVGSNKGAIIG

23-34

572.32

2+

1142.63

DVGSNKGAIIGL

23-40

843.37
562.65
422.24
915.53
458.27
785.95
524.30
393.48
314.99
674.39
337.70
561.31
430.27

2+
3+
4+
1+
2+
2+
3+
4+
5+
1+
2+
1+
1+

1684.74

DVGSNKGAIIGLMVGGVV

914.52

VGSNKGAIIG

1569.89

VGSNKGAIIGLMVGGVV

D-V
G-L
D-V

673.38

LMVGGVV

G-L

560.30
429.26

MVGGVV
VGGVV

L-M
M-V

Fragment

M/Z

23-33

24-33
24-40

34-40
35-40
36-40
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Figure 4.10. Digestion of Aβ(1-40) fibrils with (a) pre-purified type XVIII protease at an
enzyme-to-monomer ratio of 5-to-1; (b) pre-purified type XIII protease at an enzyme-tomonomer ratio of 5-to-1. Only peaks of fragments with S/B

5 are labeled. +5 and +6

charge state peaks from intact Aβ peptide leftover are labeled with “*”.
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monomer, with the peak of intact Aβ peptide comprising around 20% of the base peak
(m/z 464; [1-19]5+) (Figure 4.10). Fragments 20-34 and 36-40 were observed only with
the digestion of fibrils, while fragments 23-40 and 21-40 were observed only with the
digestion of monomer. It is interesting to note that for the digestion of fibrils the base
peak was from the fragment ion [1-19]
ion [34-40]

+

5+

at m/z 464, while the peak from the fragment

at m/z 674 was around 42% of the base peak ( Figure 4.10a). In contrast,

for the digestion of monomer, the base peak was from the fragment ion [34-40] + at m/z
674, while the peak from the fragment ion [1-19]

5+

at m/z 464 was around 50% of the

base peak (Figure 4.6c). The above observed digestion differences may be due to the fact
that digestion of insoluble fibrils is controlled not only by kinetics of cleavage but also by
kinetics of dissolution to expose cleavable peptide bonds, while the digestion of soluble
monomer is controlled only by kinetics of cleavage. As a result, there is presumably
more digestion time available for monomer than for fibrils, thus leading to different
digestion product profiles. Of course, the comparison would be more meaningful if
complete digestion was also achieved for fibrils.
For the digestion of fibrils with protease type XIII, totally 19 fragments were
observed in a very clean spectrum, with the peak of intact Aβ peptide detected with only
around 5% of the base peak intensity (Figure 4.10b). The digestion of fibrils shared 17
fragments with the digestion of monomer. Fragment 1-23 was observed only with the
digestion of monomer, while fragments 20-34 and 36-40 were observed only with the
digestion of fibrils. It is interesting to note that the base peak in Figure 4.10b is from the
[17-19]+ fragment ion. The sequence of the peptide corresponding to that ion is LVF
(leucine, valine, phenylalanine), which is a highly hydrophobic peptide and is therefore
favored in ESI mass spectra [384]. As always, electrospray intensities may not directly
reflect relative abundances. Calibration (preferably with an internal standard) would be
needed for quantitation.

Nevertheless, comparison of qualitative and even semi-

quantitative information among similar samples should be valid.

4.2.3

Proteolysis of Aβ
β(1-40) Fibrils with Enzyme Mixtures
Since sample may be limited, it would be useful if the enzymes could be
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combined to gain broad structural information in a single experiment. This would require
that they don’t inhibit or digest one another on the timescale of the experiments. As a
test, digestion of fibrils using all binary and tertiary combinations of protease type XVIII,
protease type XIII, and pepsin was conducted. Results are shown in Figure 4.11 – Figure
4.14 and summarized in Table 4.4. The binary mixture of protease type XIII and pepsin
was additive in their effects on fragmentation under the conditions used. However, the
other binary mixtures and the tertiary mixture were not additive in their effects on
fragmentation. For the mixture of protease type XVIII and pepsin, the 1-23 fragment was
missing, while for the mixture of protease type XVIII and protease type XIII, 20-34 and
23-34 fragments were missing. For the tertiary mixture, the missing fragment was 1-23.
The fact that some specific ions evident in the single-enzyme spectra may be missing or
not be detected in the mixtures can be attributed to the following two reasons. First, less
than the optimum amount of each enzyme was used in the enzyme mixtures (avoiding
problems associated with using high total enzyme concentrations), thus leading to nonstrict addition.

Second, in the presence of multiple enzymes, possible further

fragmentation of previously-generated fragments by enzymes (suggesting the importance
of experimental optimization) can lead to their relative intensity attenuation or even their
vanishing. For example, the fragment 20-40 can be further cleaved to produce fragments
20-33 and 34-40 or 20-34 and 35-40, thus leading to possible attenuation of its intensity
or possible disappearance. The use of enzyme mixtures can facilitate the cleavage of the
peptide. For example, pepsin favors the cleavage between residue 19 and 20 to produce
the fragments 1-19 and 20-40 [360].

Protease type XIII can cleave the fragment 1-19

further to produce the fragment 17-19 and 1-16. Another advantage of using enzyme
mixtures is that the amount of each enzyme needed can be significantly reduced. For
example, the use of the mixture of protease type XIII and pepsin required less than onethird of the amount of either enzyme used alone to attenuate the intact peptide peak to the
same degree, as evident in Table 4.4. This would justify the preferred use of the mixture
of protease type XIII and pepsin over using protease type XIII alone, although they
produced the same fragments.
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Figure 4.11. Digestion of Aβ(1-40) fibrils with the enzyme mixture composed of prepurified protease type XIII and pepsin. Only peaks of fragments with S/B

5 are

labeled. +5 and +6 charge state peaks from intact Aβ peptide leftover are labeled with
“*”.
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Figure 4.12. Digestion of Aβ(1-40) fibrils with the enzyme mixture composed of prepurified protease type XVIII and pepsin. Only peaks of fragments with S/B

5 are

labeled. +5 and +6 charge state peaks from intact Aβ peptide leftover are labeled with
“*”.
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Figure 4.13. Digestion of Aβ(1-40) fibrils with the enzyme mixture composed of prepurified protease type XVIII and type XIII. Only peaks of fragments with S/B  5 are
labeled. +5 and +6 charge state peaks from intact Aβ peptide leftover are labeled with
“*”.
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Figure 4.14. Digestion of Aβ(1-40) fibrils with the enzyme mixture composed of pepsin,
pre-purified protease type XVIII and type XIII. Only peaks of fragments with S/B  5
are labeled. +5 and +6 charge state peaks from intact Aβ peptide leftover are labeled
with “*”.
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Table 4.4. Summary of results from digestion of Aβ(1-40) fibrils using individual
enzymes and enzyme mixtures. Signal-to-background ratio (S/B) is based on the base
peak. Background was assessed as the average intensity between m/z 1100 and m/z
1200. The master list includes the combined fragments obtained from the digestion using
all the following enzymes either individually or in combination.

Enzyme

Weight Ratio

Observed Fragment (#)

Relative
intensity of
intact peptide
peak (+6) to
the base peak
(S/B)

Pepsin

Wpep:Wfib = 8 : 1

1-19, 4-19, 20-33, 20-34, 3440,35-40, 20-40 (7)

8%
(45)

WXIII:Wfib = 5 : 1

1-4, 1-16, 1-19, 1-20, 2-4, 4-19,
17-19, 20-33, 20-34, 20-40, 2140, 23-33, 23-34, 23-40, 24-33,
24-40, 34-40, 35-40, 36-40 (19)

5%
(139)

XVIII

WXVIII:Wfib = 5 : 1

1-4, 1-16, 1-19, 1-20, 1-23, 2-4,
4-19, 17-19, 20-33, 20-34, 2040, 23-33, 23-34, 24-33, 24-40,
34-40, 35-40, 36-40 (18)

20%
(30)

XIII+Pepsin

WXIII:Wfib = 1.25 : 1
Wpep:Wfib = 2.5 : 1

1-4, 1-16, 1-19, 1-20, 2-4, 4-19,
17-19, 20-33, 20-34, 20-40, 2140, 23-33, 23-34, 23-40, 24-33,
24-40, 34-40, 35-40, 36-40 (19)

5%
(53)

XVIII+Pepsin

WXVIII:Wfib = 2.5 : 1
Wpep:Wfib = 1.25 : 1

1-4, 1-16, 1-19, 1-20, 2-4, 4-19,
17-19, 20-33, 20-34, 20-40, 2333, 23-34, 24-33, 24-40, 34-40,
35-40, 36-40 (17)

5%
(42)

XIII + XVIII

WXVIII:Wfib = 5 : 1
WXIII:Wfib = 0.425 : 1

1-4, 1-16, 1-19, 1-20, 1-23, 2-4,
4-19, 17-19, 20-33, 20-40, 2140, 23-33, 23-40, 24-33, 24-40,
34-40, 35-40, 36-40 (18)

33%
(15)

XIII + XVIII
+ Pepsin

WXVIII:Wfib = 2.5 : 1
WXIII:Wfib = 0.625 : 1
Wpep:Wfib = 0.3 : 1

1-4, 1-16, 1-19, 1-20, 2-4, 4-19,
17-19, 20-33, 20-34, 20-40, 2140, 23-33, 23-34, 23-40, 24-33,
24-40, 34-40, 35-40, 36-40 (19)

13%
(36)

XIII

Master list: 1-4, 1-16, 1-19, 1-20, 1-23, 2-4, 4-19, 17-19, 20-33, 20-34, 20-40, 21-40, 23-33, 23-34, 2340, 24-33, 24-40, 34-40, 35-40, 36-40
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4.2.4

Structural Information Implicit in the Enzymatic Fragments
As evident from the above discussion, the use of any of the three pepsin-like

enzymes or the enzyme mixtures produced more fragments, thus increasing sequence
coverage and potentially providing more structural information than using pepsin alone in
HDX studies. Among the individual enzymes and enzyme mixtures studied here, the
mixture of protease type XIII and pepsin seems to be the best choice for the digestion of
fibrils under the conditions used, in terms of the number of fragments, intensities of
fragments and S/B of the base peaks. Digestion using this combination could provide
important insights into the secondary structures of A fibrils. Specifically, deuteration
information from enzymatic fragments such as peptides 1-4 and 2-4 could allow for
determination of solvent accessibility about the very N-terminus.

Deuterium

incorporation in fragments such as 17-19, 20-33, 20-34, 23-33, 23-34 and 24-33 could
provide detailed information about the core structure (involving residues 15-36 [40, 63,
74]) of A(1-40). The number of deuteriums incorporated into fragments 34-40, 35-40
and 36-40 should provide consistent structural information about the C-terminus, thus
helping resolve the controversy concerning whether the C-terminus is exposed or
protected [40, 63, 74]. The difference in deuterium content between the overlapping
fragments could provide further information of the N-terminus, C-terminus and the core
structure, permit verification of deuterium incorporation into certain fragments and
enable the localization of deuteriums to smaller peptides or even single residues, as
evident in Table 4.5.

4.3

Conclusions

HDX-MS methods were developed and applied to map the hydrogen bonding
pattern and extent of the -sheet network in amyloid fibrils and protofibrils. These
methods can be used to obtain information on particular aggregates, as well as to
compare structures of different aggregates. To localize the hydrogen-bonding interaction
sites within the peptide, we have coupled HDX-MS with on-line proteolysis using pepsin.
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Table 4.5. A summary of non-overlapping peptide amides derived from differences of
overlapping fragments produced by digestion of A(1-40) fibrils using the mixture of
protease type XIII and pepsin.

Overlapping Peptide Fragments

Non-overlapping backbone
peptide amides

1-4 and 1-16

5-16

1-4 and 1-19

5-19

1-4 and 1-20

5-20

1-4 and 2-4

2

1-16 and 1-19

17-19

1-16 and 1-20

17-20

1-19 and 1-20

20

1-19 and 4-19

2-4

1-19 and 17-19

2-17

4-19 and 17-19

5-17

20-33 and 20-34

34

20-33 and 20-40

34-40

20-33 and 23-33

21-23

20-33 and 24-33

21-24

20-34 and 20-40

35-40

20-34 and 23-34

21-23

20-40 and 23-40

21-23

20-40 and 24-40

21-24

20-40 and 34-40

21-34

20-34 and 35-40

21-35
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(Table 4.5 Continued)
Overlapping Peptide Fragments

Non-overlapping backbone
peptide amides

20-34 and 36-40

21-36

23-33 and 23-34

34

23-33 and 23-40

34-40

23-33 and 24-33

24

23-34 and 23-40

35-40

24-33 and 24-40

34-40

23-40 and 24-40

24

23-40 and 34-40

24-34

23-40 and 35-40

24-35

23-40 and 36-40

24-36

24-40 and 34-40

25-34

24-40 and 35-40

25-35

24-40 and 36-40

25-36

34-40 and 35-40

35

34-40 and 36-40

35-36
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The methods have been validated in that the results obtained with wild type A(1-40)
quiescent amyloid fibrils agree very well with other structural approaches applied to
identical fibrils [40, 61, 63]. The on-line HDX-MS method of analysis of aggregate
structure is rapid and reproducible.

Future development and applications of these

methods will include use of pepsin-like enzymes tolerant of low pH, and/or the use of
multi-enzyme digestion (simultaneously or sequentially), which should allow better
sequence coverage and increase resolution of exchanged deuterium localization by
generating abundant overlapping fragments.
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CHAPTER 5

ELIMINATING OXIDATION ARTIFACTS IN
ESI-MS ANALYSIS OF A

As discussed in Chapter 1, the electrospray ion source behaves like a controlledcurrent electrolytic cell, and electrochemical processes must occur within the ES capillary
to maintain charge balance during the ES process [171, 178, 194,].

Under normal

electrospray conditions, currents < 1 A are sustained. For protein and peptide analysis,
the ES capillary is usually raised to a high positive potential, and oxidation of solvent,
emitter, or/and analyte can occur at the capillary wall. Individual species are generally
oxidized in order of their increasing redox potential until the required current is supplied
[178]. If the electric field strength is too high, an electric discharge will occur, and
higher and unstable currents > 1 A will be produced [139-140]. Oxidation of solvent
or/and analyte, and corona discharge can lead to the production of reactive radicals,
which can initiate a cascade of oxidation reactions in both the solution and gas phases
[385-386].
Methionine is one of the most readily oxidized amino acid constituents of proteins
[387-392]. Oxidation of methionine residues by reactive oxygen species can result in
significant conformational and/or functional changes in peptides and proteins [393]. It
plays a crucial role in protein aging [394] and is known to decrease the biological activity
of proteins [395]. For example, the oxidation of methionine in Aβ peptides further
increases the insolubility of Aβ fibrils [396-397]. This modification may occur under
conditions of oxidative stress, aging, or/and during the pathogenesis of Alzheimer’s
disease [398]. Thus, identifying the presence and quantifying the percentage of oxidized
species in methionine-containing peptides and proteins are significant. Although ES-MS
has proved to be a powerful technique for identifying and quantifying components in
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protein mixtures, the electrospray-induced oxidation of methionine-containing peptides
and proteins can complicate interpretation by introducing oxidized artifacts [386, 399400]. In this chapter, we identify the cause and the means to control oxidation of the
methionine-containing Aβ(1-40) peptide, as well as the dependence of oxidation on
instrumental configurations.

5.1
5.1.1

Aβ
β Peptide Oxidation: Source and Cause

Identification of Aβ
β Peptide Oxidation
Figure 5.1b shows a portion of a mass spectrum of Aβ(1-40) obtained with the Q-

Star using an emitter (emitter A) that had been in service for around 200 hours of spray
time. An unusual aspect of this spectrum is that, in addition to the typical [M+5H]5+ ion
(base peak), another species with a similar isotopic pattern and with maximum intensity ~
77% ± 3% (compared to the [M+5H]5+ ion) is seen at a mass 16 Da higher than expected.
This “heavy” peak was also observed for other charge states (+4: 78% ± 6%; +6: 82% ±
4%) (Figure 5.1a). In the light of the fact that Aβ(1-40) peptides contain a methionine
residue at position 35, it may be suspected that the “heavy” ions are due to oxidative
degradation prior to and/or during analysis by ESI-MS. This hypothesis was verified by
MS analysis of the peptic fragments of A(1-40). Among the 7 fragments (1-19, 4-19,
20-33, 20-34, 34-40, 35-40 and 20-40), only the isotopic peaks of fragments 34-40, 35-40
and 20-40 had peaks shifted by 16 Da, consistent with oxidation of the methionine
residue at position 35. MS/MS analysis of the 16Da-higher cluster from the peptide (3540) produced a series of bn ions shifted by 16 Da (Figure 5.2), thus confirming that the
methionine residue was indeed modified.
Although the peak of the [M+16+5H]5+ ion was ~ 77% of the peak of the
[M+5H]5+ ion using the triaxial probe on the Q-Star, analysis of the same sample by
HPLC indicated only 4% of the oxidized species present. One possible explanation is
that MS is much more sensitive to [M+16+5H]5+ ions than to [M+5H]5+ ions. However,
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Figure 5.1. ESI mass spectra of A(1-40) peptide obtained using different instrumental
configurations (at 4.5kV): (a) Q-Star + triaxial probe (showing +4, +5, +6 charge states);
(b) Q-Star + triaxial probe (showing +5 charge state); (c) Q-Star + coaxial probe
(showing +5 charge state); (d) Quattro II + coaxial probe (showing +5 charge state); (e)
Quattro II + triaxial probe (showing +5 charge state). M is the molecular mass of the A
peptide.
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Figure 5.2. MS/MS spectra of (a) the unoxidized species ([M+H]+ ions) and (b) the
oxidized species ([M+H+16]+ ions) derived from the peptic fragment (35-40) (M = the
molecular weight of the 35-40 peptide). Signal corresponding to b-type ion series have
been annotated to show the difference

between the two spectra.
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running the same sample under the same mass spectrometric conditions using the coaxial
probe on the Q-Star instrument, resulted in the [M+16+5H]5+ species being significantly
eliminated from the spectrum (i.e., its intensity dropped to ~ 4% of the base peak) (Figure
5.1c). Comparable large extra peaks were not only about ~ 6% relative abundance
(Figure 5.1d) using the coaxial probe on Quattro II, but were not observed with that probe
in previous studies [58-59]. Furthermore, experiments with the same sample and same
voltage using the triaxial probe on Quattro II produced the [M+16+5H]5+ peak only ~ 6%
of [M+5H]5+ peak (Figure 5.1e). All this suggests that MS response difference between
[M+5H]5+ ions and [M+16+5H]5+ ions, if there is any, is not likely the cause of the
occurrence of the strong peak of the [M+16+5H]5+ ion.

Alternatively, chemical

modification of the peptide in the ES ion source using the triaxial probe on the Q-Star
resulted in excessive [M+16+5H]5+ ions.

5.1.2

Cause of Oxidation

An ES current readout on a mass spectrometer provides a means of detecting a
successful electrospray and the onset of an unwanted corona discharge. In our studies,
installation of a current meter between the power supply and the ion source enables the
monitoring of the ES current. Under the conditions of Figure 5.1a or Figure 5.1b, the
measured ES current drifted between ~ 6 µA and ~ 12.6 µA over a period of 3 min. This
is much higher than typical for ESI and the drift is inconsistent with operation as a
constant-current device [178]. Furthermore, as the emitter voltage was varied, both the
current and the oxidation extent varied in direct proportion (Figure 5.3), again suggesting
that the operation apparently did not take place in the constant current section of the ES
gap’s current.

All this could indicate the presence of corona discharge, which is

characterized by high and unstable currents (> 1 µA) [139-140].
Corona discharge depends on the applied voltage, the size, shape and spacing of
the two electrodes, and the dielectric of the medium in the gap. When a high voltage is
applied to the sharp tip of the electrode, a corona discharge will occur if the voltage
gradient exceeds the dielectric breakdown threshold of the medium in the gap. During
the onset of discharge, electrons are
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accelerated towards the electrode tip (in
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Figure 5.3. The plot of electrospray current vs emitter voltage () and the oxidation
extent vs emitter voltage (). The value of the electrospray current is the maximum value
observed at each voltage. The oxidation extent is expressed as the ratio of the intensity of
the oxidized product to the sum of the intensity of the oxidized and unoxidized species,
based on the +5 charge state peak (base peak).
deviation of ratios from triplicate mass spectra.
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Error bars represent the standard

the positive mode), exciting molecules present in the medium around the tip [139-140].
As a consequence, a reactive plasma is produced. The flux of electrons and positive ions
in the plasma is responsible for the high current. Since oxygen molecules have positive
electron affinity and readily capture free electrons, the reactive plasma could contain
radical oxygen species, which can attack at the methionine residue to result in the
oxidized species [284]

5.1.3

Origin of the Oxygen Atom

Since samples were degassed using dry N2 and extra N2 flow was supplied to the
ion source during and for 4 hours before sample injection, the oxygen atom inserted into
the Aβ peptide was not likely to be from oxygen dissolved in the sample solution and/or
present in the ion source chamber. Alternatively, the reactive oxygen species could be
from the oxygen molecules generated by oxidation of water and it was further ionized in
the process of discharge. A consequence of the high applied voltage and corresponding
high spray current using the triaxial probe on the Q-Star mass spectrometer, is that the
electrolysis of water occurs readily at the metal/solution interface. For the positive ion
ES process, the electrolytic oxidation reaction of water in Eqn 1.7 is a relatively facile
process, thereby generating oxygen molecules which can be turned into reactive oxygen
species by corona discharge at the sprayer tip. When the current is high, the reactions
shown in Eqn. 1.8 and 1.9 may also take place, creating reactive molecular species like
H2O2 and O (g) [399]. This can lead to the chemical oxidation of analytes.
Previous studies using 18O water and/or using nonaqueous MeCN as the solvent to
investigate ES-induced oxidation of peptides have established that electrolysis of water
can participate in the oxidation of peptides [386, 399-400]. In order to find out if the
electrolysis of water led to the oxidation of Aβ samples, experiments using
were carried out.

18

O water

(H218O was a generous gift from Dr. Albert A. Tuinman at the

University of Tennessee.)

Specifically, 4 M Aβ monomer in 56/44/0.5 (v/v/v)

H2O/H218O/HCOOH was run at 5 µl/min in tube 1 on the triaxial probe, while 100/0.5
(v/v) MeCN/HCOOH was run at 5 µl/min in tube 2, leading to a final solution containing
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44.1% 18O (excluding the

16

O from HCOOH). In the control, H218O was substituted by

H216O. Representative spectra acquired in these two experiments were shown in Figure
5.4.

If the oxidation of Aβ monomer results from oxygen produced during water

oxidation, then the oxidized peak should be 44.1%

18

O.

The experimental result

(averaged over +4, +5, +6 charge states) shows 42.6% ± 2.1% 18O or ~ 96.6 % ± 4.8% of
the expected value. Although this is within experimental error, the fact that the value is
low is consistent with the HPLC evidence for ~ 4% contaminant present in the original
sample.
Besides reducing sensitivity to analyte (by distributing ion intensity among
different ion signals), solvent oxidation can result in a dramatic change in the solution pH
since the oxidation of water induces the generation of protons (shown in Eqn. 1.7-1.9).
This pH change has been well described by Van Berkel et al. and Cook et al. [197, 366368]. The efffect is highly dependent on flow rate and the electrospray current and as
well as on buffering. These electrochemically induced pH changes can cause protein
unfolding if time allows [366].

For HDX studies of proteins, the decrease in pH may

result in more artifactual exchange [230] if the final pH deviates from the optimum value
[260]. Also, possible overlay of the partially deuterated peak with the oxidized peak will
lead to imprecise determination of the number of incorporated deuterium labels. Besides
possible oxidation of analytes, the produced oxygen can form bubbles and cause an
unstable electrospray [401]. Minimization of the effect is desirable for all of these
reasons.

5.2

Effects of Instrumental Configurations on the Extent of Oxidation
As discussed above, discharge is the cause of oxidation and water oxidation is

responsible for supplying the oxygen atom. Either discharge or water oxidation occurs
only with certain instrumental configurations and under certain operating conditions.
Two design parameters that affect the oxidation extent are the electrical field and current
density.

The equation (Eqn. 1.2) for
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calculating the electric field strength is
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Figure 5.4. The peak clusters of the +6 charge state of A obtained from running A in
56/44/0.5 (v/v/v) H2O/H216O/HCOOH (black dotted line) and in 56/44/0.5 (v/v/v)
H2O/H218O/HCOOH (red solid line).
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described in section 1.2.1. The current density is a function of the electrode area for a
fixed current. Effective electrode area is defined as the internal surface area of the ES
emitter capillary, from the spray-tip upstream into the capillary, over which redox
reactions actually occur [402]. This area will be the same or less than the physical area of
ES emitter capillary. The effective electrode area might be less than the physical area
because of limited electric field penetration into the liquid at the spray tip and because of
other limits to ionic transport in the solvent [402]. In an ES ion source providing a given
current, iES, in which the emitter is a conductive tubular capillary of radius r, an average
current density j, for an effective electrode length l, can be calculated using Eqn. 6.1
[402]:

j=

iES
2πrl

Eqn. 6.1

Note that the current is considered to be distributed evenly along the length of electrode
for the following discussion.

5.2.1

Oxidation extent on the Q-Star: triaxial probe vs. coaxial probe

Several factors can contribute to high oxidation extent on the Q-Star triaxial
probe. First, because of the low conductivity of MeCN (as indicated by negligible
current when running pure acetonitrile in Tube 2 in Figure 2.1), good electrical contact is
made ~ 5 mm (where the solvents mix) before the triaxial tip end. For the coaxial probe,
electrical contact is made in a smaller area only when the spraying liquid from the inner
silica Tube 1 wets the outer metal Tube 2. Also, for the coaxial probe, the presence of
silica Tube 1 at the tip affects the electric field gradient (silica is less conductive than air).
As a result of these differences, the total emitter current was only ~ 2.2 A (stable) on the
coaxial probe, compared to a maximum of ~ 12.6 A on the triaxial probe. Worth noting
is that the current density at the metal/solution contact is different for the two probes. For
the coaxial probe, it is reasonable to assume that electrical contact is limited to the
annular area at the tip of Tube 2, which has an area of ~ 3.6 × 10-8 m2 (see information
about diameters in Figure 2.1), so that the current density was ~ 60 A/m2. In the case of
the triaxial probe, the electrical contact area likely includes the 5 mm inner surface of
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Tube 2 as well as the annular area of the tip surface, which totals ~ 3.5 × 10-6 m2, so the
current density was ~ 3.6 A/m2. Therefore, the current density on the coaxial probe is ~
17 times that on the triaxial probe, while the oxidation is contradictorily lower on the
coaxial probe. Although it is not easy to define the effective electrical contact area for
the coaxial probe, this difference is large compared with the uncertainty; another factor
must affect the oxidation extent. One possibility is the composition of the spraying
solution. As detailed in Chapter 3, the mixing between the acetonitrile stream in Tube 2
and the A sample solution in Tube 1 on the triaxial probe on the Q-Star instrument is
imperfect. This suggests the resultant solution adjacent to the electrode had a higher
content of water than that using the coaxial probe. Therefore, the spraying solution on
the triaxial probe had higher conductivity and surface tension, which suggests higher
susceptibility to discharge because high electrical field is necessary for droplet formation
at the ES sprayer tip. Moreover, if the electrochemical reaction occurs only in the
aqueous portion, the concentration of A sample in the aqueous droplets would be higher
with the triaxial probe due to imperfect mixing, resulting in more effective /more rapid
methionine oxidation.
To test whether the imperfect mixing on the triaxial probe contributes to the
different oxidation extent between the coaxial probe and the triaxial probe, we ran A
sample in premixed solution (with the same final composition as that used on the coaxial
probe: 50.5/49.5/0.46 water/MeCN/formic acid) in both Tube 1 and Tube 2 (emitter A in
service for 200 h) in Figure 2.1 or only in Tube 2. The results show that the current was
~ 2.2 A and the oxidation extent was similar to that using the coaxial probe (~ 4%).
This clearly indicates that the imperfect mixing contributed to the high oxidation extent
on the triaxial probe. Worth noting is that the droplet size is bigger on the triaxial probe
(bigger outer diameter for the emitter) than on the coaxial probe. However, it is not clear
that this will affect oxidation.

5.2.2

Oxidation extent on the triaxial probe: Q-Star vs. Quattro II

The following factors contribute to the difference in promoting analyte oxidation
on the Q-Star and the Quattro II.

First,
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the electrical field strength is different. At

a voltage of 4.5kV, the electric filed strength at the sprayer tip of the triaxial probe
sprayer on the Q-Star (gap distance: ~ 1.2 cm; outer diameter of the emitter: ~ 420 µm) is
7.9 × 106 V.m-1, which is ~ 1.8 times that on Quattro II (4.4 × 106 V.m-1; corresponding
to a gap distance of ~ 2.5 cm and an outer diameter of the emitter of ~ 720 µm).
Therefore, the triaxial probe on the Q-Star is more prone to discharge. Second, the
compositions of the spraying solutions on the two triaxial probes on the two instruments
may be different. As can be seen in Table 5.1, the velocity of the analyte is 15.4 times
that of MeCN on Quattro II, while on the Q-Star the difference is only a factor of two.
Although not investigated in this study, the much bigger difference in the velocity
between the analyte and MeCN may cause worse mixing on the Quattro II than on the QStar. According to the earlier discussion, imperfect mixing favors oxidation. This
suggests oxidation could be more serious for the triaxial probe on the Quattro II, which is
contradictory to the observation. Another contributing factor could be current density.
For the triaxial probe on the Quattro II instrument, the metal/solution area (effective
electrode area) was 6.4 × 10-6 m2 (refer to Figure 2.2 for diameters) and the current was ~
3.7 A, thus leading to a current density of 0.6 A/m2, significantly lower than that for the
Q-Star (~ 3.6 A/m2, see section 5.2.1). From the above discussion, it is clear that a
combination of the discussed factors (and yet-to–be discovered factors) that had caused
the oxidation difference on the triaxial probe on the two instruments.
Worth noting is that for the standard coaxial probe on the Quattro II instrument,
unlike the coaxial probe on the Q-Star, the sample transfer line is a ~ 23 cm long stainless
steel tube (Tube 1 in Figure 2.3). Due to the fact that the current (~ 2.2 A) was diluted
over the whole surface of the electrode (i.e. low current density, 0.03 A/m2), only ~ 6%
relative abundance for the oxidized A was observed (Figure 5.1d).

5.3

Progression of Oxidation

The oxidation problem on the triaxial probe of the Q-Star instrument became
more pronounced as emitter A aged. By
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300 hours of use, the measured maximum

Table 5.1. The flow velocities of the MeCN stream and the sample mixture stream
calculated for the triaxial probes on the Quattro II and the Q-Star instruments. Tube 1
and Tube 2 are indicated in Figure 2.1 and Figure 2.2.

Triaxial probe

Quattro II

Q-Star

ID (Tube 1)

50 m

75 m

OD (Tube 1)

360 m

190 m

ID (Tube 2)

410 m

220 m

1.2×105 m2

3.9×104 m2

7.9×103 m2

1.8×104 m2

5.1 l/min

5.1 l/min

0.7 mm/s

2.2 mm/s

10.8 mm/s

4.8 mm/s

15.4

2.2

Annulus area
(for MeCN stream)
Tube 1 inner cross-section area
(for sample mixture stream)
Flow rate of MeCN
(= flow rate of sample)
Flow velocity of MeCN
(flow rate/annulus area)
Flow velocity of sample
(flow rate/Tube 1 inner cross-section area)
Velocity ratio
(sample/ MeCN)
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current increased to 13.5 µA (vs. ~12.6 µA at 200 h) at a voltage of 4.5 kV, and the
oxidized peak became the base peak (relative abundance of the unoxidized peak was ~
90% ± 3%) (Figure 5.5a). Installing a new emitter (emitter B; Figure 5.6a) reduced the
oxidized peak to ~ 5.2% ± 0.1% relative abundance with an emission current of ~ 0.2 µA
(stable). After ~ 50 h use, the current increased to a maximum value of ~ 5 µA (drifting
between ~ 1 and ~ 5 µA) and the oxidized peak grew to ~ 11% ± 1% of the unoxidized
peak. After ~ 100 h, the current increased to a maximum value of ~ 11 µA (drifting
between ~ 5 and ~ 11 µA) and the oxidized peak was ~ 51% ± 4% relative abundance
(Figure 5.6b). After ~ 150 h, the current increased to a maximum value of ~ 20 µA
(drifting between ~ 7 and ~ 20 µA) and the [M+5H+16]5+ ion became the base peak,
while the [M+5H]5+ ion was only 39% ± 3% of the base peak.

5.4 Control of Oxidation
Use of redox buffers

One way to reduce analyte oxidation could be to use a redox buffer to hold the
potential at the metal/solution interface below that necessary to oxidize water and thereby
eliminate oxidation [403]. Tris(2 - carboxyethyl) phosphine (TCEP) was chosen as the
reducing agent in the studies here. The Eº of TCEP is not available, but it is known that
this is a stronger reducing agent than dithiothreitol, whose redox potential is -0.110V (vs.
SHE at pH 7)) [31, 48]. Using emitter A after ~ 200h use, addition of 100 M TCEP to
the 0.5% formic acid processing solvent effectively reduced the [M + 5H+16]5+ ion from
77% ± 3% to only ~ (6.2% ± 0.3%) of the [M + 5H]5+ base peak, suggesting that TCEP
served as an effective scavenger for the oxidizing species. Since the oxidation extent
increased with increased usage time of the emitter, a corresponding increase in TCEP
concentration was required to suppress oxidation effectively. For emitter A after ~ 300h
use, ~ 150 M TCEP was required to decrease the oxidized peak to around ~ 6% of the
unoxidized peak. It is conceivable that such a high concentration of TCEP can
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Figure 5.5. Electron micrographs and mass spectra acquired using emitter A (after ~ 300
h use) in the triaxial mode on the Q-Star instrument (at 4.5 kV): (a) before polishing; (b)
after polishing.
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Figure 5.6. Electron micrographs and mass spectra acquired using emitter B in the
triaxial mode on the Q-Star instrument (at 4.5kV): (a) < 1 h in service; (b) 100 h in
service.
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contaminate the ion source. Also, results show that the presence of 100 M TCEP
reduced the sensitivity to Aβ by ~ 13%. Furthermore, the redox buffer may react with
Aβ to alter its structure and may affect the activity of pepsin during proteolysis. Thus,
the best way to counteract discharge is to eliminate it, not to find substitutes for water
and/or analyte oxidation.

Control of currents

The occurrence of discharge lowers the resistance of the gap between the emitter
and the counter electrode [141].

Thus, adding a high resistance (typically 10 GΩ,

comparable to the gap resistance) in series with the emitter can inhibit the occurrence of
discharge [187]. Placing a 0.5 GΩ resistor in series with the power supply decreased the
ES current from a maximum value of ~ 12.6 µA (for emitter A after 200 h in use) to 0.8
µA (stable). However, no MS signal could be detected under these conditions, so adding
a larger resistor was not attempted. Further studies are needed to explain the observation.

Reduction of electric field

Electrical discharge is prevented to a large extent by reduction of the electric
field, which is related to the curvature of the tip of the electrode. The higher the
curvature, the higher the potential gradient around the tip, the more serious the discharge.
Apparently, the rather rough tip surface (such as that shown in Figure 5.5a) favors the
occurrence of discharge. On the other hand, smoothing the rough tip surface reduces the
electric field gradient and reduces discharge. Oxidation was essentially eliminated after
polishing the tip of emitter A, as shown in Figure 5.5b; the current dropped to ~ 0.2 µA
and the oxidized peak intensity fell to ~ 5.2 % ± 0.1% of the [M+5H]5+ base peak.
Similarly, polishing the emitter B (Figure 5.6b) after ~ 150 h use also reduced the
oxidized peak to ~ 5.0% ± 0.2% of the unoxidized peak from ~ 256% ± 3%, and reduced
the current to ~ 0.2 µA.
In the course of these studies, it was also noted that the lifetime of emitters
depended somewhat on the shape of the emitter tip. After polishing emitter A, the
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oxidation remained under control (~ 5.4 ± 0.3% relative abundance for the oxidized
species) after an additional ~ 165 h of use (Figure 5.7a), and the emitter current had
increased only to ~ 0.4 µA (from 0.2 µA). Similarly, emitter C showed only ~ 5.0% ±
0.2% relative abundance for the oxidized species after < 1 h in service (current ~ 0.2 µA)
(Figure 5.7b), increasing to only ~ 8% ± 1% after ~ 140 h of usage (current ~ 2.6 µA).
However, the relatively square-cut emitter B started to show ~ 11% ± 1% relative
abundance for the oxidized species after being used for only ~ 50 h, increasing to ~ 51 %
± 4% after ~ 100 h of usage (Figure 5.6b) and to ~ 256% ± 3% after ~ 150 h of usage.
Rounded emitters appear to have a higher resistance to corrosion, perhaps because the
curvature reduces the electrical field, and therefore the discharge.
The pits on the corroded surfaces evident in the micrographs may suggest that
segregation or depletion of metal elements takes place as corrosion proceeds. However,
X-ray fluorescence maps of emitter B showed that the distribution of major elements
(such as Fe, Ni, Cr, Mo) was uniform (Figure 5.8). Therefore, pits may just result from
the random attack of the tip surface by the reactive plasma.

5.5 Conclusions
The electrochemical properties of electrospray mass spectrometry must be
considered when using the technique. In this study, oxidation of a methionine residue
was promoted by an electrical discharge resulting from an eroded emitter.

One

straightforward consequence is loss of sensitivity due to dilution of the signal over more
than one species.

In HDX studies, further complications can result from the mass

increase unrelated to deuterium.
All the tested stainless steel tubes were vulnerable to discharge which resulted in
corrosion. Since the magnitude of oxidation increases as the emitter ages, the addition of
a reducing agent is not an ideal way to control oxidation. Polishing the tube helps
prevent discharge and reduces its effects. Monitoring current provides a convenient way
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(a) polished emitter A (in service for ~ 165 h after polishing)
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Figure 5.7. Electron micrographs and mass spectra acquired using the emitters in the
triaxial mode on the Q-Star instrument (at 4.5 kV): (a) polished emitter A (in service for
~ 165 h after polishing); (b) emitter C (in service for < 1 h).
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(1)

(2)
(a) Fe

(b) Cr

(c)Ni

(d) Mo

Figure 5.8. (1) Electron micrograph of a certain area of the tip of emitter B (after ~ 100 h
use); (2) X-ray maps of elements (a) Fe, (b) Cr, (c) Ni and (d) Mo in the area shown in
(1).
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to diagnose the presence of discharge (current typically > 1 A) and the need for tube
polishing or replacement.
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CHAPTER 6
CONCLUSIONS AND SUGGESTIONS
FOR FUTURE WORK

Triaxial Probe
The novel triaxial probe front end to the MS described in this dissertation has
demonstrated ability to facilitate on-line digestion of A amyloid fibrils coupled with
HDX-MS, thus enabling examination of the regional distribution of deuteriums
exchanged into A fibrils. This works by first exposing fibrils to a dissolving solvent
consisting of aqueous acid plus pepsin, after which the digest gets mixed with acetonitrile
before going into the MS. The delayed introduction of co-solvent (acetonitrile) helps
reduce any possible adverse effects induced by the addition of the organic solvent. The
triaxial probe may prove very important in other aspects of HDX experiments on fibrils,
including looking at other amyloids that don’t dissolve well in the coaxial
quenching/dissolution/analysis buffer. Another possible application is to use the triaxial
probe to obtain structural information on fibrils by the comparative proteolysis of the
A(1-40) monomer and A(1-40) fibrils without resorting to HDX. Proteolytic enzymes
act on a particular sequence element within a fibril-incorporated peptide based on the
accessibility of the cleavage sites. Within the same time frame, sites cleaved in the
monomer but not in fibrils can be assumed to be involved in hydrogen bonding (-sheet),
or positioned within or near the fibril core. Experimentally, different digestion times can
be controlled by varying the length (volume) of Tube 1 (see Figure 2.1 or Figure 2.2) in
the triaxial probe or the flow rates of the sample and/or enzyme solution, and the
digestion products can be monitored by MS. By comparing the intensity-time profiles of
the digestion products from monomer and fibrils samples, information regarding which
residues in fibrils are inaccessible to the enzyme may be obtained. The intensity-time
profiles of the intact monomer sample and its digestion products can also be used to
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derive enzymatic kinetics of pepsin or pepsin-like enzymes [404].

HDX at single-residue resolution
The goal of this research was to establish the positions of each amino acid residue
of the primary sequence within the three-dimensional structure of the protofilament and
fibril. HDX-MS coupled with on-line proteolysis has enabled localization of deuterium
distribution to 4 peptides derived from A(1-40) (discussed in Chapter 4). The next step
lies in obtaining HDX data at single residue resolution. Direct MS-MS of intact peptides
is questionable because of issues related to scrambling of amide hydrogen atoms in the
gas phase [235, 304-309]. A more promising approach would involve the use of the
triaxial probe, which can facilitate MS/MS studies by converting the released monomers
into a reasonably simple mixture of more easily characterized hydrolysis products (using
pepsin or pepsin-like enzymes).

In addition to the improved sensitivity and more

straightforward interpretation afforded by MS/MS of smaller peptides, there is some
evidence in the literature suggesting that such an approach reduces the potential for
deuterium scrambling upon MS/MS of the intact peptide [235, 247]. Proteolysis using
pepsin-like enzymes either individually or in combination has potential to provide HDX
data of A fibrils at single-residue resolution without the use of MS/MS (discussed in
section 4.2). Such single-residue information can be used to corroborate that obtained
using the approach combining proteolysis and HDX-MS/MS. One drawback of any
method involving proteolysis is that deuteration information at the cleavage sites will be
lost.

HDX of conformational variants of A(1-40)
Recent studies have indicated that there are at least two conformational variants of
A(1-40) amyloid fibrils, produced by growth in low salt either with (“agitated”) or
without (“quiescent”) shaking or stirring [37]. There is little information on the nature of
the structural differences between these reported conformations. One difference may be
in the nature of the H-bonding network that defines the -sheets within the amyloid fibril.
It would be desirable to use HDX-MS and HDX-MS/MS to study these different
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conformers grown under different conditions to find out what structural differences are.
In another aspect, it would be interesting to study how temperature, pH, ionic strength
and other solution conditions influence the H/D exchange profile of A fibrils. As fibrils
are exposed to extreme conditions, identifiable elements of structure may melt out; as
fibrils are exposed to stabilizing conditions such as low temperature, additional structural
features may become stabilized and provide additional protection against HDX. For
example, it might be possible to observe melting out or consolidation of the terminal Hbonds in the amyloid -sheets by studying temperature dependence.

HDX of A fragments
It may also be important to analyze the structures of amyloid fibrils derived from
smaller A fragments such as A(25-35) (the shortest sequence having been reported to
form fibrils [35]), to test the hypothesis intrinsic to many previous fragment studies that
the core element of the fibril of the A(1-40) molecule is retained in the fibrils of the
fragments [76, 79-80].

If the HDX results show that one, two, or three sequence

elements of the A(1-40) molecule exist as protected chain elements in -sheet in the
fibril, will these same exact sequences in an A fragment - to the extent that they are
presented in the fragment - be involved in fibril structure? The results obtained in these
fibril studies will not only address the reasonableness of using fragments of a protein to
model the amyloid fibrils of the full-length protein, but will also go to the heart of the
question of the sequence requirements for amyloid formation.

HDX of other A forms and aggregation intermediates
Our current HDX studies are mainly focused on chemically synthesized A(1-40).
The same methodologies can be applied to other forms of A. Protofibrils and other
aggregation intermediates can also be similarly determined using the HDX-MS and
HDX-MS/MS methodology. Comparing the HDX-MS and HDX-MS/MS data to that for
the A(1-40) fibril, structural differences between these various forms or states can be
elucidated.

This knowledge would allow us to dissect fibril assembly and disease

pathways. Great advance has been made in characterizing protofibrils (discussed in
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section 4.1) and A(1-42) fibrils (Dave Kaleta et. al., unpublished results) using HDXMS in our group. However, structural information of protofibrils and A(1-42) fibrils at
single-residue resolution using HDX-MS is yet to be obtained. HDX-MS and HDXMS/MS methodology is also promising to give insights into the structural plasticity (i.e.
the ability to accommodate destabilizing mutations through packing adjustments within
the three-dimensional structure) observed in amyloid fibrils [63] by comparing the
protection patterns of mutants (such as proline and alanine mutants) to those of wild-type
fibrils up to single-residue resolution.

HDX of A grown in vivo
The ultimate goal of this project is to carry out HDX experiments on enriched
preparations of amyloid plaque cores from AD brains. Once the HDX-MS and HDXMS/MS methodologies have been successful in identifying the A chain folding
characteristics within synthetic A fibrils, it is feasible to apply the same methodology to
determining the exchangeable and protected portions of the A sequence within the AD
plaque core fibril.

Since neuritic plaques from AD brains are complex structures

(containing fragments of dystrophic neuritis, amyloid fibrils, other proteins, and lipids), it
is expected to see more challenges than those encountered with the HDX studies of
synthetic fibrils and protofibrils (in simple matrixes).

The MS spectra will be

complicated by the presence of multiple molecular species of A, but at the same time
these should be recognizable and quantifiable since MS is well suited to analysis of
mixtures with high sensitivity. Although fibrils isolated from plaque cores fulfill all of
the (low resolution) structural criteria for amyloid fibrils and resemble fibrils generated
from synthetic A (addressed in section 1.1), it is reasonable to ask whether this
structural similarity extends to the details of the molecular structure of the fibril. Does
the presence of lipid, the heterogeneity of the A molecules in the fibril, or the presence
of other proteins, alter fundamental aspects of the in vivo fibril’s structure? How good a
model for biologically relevant amyloid, as isolated from human tissue, are the fibrils we
can construct in vitro from synthetic peptides?

Even if high resolution structural

information of synthetic fibrils becomes available some time in the future, it is not clear
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that it will be possible to adapt the same techniques onto biological amyloid, given its
intrinsic heterogeneity. However, the methods outlined in this dissertation may in fact be
capable of a comparative analysis of synthetic and naturally derived amyloid fibrils at the
resolution offered by HDX.

Other interesting and important studies
Determination of Cr for A(1-40) in 2mM tris buffer. It has been shown that the residual
peptide monomer remaining when an A(1-40) fibril assembly reaction reaches a plateau
is a true critical concentration (Cr) value reflecting a point of dynamic equilibrium in
fibril assembly [38-41]. It is known that monomer at concentrations below the critical
concentration (Cr) in a given solvent will not grow into fibrils [41]. In our studies, PBS
buffer (20.4 mM Na2HPO4, 3.6 mM KH2PO4, 274 mM NaCl, 5.4 mM KCl) was used to
grow fibrils, while 2 mM deuterated or protonated tris was the buffer used to prepare
fibrils for HDX studies (discussed in section 2.2). The Cr value for A(1-40) in PBS
buffer has been determined to be ~ 0.8 µM over a 24 h period [40-41]. It would also be
desirable to know the Cr for fibrils in 2 mM Tris.HCl (pH 7.5). This knowledge would
contribute to our better understanding of fibril solubility in 2 mM tris buffer (so that
fibrils of adequate concentration would be used for HDX studies) and of the presence of
the fully exchanged peak B (discussed in section 4.1.3). It is likely that the Cr value for
fibrils in 2 mM Tris buffer would be higher than that in PBS buffer, and that the fibril
formation would take a longer time because of the lower salt concentration in the buffer;
higher salt concentrations tend to enhance hydrophobic interactions [405], which are
known to play a significant role in the stability of the A(1-40) fibril [63].

Study of the interaction between Thioflavin T and fibril. Thioflavin T (ThT) is a reagent
known to become strongly fluorescent upon binding to amyloid fibrils. ThT assay has
been a standard method to distinguish amyloid fibrils from non-fibrillar material. Studies
have shown that there are at least three kinds of binding sites on A(1-40) fibrils [41,
406-407]. However, none of the sites has been localized within the fibril structure [41,
406-407]. HDX-MS has been used as a powerful tool to study the interaction between
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ligands and proteins [246]. Ligand binding is predicted to mask specific regions from
deuterium exchange by steric hindrance at the binding site, and/or by changes in structure
that limit solvent exposure. As a result, the sites which are engaged in the interaction will
not exchange. It should be feasible to apply HDX-MS to characterize the interaction
between ThT and A fibrils, and find out which residues in A are engaged in the
binding and what effects ThT binding has on the structure of A during the interaction.
Using HDX-MS and HDX-MS/MS coupled with proteolysis, binding sites could be
localized, on the condition that residue-specific HDX data is available for the particular
fibrils. Once the binding patterns of the complexes formed between fibrils and ThT are
available, insights could be obtained into the mechanism of ThT binding selectivity and
into structural differences between fibrils and protofibirls (low response to ThT [40, 94])
could be obtained. Knowledge of the ThT-fibril binding mechanism, along with knowing
the existence of multiple binding sites on fibrils, may be useful to the design of ligands
selective to particular forms of fibrils that are connected with the pathogenesis of AD and
potentially other protein misfolding diseases.
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